

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/26228 A1

(51) International Patent Classification⁷: **A61K 31/4184**,
31/443, 31/422, 31/427, 31/454, 31/501, 31/5377, C07D
401/14, 403/06, 403/14, 413/14, 417/14

06424 (US). **ZHANG, Yi**; 1106 Hatfield Drive, Evansville,
IN 47714 (US).

(21) International Application Number: PCT/US01/29493

(74) Agent: **DUBOFF, Samuel, J.**; Bristol-Myers Squibb
Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(22) International Filing Date:
27 September 2001 (27.09.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/235,804 27 September 2000 (27.09.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).

Published:
— with international search report

(72) Inventors: **YU, Kuo-Long**; 1375 Saylor Court, Zionsville,
IN 46077 (US). **CIVIELLO, Rita**; 90 Cow Hill Road,
Killingworth, CT 06419 (US). **COMBRINK, Keith**; 51
Nicholas Road, Wallingford, CT 06492 (US). **GULGEZE,**
Hatice, Belgin; 623 Town Colony Drive, Middletown, CT
06457 (US). **PEARCE, Bradley, C.**; 26 Spice Hill Drive,
East Hampton, CT 06424 (US). **WANG, Xiangdong**; 975
Little Meadow Road, Guilford, CT 06437 (US). **MEAN-**
WELL, Nicholas, A.; 15 Valli Drive, East Hampton, CT

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/26228 A1

(54) Title: BENZIMIDAZOLONE ANTIVIRAL AGENTS

(57) Abstract: The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazonone derivatives for the treatment of respiratory syncytial virus infection.

BENZIMIDAZOLONE ANTIVIRAL AGENTS**CROSS REFERENCE TO RELATED APPLICATION**

5

This application claims the benefit of U.S. Provisional Application Serial Number 60/235,804 filed on September 27, 2000.

BACKGROUND OF THE INVENTION

10

1. Field of the Invention

15 The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection.

2. Background Art

20 Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory tract infection in infants, children, elderly and immunocompromised persons. Severe infection of the virus may result in bronchiolitis or pneumonia which may require hospitalization or result in death. (*JAMA*, 1997, 277, 12). Currently only Ribavirin is approved for the treatment of this viral infection.


25 Ribavirin is a nucleoside analogue which is administered intranasally as an aerosol. The agent is quite toxic, and its efficacy has remained controversial. RespiGam, approved for prophylaxis in high risk pediatric patients, is an intravenous immunoglobulin which effectively neutralizes the virus. Recently, Synagis, a monoclonal antibody administered through intramuscular injection has also been

30 approved for use in high risk pediatric patients. However, both drugs are very expensive. Accordingly, inexpensive, safe and effective antiviral agents against respiratory syncytial virus will be beneficial for patients.

Many agents are known to inhibit respiratory syncytial virus


35 (De Clercq, *Int. J. Antiviral Agents*, 1996, 7, 193). Y. Tao et al. (EP 0 058 146 A1, 1998) disclosed that Ceterizine, a known antihistamine, exhibited anti-RSV activity. Tidwell et al., *J. Med. Chem.* 1983, 26, 294 (US Patent 4,324,794, 1982), and Dubovi

et al., *Antimicrobial Agents and Chemotherapy*, 1981, 19, 649, reported a series of amidino compounds with the formula shown below as inhibitors of RSV.




5

Hsu et al., US Patent 5,256,668 (1993) also disclosed a series of 6-aminopyrimidones that possess anti-viral activity against RSV.



10


Y. Gluzman, et al., (AU Patent, Au-A-14,704, 1997) and P. R. Wyde et al. (*Antiviral Res.* 1998, 38, 31) disclosed a series of triazine containing compounds that were useful for the treatment and/or prevention of RSV infection.




15

In addition, T. Nitz, et al., (WO Patent, WO 00/38508, 1999) disclosed a series of triaryl containing compounds that were useful for the treatment and/or prevention of RSV and related pneumoviral infections.


20



A related series of compounds were first disclosed by F. Pagani and F. Sparatore in *Boll Chim Farm.* 1965, 104, 427 and by G. Paglietti, et al. in *Il Farmaco, Ed. Sci.* 1975, 30, 505, and found to possess analgesic and anti-arrhythmic activity. The structural formula for these compounds are depicted in Formula Ia and Ib.




Formula Ia





Formula Ib

In Formula Ia and Ib, A is $-(CH_2)_n-N(R)_2$, $n = 2$ or 3 , $R = \text{Me}$ or Et ,




Another series of closely related compounds that Sparatore had disclosed were in *Il Farmaco Ed. Sci.* 1967, 23, 344 (US patent 3,394, 141, 1968). Some of the compounds were reported to have analgesic, anti-inflammatory or anti-pyretic activities. The structure of these compounds is depicted in formula Ic. In Formula Ic, $C = \text{H}, \text{CF}_3$, or NO_2 . D is $-(CH_2)_n-NR_2$, $n = 2$ or 3 , $R = \text{Me}$ or Et , or




Formula 1c

20 Another series of compounds structurally related to this invention are pyrido[1,2-a]benzoazoles and pyrimidio[1,2a]benzimidazoles disclosed by S. Shigeta et al in *Antiviral Chem. & Chemother.* 1992, 3, 171. These compounds have demonstrated inhibition of orthomyxovirus and paramyxovirus replication in HeLa cells. The structures of these compounds are shown in formulas Id and Ie, in which

R = NH, S, or O; Q = -NHCOPh, -COOH, COOEt, or CN; T = COMe, CN, or COOEt; G = O or NH.




Formula 1d




Formula 1e

5


Another series of 2-aminobenzimidazoles have been reported by E. Janssens, et al. as inhibitors of RSV in a series of recent publications and representative examples formula 1f-1h are shown below from PCT WO 01/00611 A1; PCT WO 01/00612 and PCT WO 01/00615, respectively all published on January 4, 2001.



Formula 1f




Formula 1g



Formula 1h

10


A bis-benzimidazole with an ethylenediol linker shown below has also been reported as a potent inhibitor of rhinoviruses (Roderick, et al. *J. Med. Chem.* 1972, 15, 655.




Other structurally related compounds are bis-benzimidazoles which possess antifungal activity (B. Cakir, et al. *Eczacilik Fak. Derg.* 1988, 5, 71.

20

5

R = H, NO₂

Also, H. R. Howard et al. reported a series of benzimidazolone-1-acetic acids that possessed aldolase reductase inhibitory activity (*Eur. J. Med. Chem.* 1992, 27, 779-789).



X = O, S

Other prior art related to the chemical structure of the present invention:

10

(1) F. Sparatore, et al, "Derivati Benzotriazolici Attivi Sull'accrescimento Delle Piante," *Il Farmaco Ed. Sci.* 1978, 33, 901.

(2) Katritzky, A. R. et al, "Synthesis and Transformations Of Substituted Benzazolyl- and Tetrazolyl(benzotriazol-1-yl)methanes," *J. Heterocyclic Chem.* 1996, 33, 1107.

(3) Terri A. Fairley, et al. "Structure, DNA Minor Groove Binding, And Base Pair Specificity of Alkyl and Aryl-Linked Bis(amidinobenzimidazoles) and Bis(amidinoindoles), *J. Med. Chem.* 1993, 36, 1746.


(4) R. K. Upadhyay et al, "New Synthesis and Biological Evaluation," *Indian J. Heterocyclic Chem.* 1994, 4, 121.

(5) A. R. Katritzky, et al, "A New Route to N-substituted Heterocycles," *Tetrahedron*, 1993, 49, 2829.

(6) K. Yu et al. in Substituted Benzimidazole Anti-viral Agents, PCT WO 00/04900 published February 3, 2000.

SUMMARY OF THE INVENTION

This invention relates to the antiviral activity against RSV found in a series of
 5 1-substituted 2-(3'-N-substituted 2-oxo-benzimidazolylmethyl)-benzimidazoles. The
 structural formula for these compounds are depicted in Formula I, and includes
 pharmaceutically acceptable salts thereof.




Formula I

wherein:

R_1 is $-(CR^vR^w)_n-X$;

R^v and R^w are independently selected from the group consisting of H, C_{1-6} alkyl, and C_{2-6} alkenyl; optionally substituted with 1-6 of the same or different halogen;

X is H, C_{1-6} alkyl, C_{2-6} alkenyl; each of said C_{1-6} alkyl, C_{2-6} alkenyl being optionally
 20 substituted with (1) one to six same or different halogen or hydroxy; (2) a member
 selected from the group consisting of phenyl, $-C(=NOH)NH_2$,
 $-CH(OH)-Ph$, $-Ph-S(O)_2C_{1-6}$ alkyl,



(3) a member from Group A1;

- 5 Group A1 is CN, OR', NR'R'', R'NCOR'', NR'CONR''R''', NR'SO₂R'', NR'COOR'', COR', COOR', OS(O)₂R', S(O)_tR' or PO(OR')₂;

n is 1-6;

- 10 t is 0-2;

R₂ is

- 15 (i) H, C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl, or a functionality selected from Group A2 or Group B; each of said C₁₋₆ alkyl, C₂₋₆ alkenyl, and phenyl being optionally substituted with (1) one to six same or different halogen or hydroxy or (2) one to two same or different members of Group A or Group B;
- 20 (ii) -(CR^xR^y)_n-(CO)_p-C₆H₄-(Z₁)(Z₂), wherein Z₁ and Z₂ are each independently selected from the group consisting of Group A, Group B, and -(CH₂)_n-Z'; wherein said Z' is heterocycle or -(NR_dR_eR_f) + (halogen)-; and the Z₁ and Z₂ groups may each be in the ortho, meta or para position relative to the -(CR^xR^y)_n-(CO)_p- group; wherein R_d, R_e and R_f are independently C₁₋₆ alkyl, C₂₋₆ alkenyl, OH or C₁₋₆ alkyl COOH;

25

p is 0 or 1;

n' is 1-6; or

5 (iii) $-(CR^xR^y)_{n''}$ -heterocycle;


n'' is 0-6;

R₃, R₆, R₇ and R₁₀ are each independently H;

10

R₅, R₈ and R₉ are each independently H, halogen or CF₃;

R₄ is selected from the group consisting of H, halogen, CN, -C(O)C₁₋₆ alkyl and



15

R₁₁, R₁₂ are each independently H;

R^x, R^y are each independently H or C₁₋₆ alkyl;

20 Group A2 is COR', COOR', CONRR'' or CONR'SO₂R'';

Group A3 is CN, NO₂, OR', OCONR'R'', NR'R'', N(R')COR'', N(R')CONR''R''',
NR'SO₂R'', NR'COOR'', SO_mR', SO₂NR'R'', SO₂NR'COR'' or PO(OR')₂;

25 Group A is a member selected from Group A2 and Group A3;

R', R'', R''' are each independently selected from the group consisting of H,
C₁₋₆ alkyl, phenyl and heterocycle; and each of said C₁₋₆ alkyl, phenyl and heterocycle
being optionally substituted with (1) one to six of same or different halogen or

30 hydroxy; (2) one to two of the same or different members of Group A' or Group B; or
(3) heterocycle; or R' and R'' taken together form a 5 to 6 membered aromatic or non-
aromatic ring containing one to four of the same or different heteroatoms selected
from the group consisting of N, S and O;

Group A' is halogen, CN, NO₂, OR^a, OCONR^aR^b, NR^aR^b, R^aNCOR^b, NR^aCONR^bR^c, NR^aSO₂R^b, NR^aCOOR^b, COR', CR^cNNR^aR^b, CR^aNOR^b, COOR^a, CONR^aR^b, CONR^aSO₂R^b, SO_mR^a, SO₂NR^aR^b, SO₂NR^aCOR^b or PO(OR^a)₂;

- 5 R^a, R^b, R^c are each independently selected from the group consisting of H and C₁₋₆ alkyl;

Group B is -(CH₂)_nQ, -(CH₂)_nSO_m-R₁₃ or -COQ;

- 10 Q is an N-linked amino acid selected from the group consisting of alanine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, pipecolic acid, α-amino-butyric acid, α-amino-propanoic acid, 2-amino-3-phenopropionic acid and iminodiacetic acid; wherein Q is linked to the adjacent carbon atom in Group B through a nitrogen atom of said N-linked amino acid; wherein said N-linked amino
15 acid includes D- or L-enantiomers or mixtures thereof;

R₁₃ is selected from a group consisting of H and C₁₋₆ alkyl; said C₁₋₆ alkyl being optionally substituted with (1) one to five hydroxy groups or (2) two of the same or different functionalities selected from the group consisting of COOR^x and CONR^xR^y;

20

m, m' and m'' are independently 0-2;

n''' is 1-6;

- 25 heterocycle is a 5-6 membered aromatic or non-aromatic ring which contains one to four heteroatoms independently selected from the group consisting of O, N and S; wherein said aromatic or non-aromatic ring is optionally fused to a phenyl ring; wherein the aromatic or non-aromatic ring is optionally substituted with one to five of the same or different substituents selected from the group consisting of C₁₋₆ alkyl,
30 Group A and Group B; and halogen is bromine, chlorine, fluorine or iodine.

- In a preferred embodiment, the heterocycle is an aromatic ring selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl,
35 1,2,4-oxadiazol-5-one, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl,

pyrazinyl, 1,3,5-triazinyl, indoliziny, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, tetrazole, uridiny and cytosiny.

5 In another preferred embodiment, the heterocycle is a non-aromatic ring selected from the group consisting of pyrrolidine, imidazoline, 2-imidazolidone, 2-pyrrolidone, pyrrolin-2-one, tetrahydrofuran, 1,3-dioxolane, piperidine, tetrahydropyran, oxazoline, 1,3-dioxane, 1,4-piperazine, morpholine and thiomorpholine.

10


In another preferred embodiment in R_2 , substituents R^x and R^y are each hydrogen. Also preferred is R_{11} and R_{12} each being hydrogen. Still more preferred are compounds wherein n' is 1 and n'' is 3-4.

15

In another preferred embodiment, n is 1-4.

In another preferred embodiment are compounds wherein:


20 R_1 is vinyl, allyl, 3-methyl-2-butene or $-(CH_2)_n-X$, wherein n is 2-4, and X is a functionality selected from the group consisting of



R_2 is

25


(i)



wherein R_{17} is H or C_{1-4} alkyl;

(ii) $-CH_2-C_6H_4-Z$;

- 5 (iii) $-(CH_2)_k-Z''$, wherein k is 1-6; wherein Z and Z'' are each independently selected from the group consisting of:



—NHCOR₁₅, —NHSO₂R₁₅, —NHSO₂CF₃, —SR₁₅, —SO₂R₁₅, —SO₂NR₁₅R₁₆ and —SO₃H;
a and b are each independently 0-2; and

R₁₅ and R₁₆ are each independently H, C₁₋₄ alkyl, wherein said C₁₋₄ alkyl is optionally substituted with 1-3 same or different halogens.

5 In another embodiment of the invention there is provided a method for treating mammals infected with RSV, and in need thereof, which comprises administering to said mammal a therapeutically effective amount of one or more of the aforementioned compounds of having Formula I, including pharmaceutically acceptable salts thereof.

10

Another embodiment includes a pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned anti-RSV compounds of having Formula I, including pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.

15

The term pharmaceutically acceptable salt includes solvates, hydrates, acid addition salts, base addition salts, and the salts of quarternary amines and pyridiniums. The acid addition salts are formed from a compound of Formula I and a pharmaceutically acceptable inorganic or organic acid including but not limited to
20 hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, citric, malonic, fumaric, maleic, sulfamic, or tartaric acids. The counter ion of quaternary amines and pyridiniums include chloride, bromide, iodide, sulfate, phosphate, methansulfonate, citrate, acetate, malonate, fumarate, sulfamate, and tartrate. The base addition salts include but are not limited to salts such as sodium, potassium,
25 calcium, lithium and magnesium.

Halogen means bromine, chlorine, iodine and fluorine.

DETAILED DESCRIPTION OF THE INVENTION

30


Compounds of Formula I may be prepared using the procedures outlined in **Schemes I - V**.

Compounds of Formula I can be prepared as shown in **Scheme I**. Starting
35 from the methansulfonamide of **IV**, alkylation with N-isopropylidenebenzimidazolone **V** in the presence of an appropriate base, such as NaH or a phosphazene base such as BTPP, followed by cleavage of the

- methanesulfonamide with tetrabutylammonium fluoride (TBAF) gives compounds of Formula VI. Alkylation of compounds of Formula VI with R_1 -LG where LG is a leaving group, preferably halide or sulfonate such as mesylate using an appropriate base such as NaH or Cs_2CO_3 provides compounds of Formula VII. Alternatively, compounds with Formula VII can be obtained through Michael addition of VI with acrylonitrile, vinyl sulfone, or an ester of acrylic acid. Alkylation of VI may give mixtures of regioisomers when R_3 - R_6 are non-equivalent. These mixtures may be purified by various chromatographic techniques. Alternatively, single regioisomers can be obtained by employing a reaction sequence like that described in Scheme IVa.
- 10 Cleavage of the isopropylidene moiety with acid such as hydrochloric acid or acetic acid followed by a second alkylation step with R_2 -LG provides compounds of Formula I.

Scheme I

15




- Compound IV can be prepared using the reaction sequence depicted in Scheme Ia. When R_4 and R_5 are equivalent reaction of 2-chloromethylbenzimidazole (II) with methanesulfonyl chloride (MsCl) and
- 20

triethylamine gives compounds of Formula **III**. The chloride can be refluxed with potassium iodide in acetone to produce **IV**, as described in PCT WO 00/04900.

Scheme Ia

5




Compounds of Formula **I** can also be prepared as shown in **Scheme II**.



Alkylation of the substituted benzimidazolone of Formula **XIII** with a chloride **XI** in the presence of an appropriate base such as BTPP, Cs_2CO_3 , or NaH , gives compounds of Formula **I**.

Scheme II


15




The synthesis of intermediates **XI** and **XIII** are depicted below in Schemes **IIa** and **IIb**, respectively. When R_4 and R_5 are equivalent selective N-alkylation of 2-hydroxybenzimidazole (**IX**) with $\text{R}_1\text{-LG}$ or a Michael acceptor, such as acrylonitrile ($\text{R} = \text{CN}$), followed by conversion of the hydroxyl group of **X** to the chloride with SOCl_2 affords intermediate of Formula **XI**. Reaction of N-isopropylidenebenzimidazolone **V** with $\text{R}_2\text{-LG}$ in the presence of an appropriate base such as NaH , BTPP, or Cs_2CO_3 affords intermediate **XII**. Cleavage of the isopropylidene moiety with acid gives compounds of Formula **XIII**.

Scheme IIa5 **Scheme IIb**


10 Additionally, a hybrid method from Schemes I and II may be employed for the preparation of compounds of Formula I as depicted in **Scheme III**. Coupling of intermediates XI and V in the presence of an appropriate base affords compounds of Formula VII. Cleavage of the isopropylidene moiety and reaction with R₂-LG utilizing the same procedures described in Scheme I gives compounds of Formula I

Scheme III


- 5 In a different approach, compounds of Formula I were prepared using the synthetic route illustrated in **Scheme IV**. Substituted phenylenediamine **XIV** can be coupled with either the acid **XV** through an amide coupling agent, such as a carbodiimide, or with the acid chloride **XVI** and a base. The crude material is directly cyclized to the benzimidazole in warm acetic acid to give compounds of
- 10 **Formula I**. Alternatively, the phenylenediamine **XIV** can directly react with acid **XV** in the presence of EEDQ or the acid chloride **XVI** to give compounds of **Formula I**. In a slightly modified procedure depicted in **Scheme IV**, phenylenediamine **XIV** can be coupled with acid **XV** or acid chloride **XVI** in the same manner described above to give compounds of **Formula XXIII** which then can react with R₁-LG in the
- 15 presence of an appropriate base to afford compounds of **Formula I**.

Scheme IV


- 5 The preparation of phenylenediamines **XXI** is described in **Scheme IVa**. Coupling of a 1-fluoro-2-nitrobenzene derivative **XIX** and the appropriate amine produces compounds of Formula **XX**. Reduction of compound **XX** under catalytic hydrogenation conditions to give phenylenediamine **XXI**.

10 **Scheme IVa**

- 15 The right-hand benzimidazolone intermediates **XXI I** and **XXIII** can be prepared using standard alkylation chemistry and deprotection procedures as depicted in **Scheme IVb** starting with the known compound of Formula **XXII**.

Scheme IVb

- 5 Further modification of compounds at the R_2 side-chain can be accomplished by extension of the side-chain with one or more linkers as described in **Scheme V**. Alkylation of compounds of Formula **VIII** with a linker ($Y\text{-LG}$) in the presence of an appropriate base such as Cs_2CO_3 , NaH , or $BTPP$ affords intermediates **XXIV**. Intermediate **XXIV** is then extended through standard coupling and alkylation reactions to give compounds of Formula **I**.
- 10

Scheme V

15

Abbreviations used herein, including in Schemes I-V, experimental section unless indicated otherwise:

AcOH: acetic acid

AIBN: azobisisobutyronitrile

- BEMP: 2-*t*-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorane
BTPP: *t*-butylimino-tri(pyrrolidino)phosphorane
DEAD: diethyl azodicarboxylate
5 DMF: dimethylformamide
EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
EEDQ: 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
Et: ethyl
Et₂O: diethyl ether
10 EtOAc: ethyl acetate
EtOH: ethyl alcohol
HOAc: glacial acetic acid
Me: methyl
MeOH: methyl alcohol
15 MTBD: 1,3,4,6,7,8-hexahydro-1-methyl-2H-pyrimido[1,2-*a*] pyrimidine
Ph: phenyl
Prep HPLC: preparative high performance liquid chromatography
PyBroP: bromotripyrrolidinophosphonium hexafluorophosphate
TBAF: tetrabutylammonium fluoride
20 TEA: triethylamine
TFA: trifluoroacetic acid
THF: tetrahydrofuran
Tr: triphenylmethyl (trityl) group
- 25 It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established infections or symptoms.
- It will be further appreciated that the amount of a compound of the invention
30 required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician or veterinarian. In general however, a suitable dose will be in the range of from about 0.01 to 750 mg/kg of body weight per day
35 preferably in the range of 0.1 to 100 mg/kg/day, most preferably in the range of 0.5 to 25 mg/kg/day.

Treatment is preferably commenced before or at the time of infection and continued until virus is no longer present in the respiratory tract. However, the treatment can also be commenced when given post-infection, for example after the appearance of established symptoms.

5

Suitable treatment is to administer the compound 1-4 times daily and continue for 3-7 days, e.g. 5 days, post infection, depending upon the particular compound used.

10

The desired dose may be administered as a single dose or in divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

15

The compound is conveniently administered in unit dosage form, for example, containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.

20

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.

25

The invention thus further provides a pharmaceutical formulation comprising a compound of the formula I, but not subject to the proviso thereto, or a pharmaceutically acceptable salt or derivative thereof together with a pharmaceutically acceptable carrier thereof.

30

The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical formulations may be in the form of conventional formulations for the intended mode of administration.

35

For intranasal administration according to the method of the invention the compounds of the invention may be administered by any of the methods and formulations employed in the art for intranasal administration.

Thus in general the compounds may be administered in the form of a solution or a suspension or as a dry powder. Solid carriers include, for example, starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin.

5 Solutions and suspensions will generally be aqueous, for example prepared from water alone (for example sterile or pyrogen-free water), or water and a physiologically acceptable co-solvent (for example ethanol, propylene glycol, and polyethylene glycols such as PEG 400).

10 Such solutions or suspensions may additionally contain other excipients, for example, preservatives (such as benzalkonium chloride), solubilizing agents/surfactants such as polysorbates (e.g. Tween 80, Span 80, benzalkonium chloride), buffering agents, isotonicity-adjusting agents (for example sodium chloride), absorption enhancers and viscosity enhancers. Suspensions may
15 additionally contain suspending agents (for example microcrystalline cellulose, carboxymethyl cellulose sodium).

 Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations
20 may be provided in single or multidose form. In the latter case a means of dose metering is desirably provided. In the case of a dropper or pipette this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray this may be achieved for example by means of a metering atomizing spray pump.

25 Intranasal administration may also be achieved by means of an aerosol formulation in which the compound is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example dichlorodifluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane,
30 carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.


Experimental Section

35

Proton nuclear magnetic resonance (^1H NMR) spectra were recorded on a Bruker Advance 500, AC-300, Bruker DPX-300 or a Varian Gemini 300

spectrometer. All spectra were determined in CDCl_3 , CD_3OD , or $\text{DMSO}-d_6$ and chemical shifts are reported in δ units relative to tetramethylsilane (TMS). Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; b, broad peak; dd, doublet of doublets; dt, doublet of triplets. Mass spectroscopy was performed on a Finnigan SSQ 7000 quadrupole mass spectrometer in both positive and negative electrospray ionization (ESI) modes or on a LC-MS using Shimadzu LC-10AS with micromass platform LC single quadrupole mass spectrometer in positive electrospray ionization. High resolution mass spectroscopy was recorded using a Finnigan MAT 900. Infrared (IR) spectra were recorded on a Perkin-Elmer system 2000 FT-IR. Elemental analysis was performed with a Perkin-Elmer series II, model 2400 CHN/O/S analyzer. Column chromatography was performed on silica gel from VWR Scientific. Preparative HPLC was performed using a Shimadzu LC-8A on a C18 column eluted with mixture of MeOH in water with 0.1 % trifluoroacetic acid.

Preparation of Compounds as depicted in Scheme I:



To a solution of 2-(chloromethyl)benzimidazole (80 g, 0.48 mol) and methanesulfonyl chloride (58.3 mL, 0.75 mol) in CH_2Cl_2 (0.5 L), triethylamine (136 mL, 0.97 mol) was added dropwise under nitrogen. The resulting mixture was stirred at room temperature for 6 hours. The mixture was filtered and the filtrate was evaporated. The residue was triturated with MeOH and filtered to afford 74.9 g (64% yield) of compound 1 as a brown solid:

^1H NMR (CDCl_3) δ 3.44 (s, 3 H), 5.11 (s, 2 H), 7.40-7.49 (m, 2 H), 7.76-7.82 (m, 1 H), 7.85-7.91 (m, 1 H);


IR (KBr, cm^{-1}) 3027, 2920, 1371, 1349, 1177, 1144, 1059;

MS m/e 245 (MH^+);

Anal. Calcd for $\text{C}_9\text{H}_9\text{ClN}_2\text{O}_2\text{S}$: C, 44.18; H, 3.71; N, 11.45

Found: C, 44.09; H, 3.57; N, 11.49.

24



A solution of potassium iodide (206 g, 1.24 mol) and compound **1** (74.8 g, 0.414 mol) in acetone (1 L) was stirred at reflux under nitrogen for 4 hours. The solid was filtered and the filtrate was evaporated. The crude product was triturated in MeOH and filtered to give 83 g (60% yield) of compound **2** as a solid:

¹H NMR (CDCl₃) δ 3.48 (s, 3 H), 4.97 (s, 2 H), 7.40-7.50 (m, 2 H), 7.75-7.85 (m, 2 H);


IR (KBr, cm⁻¹) 3022, 2916, 1366, 1173, 1055, 966, 763, 745;

MS m/e 336 (MH⁺);

Anal. Calcd for C₉H₉IN₂O₂S: C, 32.16; H, 2.70; N, 8.33

Found: C, 32.05; H, 2.63; N, 8.22.


15



2-(Iodomethyl)-1-(methanesulfonyl) benzimidazole, **2**, (160 g, 0.476 mol) and 1-isopropenyl-2-benzimidazolone (prepared using the procedure described by J. Davoll, J. Chem. Soc. 1960, p308) were dissolved in 2 L of anhydrous THF and the solution cooled in a ice bath. To the solution, BTPP (223 g, 0.714 mol) was slowly added. The ice bath was removed, and the mixture was stirred at room temperature for 1.5 hours. The solution was evaporated. The residue was dissolved in ethyl acetate, washed with water, brine, dried over magnesium sulfate and evaporated. The residue was dissolved in THF (1 L) and tetrabutylammonium fluoride hydrate (130.7 g, 0.5 mol) was added. The mixture was stirred at reflux for 5 hours. The solvent was evaporated. The residue was dissolved in EtOAc, washed with water, brine, dried over magnesium sulfate, and evaporated. The residue was purified through a short silica gel column with EtOAc in CH₂Cl₂ (10 to 100%) to give 92.0 g (72% yield) of compound **3** as a solid:

^1H NMR (CDCl_3) δ 2.24 (s, 3 H), 5.22 (s, 1H), 5.41 (s, 3H), 7.09-7.17 (m, 3H), 7.26-7.30 (m, 2H), 7.39 (d, $J = 6.9$ Hz, 1H), 7.60 (dd, $J = 3.3, 6.0$ Hz, 2H);
MS m/e 305 (MH^+).


5 **Compound 4 (Scheme I)**



To compound 3 (30.4 g, 100 mmol) in DMF (200 mL) was added NaH (60% in mineral oil, 5.2 g, 130 mmol) in several portions at room temperature. After stirring for 30
10 minutes, 1-bromo-3-methylbutane (16.62 g, 110 mmol) was added to the suspension and the mixture was stirred at 70 °C overnight. The crude product was purified by flash chromatography to give 33.7 g (90% yield) of compound 4 as a white solid:

^1H NMR (CDCl_3) δ 0.94 (d, $J = 6.6$ Hz, 6 H), 1.37-1.45 (m, 2 H), 1.64-1.75 (m, 1 H), 2.25 (s,
15 3 H), 4.31 (bt, $J = 8.1$ Hz, 2 H), 5.21 (s, 1 H), 5.38 (s, 1 H), 5.40 (s, 2 H), 7.01-7.10 (m, 3 H), 7.25 -7.35 (m, 3 H), 7.46-7.47 (m, 1 H), 7.79-7.82 (m, 1 H);
IR (KBr, cm^{-1}) 2962, 1702, 1491, 1471, 1395, 1331, 740, 734;
MS m/e 375 (MH^+);

Anal. Calcd for $\text{C}_{23}\text{H}_{26}\text{N}_4\text{O}$: C, 73.77; H, 7.00; N, 14.96
20 Found: C, 73.82; H, 6.94; N, 14.91.




Compound 5 (Scheme I)

25 Compound 5 was prepared as described for compound 4 using 1-ethyl-1,3-dihydrobenzoimidazol-2-one.

¹H NMR (CDCl₃) δ 0.92 (d, J = 6.6 Hz, 6H), 1.32-1.40 (m, 5H), 1.63-1.72 (m, 1H), 3.90-4.01 (m, 2H), 4.27-4.33 (m, 2H), 5.43 (s, 2H), 6.90-7.12 (m, 4H), 7.26-7.29 (m, 2H), 7.44 (d, J = 7.6 Hz, 1H), 7.79-7.82 (m, 1H), 8.46 (bs, 1H); MS m/e 363 (MH⁺).

5

Compound 6 (Scheme I)

10 To compound 4 (33.7 g, 90 mmol) was added to 10% conc. HCl in MeOH (100 mL) and the reaction mixture was stirred at 75 °C for 1 h. The solvent was evaporated, and to the residue was added saturated NaHCO₃. The mixture was extracted with CH₂Cl₂. The combined extracts were washed with water and brine, and then dried over MgSO₄. The solvent was evaporated, and the residue was passed
15 through a short silica gel column to give a product which crystallized from CH₂Cl₂/EtOAc to give 22.83 g (84% yield) of compound 6 as white solid:

¹H NMR (CDCl₃) δ 1.89 (d, J = 6.6 Hz, 6 H), 1.38-1.46 (m, 2 H), 1.67-1.74 (m, 1 H), 4.29-4.35 (m, 2 H), 5.46 (s, 2 H), 7.01-7.08 (m, 3 H), 7.28-7.31 (m, 3 H), 7.42-7.44
20 (m, 1 H), 7.81-7.84 (m, 1 H), 9.78 (bs, 1 H);


IR (KBr, cm⁻¹) 2957, 1696, 1489, 1458, 1390, 1332, 749, 737;

MS m/e 335 (MH⁺);

Anal. Calcd for C₂₀H₂₂N₄O: C, 70.69; H, 6.70; N, 16.49

Found: C, 70.43; H, 6.69; N, 16.25.

Compound 7 (Scheme I)



5 A solution of compound 6 (212 mg, 0.63 mmol) and methyl 4-(bromomethyl)-benzoate (160 mg, 0.70 mmol) in THF (2 mL) was cooled to 0° and BTPP (219 mg, 0.7 mmol) was added dropwise under nitrogen. The resulting mixture was stirred at 0° for 0.5 h then at room temperature for 2 hours. The mixture was diluted with EtOAc and washed with water. The organic extracts were dried
10 with MgSO₄ and evaporated. The residue was purified by flash chromatography (gradient, hexanes:EtOAc 2:1 to 1:2) to give (219 mg, 71% yield) of compound 7 as a white solid:

¹H NMR (CDCl₃) δ 0.94 (d, J = 6.6 Hz, 6 H), 1.47 (m, 2 H), 1.70 (m, 1 H), 3.91 (s, 3 H), 4.34 (m, 2 H), 5.16 (s, 2 H), 5.49 (s, 2 H), 6.82 (d, J = 8.9 Hz, 1 H), 7.02 (m, 2 H), 7.29 (m, 3 H), 7.38 (d, J = 8.3 Hz, 2 H), 7.50 (d, J = 7.3 Hz, 1 H), 7.82 (m, 1 H), 7.99 (d, J = 8.3 Hz, 2 H);


IR (KBr, cm^{-1}) 3418, 2952, 1707, 1495, 1406, 1279, 748;

MS m/e 483 (MH⁺);

Anal. Calcd for $C_{29}H_{30}N_4O_3$: C, 72.18; H, 6.27; N, 11.61

20 Found: C, 71.95; H, 6.20; N, 11.41.

Compound 8




5 Compound 7 (130 mg, 0.27 mmol) was dissolved in methanol (2 mL). A solution of 1N NaOH (0.81 mL, 0.81 mmol) was added and the resulting mixture was heated to reflux for 3 h then cooled to room temperature. The solution was concentrated, and adjusted to pH 5 with 1N HCl. The precipitate was filtered and dried to give 81 mg (63% yield) of compound 8. The acid was then converted to a sodium salt by adding aqueous NaHCO₃, and the resulting solution was adjusted to pH 8 with 1N HCl. The solution was evaporated to give the sodium salt of compound 8 as a white solid:

¹H NMR (DMSO-d₆) δ 0.91 (d, J = 6.6 Hz, 6 H), 1.46 (m, 2 H), 1.65 (m, 1 H), 4.32 (m, 2 H), 5.09 (s, 2 H), 5.42 (s, 2 H), 6.99 (m, 2 H), 7.10 (m, 1 H), 7.29 (m, 5 H), 7.51 (d, J = 7.3 Hz, 1 H), 7.60 (d, J = 7.3 Hz, 1 H), 7.78 (d, J = 8.3 Hz, 2 H); IR (KBr, cm⁻¹) 3396, 2956, 1703, 1612, 1598, 1329, 750; MS m/e 469 (MH⁺);

Anal. Calcd for C₂₈H₂₇N₄O₃Na•1.5NaCl•2H₂O: C, 54.79; H, 5.09; N, 9.12

Found: C, 55.08; H, 5.35; N, 8.86.

Compound 9




To a suspension of acid **8** (6.80 g, 14.5 mmol) in DMF (200 mL) at 0 °C was added PyBroP (7.41 g, 15.9 mmol). The suspension was stirred at 0 °C until it turned to a clear solution (about 30 minutes). Diisopropylethylamine (7.49 g, 57.9 mmol) and (L)-aspartic acid dimethyl ester hydrochloride (3.14 g, 15.9 mmol) were added and the resulting solution was stirred at ambient temperature overnight. The solvent was evaporated and the residue was purified by column chromatography (hexane : EtOAc 3:1 to 1:4) to afford 8.30 g (94% yield) of compound **9** as a white solid:

¹H NMR (DMSO-d₆) δ 0.90 (d, J = 6.6 Hz, 6H), 1.41-1.48 (m, 2H), 1.59-1.68 (m, 1H), 2.72-2.97 (m, 2H), 3.57 (s, 3H), 3.61 (s, 3H), 4.29 (t, J = 7.9 Hz, 2H), 4.76-4.83 (m, 1H), 5.17 (s, 2H), 5.42 (s, 2H), 6.98-7.25 (m, 6H), 7.44 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 7.5 Hz, 1H), 7.59 (d, J = 7.3 Hz, 1H), 7.78 (d, J = 8.3 Hz, 2H), 8.88 (d, J = 7.7 Hz, 1H);


IR (KBr, cm⁻¹) 3312, 2953, 1740, 1708, 1495, 1170, 846, 748;

MS m/e 612 (MH⁺);




Compound **10** was prepared as described for compound **7** using methyl bromoacetate and sodium hydride as the base.

¹H NMR (CDCl₃) δ 0.94 (d, J = 6.6 Hz, 6H), 1.42-1.56 (m, 2H), 1.64-1.73 (m, 1H), 3.76 (s, 3H), 4.29 (t, J = 8.2 Hz, 2H), 4.66 (s, 2H), 5.44 (s, 2H), 6.84-6.90 (m, 1H), 7.04-7.10 (m, 3H), 7.27-7.30 (m, 2H), 7.44-7.52 (m, 1H), 7.76-7.82 (m, 1H); MS m/e 406 (MH⁺).

**Table 1** – Additional examples prepared as described for compound 9.

#	R ₂	¹ H-NMR Data	MS Data
11a		(CDCl ₃) δ 0.91 (d, J = 6.6 Hz, 6H), 0.99-1.13 (m, 2H), 1.43-1.51 (m, 4H), 1.56-1.69 (m, 2H), 1.84-1.98 (m, 4H), 2.00-2.16 (m, 1H), 2.80-3.08 (m, 2H), 3.28 (t, J = 6.3 Hz, 2H), 3.70 (s, 3H), 3.75 (s, 3H), 4.29 (t, J = 8.2 Hz, 2H), 4.83-4.89 (m, 1H), 5.30 (s, 2H), 5.45 (s, 2H), 6.50 (d, J = 8.1 Hz, 1H), 6.90-6.96 (m, 1H), 7.06-7.09 (m, 2H), 7.21-7.24 (m, 1H), 7.31-7.34 (m, 4H), 7.43-7.50 (m, 2H), 7.75-7.78 (m, 1H)	751 (MH ⁺)
11b		(DMSO-d ₆) δ 0.91 (d, J = 6.5 Hz, 6H), 1.47-1.54 (m, 2H), 1.64-1.70 (m, 1H), 1.73-1.77 (m, 1H), 3.07-3.19 (m, 2H), 3.45-3.51 (m, 2H), 3.57-3.66 (m, 2H), 3.70-3.79 (m, 2H), 4.38 (t, J = 8.1 Hz, 2H), 4.58 (d, J = 8.3 Hz, 2H), 5.04 (d, J = 3.0 Hz, 1H), 5.17 (s, 2H), 5.51 (s, 2H), 7.00-7.03 (m, 2H), 7.08-7.13 (m, 1H), 7.25-7.36 (m, 3H), 7.42 (d, J = 8.4 Hz, 2H), 7.63 (t, J = 6.7 Hz, 2H), 7.80 (d, J = 8.3 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.98 (d, J = 7.2 Hz, 1H)	630 (MH ⁺)
11c		(CDCl ₃) δ 0.90 (d, J = 6.6 Hz, 6H), 1.03-1.14 (m, 2H), 1.39-1.66 (m, 7H), 1.91-2.06 (m, 4H), 2.24-2.33 (m, 1H), 3.35 (t, J = 6.4 Hz, 2H), 3.68 (s, 3H), 4.27-4.34 (m, 2H), 5.32 (s, 2H), 5.52 (bs, 2H), 7.00-7.13 (m, 4H), 7.16-7.19 (m, 1H), 7.30-7.35 (m, 4H), 7.49-7.62 (m, 2H), 7.82-7.87 (m, 1H)	622 (MH ⁺)

5

Compound 12


10

To a solution of compound 9 (3.3 g, 5.39 mmol) in MeOH (100 mL) was added 1 N NaOH (32 mL) and the solution was stirred at 60 °C for 10 min. The solvent was evaporated. The residue was dissolved in water and adjusted to pH 2

with 1N HCl, extracted with THF and then EtOAc. The combined extracts were washed with brine, dried over MgSO_4 , and evaporated. The residue was triturated in EtOAc to give 2.55 g of compound **12** as a free acid. To the acid in methanol (50 mL) was added 2 equivalents of 1 N NaOH and solvent was evaporated. The residue was triturated with Et_2O to give 2.53 g of the disodium salt of compound **12** as a white solid:

^1H NMR (CD_3OD) δ 0.95 (d, $J = 6.6$ Hz, 6 H), 1.43-1.51 (m, 2 H), 1.64-1.73 (m, 1 H), 2.82 (d, $J = 5.9$ Hz, 2 H), 4.35-4.40 (m, 2 H), 4.70 (t, $J = 5.9$ Hz, 1 H), 5.24 (s, 2 H), 5.51 (s, 2 H), 7.02-7.06 (m, 3 H), 7.18-7.36 (m, 3 H), 7.45-7.51 (m, 3 H), 7.67 (dd, $J = 1.7, 7.0$ Hz, 1 H), 7.88 (d, $J = 8.3$ Hz, 2 H);
IR (KBr, cm^{-1}): 3411, 2956, 1706, 1612, 1494, 1407, 854, 749;
MS m/e 584 (MH^+).

15 Compound 13



A mixture of acid **8** (3.20 g, 6.82 mmol), 2-carbomethoxybenzenesulfonamide (1.76 g, 8.18 mmol), EDC (1.57 g, 8.18 mmol), and DMAP (1.00 g, 8.18 mmol) in CH_2Cl_2 (150 ml) was stirred at ambient temperature for 12 hours. The solution was diluted with CH_2Cl_2 (150 ml), washed with 1N HCl (200 ml) and brine. The organic phase was dried over MgSO_4 and evaporated. The residue was purified on a silica gel column which was pre-treated with 0.1% acetic acid in CH_2Cl_2 and eluted with EtOAc, and then 5% to 10% MeOH in EtOAc to afford 4.13 g (91%) of compound **13** as white solid:

^1H NMR (CD_3OD) δ 0.91 (d, $J = 6.6$ Hz, 6 H), 1.40-1.48 (m, 2 H), 1.60-1.69 (m, 1 H), 3.74 (s, 3 H), 4.34 (t, $J = 8.0$ Hz, 2 H), 5.19 (s, 2 H), 5.48 (s, 2 H), 7.03-7.04 (m, 3 H), 7.17-7.21 (m, 1 H), 7.27-7.38 (m, 4 H), 7.46-7.58 (m, 4 H), 7.64-7.67 (m, 1 H), 8.00 (d, $J = 8.2$ Hz, 2 H), 8.12-8.15 (m, 1 H);


IR (KBr, cm^{-1}) 3424, 2955, 1709, 1612, 1590, 1542, 1493, 1435, 1348, 1301, 1258, 750;

MS m/e 666 (MH^+);

Anal. Calcd for $\text{C}_{36}\text{H}_{35}\text{N}_5\text{O}_6 \cdot 1.85\text{H}_2\text{O}$: C, 61.85; H, 5.58; N, 10.02

5 Found: C, 62.24; H, 5.41; N, 9.57.

Compound 14




10 Prepared as described for compound 13.

$^1\text{H-NMR}$ (CD_3OD) δ 0.95 (d, $J = 6.4$ Hz, 6H), 1.35 (t, $J = 7.1$ Hz, 6H), 1.59-1.72 (m, 3H), 4.12-4.23 (m, 4H), 4.47-4.52 (m, 2H), 5.24 (s, 2H), 5.67 (s, 2H), 7.12-7.14 (m, 3H), 7.24-7.27 (m, 1H), 7.49-7.57 (m, 4H), 7.73 (t, $J = 7.1$ Hz, 2H), 7.82 (d, $J = 8.3$ Hz, 2H), 7.97-8.01 (m, 2H), 8.23 (dd, $J = 3.4, 8.4$ Hz, 2H);

15 MS m/e 744 (MH^+);

Compound 15



20

A solution of ester 13 (0.53 g, 0.85 mmol) in THF (1 ml) and MeOH (5 ml) was treated with 1N NaOH (4.23 ml, 4.23 mmol). The solution was stirred at reflux for 12 h. After cooling to room temperature, the solution was acidified with 1N HCl to pH 4.5 and evaporated. The residue was triturated in hot H_2O (10 ml) and filtered.

25 The solid was washed with H_2O and dried in vacuum to give 0.49 g (89% yield) of compound 15 as a white solid:

¹HNMR (CD₃OD) δ 0.91 (d, J = 6.6 Hz, 6 H), 1.43-1.50 (m, 2 H), 1.60-1.69 (m, 1 H), 4.36 (t, J = 8.1 Hz, 2 H), 5.22 (s, 2 H), 5.51 (s, 2 H), 7.03-7.06 (m, 3 H), 7.20-7.21 (m, 1 H), 7.28-7.37 (m, 2 H), 7.44-7.52 (m, 3 H), 7.60-7.69 (m, 4 H), 7.91 (d, J = 8.3 Hz, 2 H), 8.19-8.21 (d, J = 7.4 Hz, 1 H);

IR (KBr, cm⁻¹): 3424, 2957, 1710, 1612, 1591, 1563, 1528, 1512, 1492, 1439, 1406, 1348, 1173, 750;

MS m/e 652 (MH⁺);

Anal. Calcd for C₃₅H₃₃N₅O₆•H₂O C, 62.77; H, 5.27; N, 10.46

10 Found: C, 62.61; H, 5.45; N, 10.27.

A suspension of the acid (1.20 g, 1.84 mmol) in MeOH (50 ml) was triturated with 1N NaOH (3.67 ml, 3.67 mmol) to pH 7.8 and filtered. The filtrate was lyophilized to yield 1.20 g (94% yield) of a white solid as a disodium salt of compound 15:

¹HNMR (CD₃OD) δ 0.91 (d, J = 6.6 Hz, 6 H), 1.41-1.49 (m, 2 H), 1.62-1.69 (m, 1 H), 4.36 (t, J = 8.1 Hz, 2 H), 5.20 (s, 2 H), 5.49 (s, 2 H), 7.00-7.04 (m, 3 H), 7.17-7.20 (m, 1 H), 7.25-7.49 (m, 8 H), 7.65-7.68 (m, 1 H), 7.99-8.03 (m, 3 H);


20 IR (KBr, cm⁻¹) 3424, 2956, 1707, 1608, 1592, 1565, 1504, 1493, 1403, 1330, 1154, 750;

MS m/e 652 (MH⁺);

Anal. Calcd for C₃₅H₃₁N₅Na₂O₆•4H₂O: C, 54.75; H, 5.12; N, 9.12

Found: C, 54.87; H, 5.01; N, 9.11.

Compound 16



5 Compound **16** was prepared by the same procedure as compound **9** using acid **8** and dimethylamine hydrochloride:

¹H NMR (CD₃OD) δ 1.66-1.76 (m, 3H), 2.98 (s, 3H), 3.10 (s, 6H), 4.57 (t, J = 8.3 Hz, 2H), 5.23 (s, 2H), 5.76 (s, 2H), 7.16-7.21 (m, 2H), 7.29-7.31 (m, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.59-7.66 (m, 2H), 7.76 (d, J = 7.8 Hz, 1H), 7.86 (d, J = 8 Hz, 1H);


MS m/e 496 (MH⁺);

IR (KBr, cm^{-1}) 3424, 1708, 1634, 1494, 1404, 1190, 751

Anal. Calcd for $C_{30}H_{33}N_5O_2 \cdot 1.0TFA \cdot H_2O$: C, 61.24; H, 5.78; N, 11.16

15 Found: C, 61.10; H, 5.41; N, 10.83

Compound 17



20 Compound 17 was prepared as a white powder in 87% yield using the same procedure as compound 7 with compound 6 and *m*-bromomethylbenzoic acid methyl ester:

^1H NMR (CDCl_3) δ 0.94 (d, $J = 6.6$ Hz, 6H), 1.47 (m, 2H), 1.69 (m, 1H), 3.91 (s, 3H), 4.32 (m, 2H), 5.15 (s, 2H), 5.46 (s, 2H), 6.84 (d, $J = 8.9$ Hz, 1H), 6.99 (m, 2H), 7.31 (m, 3H), 7.40 (m, 2H), 7.52 (d, $J = 7.3$ Hz, 1H), 7.81 (m, 1H), 7.97 (d, $J = 8.3$ Hz, 1H), 8.05 (s, 1H);


5 IR (KBr, cm^{-1}) 3405, 2952, 1707, 1497, 1407, 1291, 747.

MS m/e 483 (MH^+);

Anal. Calcd for $\text{C}_{29}\text{H}_{30}\text{N}_4\text{O}_3$: C, 72.18; H, 6.27; N, 11.61

Found: C, 72.08; H, 6.32; N, 11.42

10 **Compound 18**



Compound 18 was prepared as a white powder in 77% yield using the same procedure as for compound 8:

15


^1H NMR ($\text{DMSO}-d_6$) δ 0.90 (d, $J = 6.6$ Hz, 6H), 1.43 (m, 2H), 1.64 (m, 1H), 4.32 (m, 2H), 5.09 (s, 2H), 5.42 (s, 2H), 6.99 (m, 2H), 7.08 (m, 1H), 7.19 (m, 5 H), 7.49 (d, $J = 7.3$ Hz, 1H), 7.59 (d, $J = 7.3$ Hz, 1H), 7.72 (d, $J = 8.3$ Hz, 1H), 7.81 (s, 1H);

IR (KBr, cm^{-1}) 3401, 2955, 1702, 1565, 1493, 1391, 750;

20 MS m/e 469 (MH^+);

Anal. Calcd for $\text{C}_{28}\text{H}_{27}\text{N}_4\text{O}_3\text{Na} \cdot 2.25 \text{H}_2\text{O}$: C, 63.32; H, 5.97; N, 10.55

Found: C, 63.31; H, 5.62; N, 10.41

Compound 19


Compound 6 (5.0 g, 14.95 mmol), *o*-bromomethylbenzoic acid methyl ester (4.43g, 19.44 mmol) and Cs₂CO₃ (14.62, 44.85 mmol) were stirred at reflux in acetone (200 mL) for 1 hour. The solvent was evaporated and the residue dissolved in CH₂Cl₂ and filtered. The filtrate was washed with water, dried over MgSO₄ and evaporated. The residue was triturated in EtOAc to give 6.37 g (88% yield) of compound 19 as a white solid:

10

¹H NMR (CDCl₃) δ 0.93 (d, J = 6.6 Hz, 6 H), 1.42-1.50 (m, 2 H), 1.65-1.74 (m, 1 H), 3.96 (s, 1 H), 4.29-4.35 (m, 2 H), 5.46 (s, 2 H), 5.58 (s, 2 H), 6.79 (d, J = 7.9 Hz, 1 H), 6.95-7.06 (m, 3 H), 7.27-7.38 (m, 4 H), 7.48 (d, J = 7.1 Hz, 1 H), 7.78-7.81 (m, 1 H), 8.06 (dd, J = 1.6, 7.6 Hz, 1 H);

15 IR (KBr, cm⁻¹) 1707, 1497, 1403, 1284, 1257, 739;MS m/e 483 (MH⁺);Anal. Calcd for C₂₉H₃₀N₄O₃: C, 72.18; H, 6.27; N, 11.61

C, 71.96; H, 6.21; N, 11.41.

20 **Compound 20**

20

Compound 20 was prepared using the same procedure as for compound 8.

¹H NMR (DMSO-d₆) δ 0.91 (d, J = 6.7 Hz, 6 H), 1.40-1.47 (m, 2 H), 1.61-1.70 (m, 1 H), 4.30-4.35 (m, 2 H), 5.43 (s, 2 H), 5.55 (s, 2 H), 6.85 (dd, J = 1.5, 7.9 Hz, 1 H), 6.89-6.98 (m, 2 H), 7.06-7.26 (m, 6 H), 7.50 (d, J = 7.4 Hz, 1 H), 7.61 (d, J = 6.8 Hz, 1 H), 7.69 (dd, J = 1.9, 7.4 Hz, 1 H);

IR (KBr, cm⁻¹) 3403, 2956, 1701, 1609, 1586, 1562, 1493, 1396, 742;


MS m/e 469 (MH⁺);

Anal. Calcd for C₂₉H₂₇NaN₄O₃• 1.85 H₂O: C, 64.19; H, 5.90; N, 10.64

Found: C, 63.78; H, 5.49; N, 10.50.

10

Compound 21




15 Compound 21 was prepared using the same procedure as for compound 7 with compound 6 and 5-bromovaleronitrile:

¹H NMR (CDCl₃) δ 0.94 (d, J = 6.6 Hz, 6H), 1.43 (m, 2H), 1.63-1.81 (m, 3H), 1.97 (m, 2H), 2.46 (t, J = 7.1 Hz, 2H), 3.99 (t, J = 6.8 Hz, 2H), 4.30 (m, 2H), 5.40 (s, 2H), 6.96-7.12 (m, 3H), 7.29 (m, 3H), 7.44 (d, J = 7.2 Hz, 1H), 7.80 (m, 1H);

20

MS m/e 416 (MH⁺).

Compound 22




22

25

Nitrile 21 (2.89g, 6.96 mmol), ammonium chloride (1.12g, 20.87 mmol)

and sodium azide (1.36 g, 20.87 mmol) were mixed in anhydrous DMF (100 mL) and stirred at 110 °C for 1 day. After additional ammonium chloride (1.12g, 20.87 mmol) and sodium azide (1.36 g, 20.87 mmol) were added, the mixture was stirred for additional 2 days at 110 °C. The solvent was evaporated and the residue purified by silica gel column chromatography (gradient, MeOH in EtOAc 0 to 10%). The residue was dissolved in 1 N NaOH and chromatographed on a C18 column using 10 to 40% MeOH/water to give 1.2 g (38% yield) of compound 22:










¹H NMR (CDCl₃) δ 0.94 (d, J = 6.6 Hz, 6H), 1.60 (m, 2H), 1.70 (m, 1H), 1.91 (m, 2H), 2.00 (m, 2H), 3.03 (t, J = 7.1 Hz, 2H), 4.00 (t, J = 6.8 Hz, 2H), 4.29 (m, 2H), 5.40 (s, 2H), 6.90 (m, 1H), 7.03 (m, 2H), 7.20-7.36 (m, 4H), 7.60 (d, J = 7.5 Hz, 1H); MS m/e 459 (MH⁺).














15

Table 2- Compounds listed below were prepared by alkylation of compound 6 as described for the preparation of compound 7.


#	R ₂	¹ H-NMR Data	MS Data
23a ^a		(CDCl ₃) δ 0.97 (d, J = 6.6 Hz, 6H), 1.46-1.54 (m, 2H), 1.67-1.74 (m, 1H), 4.38-4.43 (m, 2H), 5.21 (s, 2H), 5.58 (bs, 2H), 6.82 (d, J = 7.4 Hz, 1H), 7.02-7.14 (m, 2H), 7.38 (bs, 3H), 7.49 (d, J = 8.7 Hz, 2H), 7.64-7.71 (m, 1H), 7.84-7.92 (m, 1H), 8.20 (d, J = 8.8 Hz, 2H)	470 (MH ⁺)
23b ^b		(CDCl ₃) δ 0.96 (d, J = 6.5 Hz, 6H), 1.32 (t, J = 7.1 Hz, 6H), 1.45-1.74 (m, 3H), 4.03-4.19 (m, 4H), 4.38 (t, J = 7.9 Hz, 2H), 5.16 (s, 2H), 5.54 (s, 2H), 6.84-6.87 (m, 1H), 7.03-7.08 (m, 2H), 7.41-7.45 (m, 5H), 7.53-7.59 (m, 1H), 7.75-7.86 (m, 3H)	561 (MH ⁺)
23c ^c		(DMSO-d ₆) δ 0.90 (d, J = 6.6 Hz, 6H), 1.40 (s, 9H), 1.39-1.47 (m, 2H), 1.61-1.65 (m, 1H), 4.20-4.33 (m, 2H), 4.59 (s, 2H), 5.03 (s, 2H), 5.40 (s, 2H), 6.85 (d, J = 8.6 Hz, 2H), 6.97-7.00 (m, 2H), 7.14-7.26 (m, 4H), 7.29 (d, J = 14.7 Hz, 2H), 7.50 (d, J = 7.7 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H)	554 (MH ⁺)
23d ^c		(DMSO-d ₆) δ 0.91 (d, J = 6.6 Hz, 6H), 1.44 (s, 11H), 1.54-1.68 (m, 1H), 4.31-4.38 (m, 2H), 4.81 (s, 2H), 5.16 (s, 2H), 5.43 (s, 2H), 6.82-7.08 (m, 4H),	554 (MH ⁺)

		7.10-7.12 (m, 2H), 7.15-7.31 (m, 4H), 7.51-7.58 (m, 1H), 7.59-7.64 (m, 1H)	
23e ^c		(DMSO-d ₆) δ 0.90 (d, J = 6.6 Hz, 6H), 1.37 (s, 9H), 1.41-1.48 (m, 2H), 1.59-1.66 (m, 1H), 4.28-4.34 (m, 2H), 4.59 (s, 2H), 5.05 (s, 2H), 5.40 (s, 2H), 6.76-6.80 (dd, J = 2.2, 7.9 Hz, 1H), 6.90-7.01 (m, 4H), 7.09-7.26 (m, 5H), 7.48 (d, J = 7.4 Hz, 1H), 7.58 (d, J = 7.3 Hz, 1H)	554 (MH ⁺)
23f ^a		(DMSO-d ₆) δ 0.91 (d, J = 5.3 Hz, 6H), 1.17 (d, J = 7.1 Hz, 3H), 1.30 (d, J = 7.1 Hz, 3H), 1.48-1.60 (m, 2H), 1.61-1.75 (m, 1H), 4.07 (q, J = 7.2 Hz, 2H), 4.22 (q, J = 6.9 Hz, 2H), 4.43 (t, J = 7.8 Hz, 2H), 4.82 (s, 2H), 5.12 (s, 2H), 5.58 (s, 2H), 7.00-7.01 (m, 2H), 7.10-7.23 (m, 2H), 7.30-7.43 (m, 5H), 7.60 (d, J = 7.5 Hz, 1H), 7.68-7.73 (m, 2H)	641 (MH ⁺)
23g ^a		(DMSO-d ₆) δ 0.90 (d, J = 6.5 Hz, 6H), 1.41-1.55 (m, 2H), 1.49-1.67 (m, 1H), 3.75 (s, 3H), 3.79 (s, 3H), 4.82 (t, J = 7.6 Hz, 2H), 5.16 (s, 2H), 5.43 (s, 2H), 6.88 (d, J = 8.0 Hz, 1H), 6.99-7.04 (m, 2H), 7.15-7.26 (m, 5H), 7.53 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 7.9 Hz, 2H)	512 (MH ⁺)
23h ^a		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.38-1.45 (m, 2H), 1.56-1.64 (m, 1H), 3.64 (s, 3H), 4.24 (t, J = 7.8 Hz, 2H), 5.30 (s, 2H), 5.49 (s, 2H), 6.88-6.91 (m, 1H), 6.91-7.02 (m, 2H), 7.15-7.27 (m, 3H), 7.50 (d, J = 7.8 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.71 (t, J = 7.8 Hz, 1H), 7.99 (d, J = 6.9 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H)	527 (MH ⁺)
23i ^a		(DMSO-d ₆) δ 0.93 (d, J = 6.3 Hz, 6H), 1.42-1.58 (m, 2H), 1.60-1.78 (m, 1H), 3.91 (s, 3H), 4.36 (t, J = 7.5 Hz, 2H), 5.48 (s, 2H), 5.59 (s, 2H), 6.99-7.10 (m, 2H), 7.12-7.30 (m, 4H), 7.35 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 7.5 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 8.18 (dd, J = 1.5, 7.9 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H)	527 (MH ⁺)
23j ^a		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.40-1.50 (m, 2H), 1.58-1.65 (m, 1H), 4.31 (t, J = 7.8 Hz, 2H), 5.22 (s, 2H), 5.43 (s, 2H), 6.95-7.10 (m, 2H), 7.10-7.18 (m, 4H), 7.42-7.56 (m, 3H), 7.60 (d, J = 7.5 Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H)	449 (MH ⁺)
23k ^d		(CDCl ₃) δ 0.95 (d, J = 6.5 Hz, 6H), 1.42-1.51 (m, 2H), 1.63-1.78 (m, 1H), 4.41 (t, J = 8.4 Hz, 2H), 5.18 (s, 2H), 5.59 (s, 2H), 6.88-6.89 (m, 1H), 7.02-7.08 (m, 2H), 7.36-7.38 (m, 3H), 7.51-7.62 (m, 3H), 7.80-7.87 (m, 3H), 10.0 (s, 1H)	453 (MH ⁺)
23l ^d		(CD ₃ OD) δ 0.95 (d, J = 6.5 Hz, 6H), 1.61-1.66 (m, 3H), 2.65 (s, 6H), 4.50-4.53 (m, 2H), 5.27 (s, 2H), 5.70 (s, 2H), 7.14-7.17 (m, 3H), 7.25-7.28 (m, 1H), 7.53-7.64 (m, 4H), 7.71-7.79 (m, 4H)	532 (MH ⁺)

		H)	
23m _d		(CD ₃ OD) δ 0.95 (d, J = 6.5 Hz, 6 H), 1.61-1.66 (m, 3 H), 2.65 (s, 6 H), 4.50-4.53 (m, 2 H), 5.27 (s, 2 H), 5.70 (s, 2 H), 7.14-7.17 (m, 3 H), 7.25-7.28 (m, 1 H), 7.53-7.64 (m, 4 H), 7.71-7.79 (m, 4 H)	503 (MH ⁺)
23n ^c		(DMSO-d ₆) δ 0.93 (d, J = 5.5 Hz, 6H), 1.15 (d, J = 6.2 Hz, 6H), 1.19 (d, J = 6.2 Hz, 6H), 1.46-1.53 (m, 2H), 1.61-1.67 (m, 1H), 4.29-4.34 (s, 2H), 4.35 (s, 2H), 4.52-4.62 (m, 2H), 5.37 (s, 2H), 6.98-7.07 (m, 2H), 7.09-7.26 (m, 4H), 7.48-7.56 (m, 2H)	512 (MH ⁺)
23o ^c		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.22-1.42 (m, 4H), 1.58-1.74 (m, 3H), 1.91-2.01 (m, 2H), 3.88 (t, J = 6.9 Hz, 2H), 4.29 (t, J = 8.1 Hz, 2H), 4.58 (t, J = 8.1 Hz, 2H), 5.35 (s, 2H), 6.98-7.07 (m, 2H), 7.14-7.30 (m, 4H), 7.49 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 7.4 Hz, 1H), 8.12 (t, J = 7.1 Hz, 2H), 8.56 (t, J = 7.9 Hz, 1H), 9.04 (d, J = 5.5 Hz, 2H)	482 (MH ⁺)
23p ^c		(CDCl ₃) δ 0.85 (d, J = 6.6 Hz, 6H), 1.06 (t, J = 7.4 Hz, 3H), 1.34-1.41 (m, 2H), 1.61-1.86 (m, 3H), 3.87 (t, J = 7.3 Hz, 2H), 4.25-4.31 (m, 2H), 5.53 (s, 2H), 6.95-7.08 (m, 3H), 7.23-7.31 (m, 3H), 7.40 (dd, J = 0.6, 1.6 Hz, 1H), 7.77-7.80 (m, 1H)	377 (MH ⁺)
23q ^c		(CDCl ₃) δ 0.93 (d, J = 6.6 Hz, 6H), 1.36-1.43 (m, 2H), 1.60-1.73 (m, 1H), 2.08-2.20 (m, 2H), 2.40 (s, 6H), 2.54 (t, J = 6.9 Hz, 2H), 4.00 (t, J = 6.9 Hz, 2H), 4.26 (t, J = 6.9 Hz, 2H), 5.38 (s, 2H), 6.90-7.10 (m, 3H), 7.22-7.31 (m, 3H), 7.37-7.40 (m, 1H), 7.74-7.80 (m, 1H)	420 (MH ⁺)
23r ^b		(CDCl ₃) δ 0.95 (d, J = 6.6 Hz, 6H), 1.35-1.43 (m, 2H), 1.64-1.75 (m, 1H), 2.36 (s, 6H), 2.67 (t, J = 7.2 Hz, 2H), 4.05 (t, J = 7.2 Hz, 2H), 4.27-4.32 (m, 2H), 5.42 (s, 2H), 7.00-7.11 (m, 3H), 7.28-7.34 (m, 3H), 7.40-7.43 (m, 1H), 7.79-7.83 (m, 1H)	406 (MH ⁺)
23s ^b		(CDCl ₃) δ 0.96 (d, J = 6.6 Hz, 6H), 1.41 (s, 9H), 1.65-1.74 (m, 1H), 2.72 (t, J = 7.5 Hz, 2H), 4.18 (t, J = 7.4 Hz, 2H), 4.27-4.33 (m, 2H), 5.40 (s, 2H), 6.99-7.09 (m, 3H), 7.25-7.31 (m, 3H), 7.43 (d, J = 7.4 Hz, 1H), 7.78-7.81 (m, 1H)	463 (MH ⁺)
23t ^b		(CDCl ₃) δ 0.95 (d, J = 6.6 Hz, 6H), 1.26 (t, J = 7.1 Hz, 3H), 1.36-1.44 (m, 2H), 1.65-1.74 (m, 1H), 2.06-2.15 (m, 2H), 2.43 (t, J = 7.2 Hz, 2H), 3.98 (t, J = 7.2 Hz, 2H), 4.14 (q, J = 7.1 Hz, 2H), 4.28-4.33 (m, 2H), 5.42 (s, 2H), 7.00-7.11 (m, 3H), 7.28-7.34 (m, 3H), 7.44 (d, J = 7.2 Hz, 1H), 7.79-7.82 (m, 1H)	449 (MH ⁺)
23u ^b		(CD ₃ OD) δ 1.66-1.72 (m, 2H), 1.83-1.88 (m, 2H), 2.41 (t, J = 7.2 Hz, 2H), 3.14 (s, 6H), 3.62 (s, 3H), 3.87 (t, J = 8.0 Hz, 2H), 4.02 (t, J = 6.8 Hz, 2H),	450 (MH ⁺)




		5.19 (t, J = 7.8 Hz, 2H), 5.86 (s, 2H), 7.22-7.34 (m, 3H), 7.45-7.48 (m, 1H), 7.67-7.79 (m, 3H), 8.11 (d, J = 8.0 Hz, 1H)	
23v ^b		(CDCl ₃) δ 0.95 (d, J = 6.56 Hz, 6H), 1.26-1.88 (m, 9H), 2.36 (t, J = 6.99, 2H), 3.94 (t, d = 7.05 Hz, 2H), 4.29 (m, 2H), 5.41 (s, 2H), 6.95-7.81 (m, 8H)	430 (MH ⁺)
23w ^b		(CD ₃ OD) δ 0.97 (dd, J = 2.8, 6.6 Hz, 6H), 1.36-1.64 (m, 2H), 1.68-1.78 (m, 1H), 3.67-3.72 (m, 1H), 3.70 (s, 3H), 3.84-3.87 (m, 1H), 4.02 (dd, J = 14.1, 18.0 Hz, 2H), 4.28-4.87 (m, 2H), 5.01-5.12 (m, 1H), 5.47 (dd, J = 16.3, 22.1 Hz, 2H), 7.05-7.17 (m, 3H), 7.28-7.33 (m, 3H), 7.49 (d, J = 7.3 Hz, 1H), 7.65 (d, J = 7.1 Hz, 1H)	506 (MH ⁺)











a, Cs₂CO₃ used as base; b, BEMP used as base; c, BTPP used as base; d, prepared as described in J. Am. Chem. Soc. 1991, 4208; e, NaH used as base.



5

Table 3- Compounds were prepared by converging the acetic acid or benzoic acid to an acid chloride with SOCl₂ or oxalyl chloride and treating the acid chloride with corresponding amine unless otherwise noted.

#	R ₂	¹ H-NMR Data	MS Data
24a		(DMSO-d ₆) δ 0.92 (d, J = 6.5 Hz, 6H), 1.15-1.28 (m, 5H), 1.38-1.60 (m, 2H), 1.60-1.75 (m, 3H), 1.99-2.20 (m, 1H), 2.20-2.30 (m, 1H), 3.98-4.04 (m, 1H), 4.11 (q, J = 7.0 Hz, 2H), 4.18-4.31 (m, 3H), 4.62-4.84 (m, 1H), 4.91-5.00 (m, 2H), 5.37 (s, 2H), 6.95-7.10 (m, 3H), 7.15-7.26 (m, 3H), 7.50 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.4 Hz, 1H)	531 (MH ⁺)
24b		(DMSO-d ₆) δ 0.90 (dd, J = 2.8, 6.5 Hz, 6H), 1.35-1.45 (m, 2H), 1.47-1.71 (m, 1H), 3.17 (s, 3H), 4.00-4.21 (m, 1H), 4.32 (t, J = 7.2 Hz, 2H), 4.71 (s, 1H), 4.86 (s, 1H), 5.40 (d, J = 4.9 Hz, 2H), 6.92 (t, J = 7.0 Hz, 1H), 6.99-7.07 (m, 2H), 7.16-7.34 (m, 3H), 7.50 (d, J = 7.9 Hz, 1H), 7.59-7.65 (m, 1H), 7.88 (d, J = 6.5 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H), 8.35 (d, J = 7.4 Hz, 1H)	525 (MH ⁺)
24c		(DMSO-d ₆) δ 0.90 (d, J = 6.6 Hz, 6H), 1.30 (t, J = 7.1 Hz, 3H), 1.35-1.55 (m, 2H), 1.61-1.75 (m, 1H), 4.26-4.33 (m, 4H), 4.79 (m, 2H), 5.39 (m, 2H), 7.02-7.06 (m, 2H), 7.16-7.28 (m, 5H), 7.40-7.55 (m, 2H), 7.56-7.72 (m, 2H), 7.80-7.81 (m, 1H), 8.26 (s, 1H)	539 (MH ⁺)
		(DMSO-d ₆) δ 0.90 (d, J = 6.6 Hz, 6H),	540 (MH ⁺)

24d		1.30 (t, J = 7.1 Hz, 3H), 1.40-1.44 (m, 2H), 1.51-1.67 (m, 1H), 4.24-4.34 (m, 3H), 4.81 (s, 2H), 5.40 (s, 2H), 7.03-7.05 (m, 2H), 7.08-7.26 (m, 4H), 7.50 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 8.7 Hz, 2H)	
24e		(CDCl ₃) δ 0.94 (d, J = 6.54 Hz, 6H), 1.48 (m, 1H), 1.66 (m, 1H), 3.17 (s, 3H), 4.03 (m, 1H), 4.42 (m, 3H), 5.34 (m, 2H), 6.55 (m, 1H), 6.69 (d, J = 7.68 Hz, 1H), 7.11 (m, 1H), 7.34 (m, 5H), 7.55 (t, J = 7.65 Hz, 1H), 7.66 (t, J = 7.56 Hz, 1H), 7.88 (d, J = 9.06 Hz, 1H), 8.29 (d, J = 7.65 Hz, 1H)	526 (MH ⁺)
24f		(CDCl ₃) δ 0.95 (d, J = 8.78 Hz, 6H), 1.48 (m, 2H), 1.64 (m, 1H), 4.32 (m, 2H), 4.76 (s, 2H), 5.44 (s, 2H), 7.07 - 7.76 (m, 11H), 8.24 (d, J = Hz, 1H), 8.66 (s, 1H)	493 (MH ⁺)
24g		(CDCl ₃) δ 0.96 (d, J = 6.6 Hz, 6H), 1.52 - 1.69 (m, 3H), 3.28 (s, 3H), 4.37 (m, 4H), 5.52 (s, 2H), 6.83-7.89 (m, 12H)	516 (MH ⁺)
24h		(CDCl ₃) δ 0.80 (d, J = 6.6 Hz, 6H), 1.37 (m, 2H), 1.56 (m, 1H), 4.18 (m, 2H), 4.61 (s, 1H), 5.33 (s, 1H), 6.29 (m, 1H), 6.46 (m, 1H), 6.58 (m, 1H), 6.89 - 7.33 (m, 8H), 7.65 (m, 1H)	524 (MH ⁺)
24i		(CDCl ₃) δ 0.97 (d, J = 6.57 Hz, 6H), 1.29-1.69 (m, 3H), 3.84 (s, 3H), 4.32 (m, 2H), 4.72 (s, 1H), 5.46 (s, 1H), 6.55 (d, J = 3.66 Hz, 1H), 6.91-7.43 (m, 8H), 7.77 (m, 1H)	516 (MH ⁺)
24j		(CDCl ₃) δ 0.96 (d, J = 6.51 Hz, 6H), 1.25 (t, J = 7.14 Hz, 3H), 1.38 (m, 2H), 1.55 (m, 1H), 3.65 (s, 2H), 4.06 (q, J = 7.14 Hz, 2H), 4.30 (m, 2H), 4.81 (s, 2H), 5.42 (s, 2H), 6.80 (s, 1H), 7.00 - 7.61 (m, 4H), 7.74 (m, 1H)	561 (MH ⁺)
24k		(CDCl ₃) δ 0.99 (d, J = 6.6 Hz, 6H), 1.57 (m, 2H), 1.74 (m, 1H), 4.35 (m, 2H), 5.08 (s, 2H), 5.52 (s, 2H), 7.00 - 7.45 (m, 7H), 7.82 (m, 1H), 8.82 (s, 1H)	476 (MH ⁺)
24l ^a		(DMSO-d ₆) δ 0.90-0.98 (m, 6H), 1.15-1.23 (m, 2H), 1.60-1.72 (m, 1H), 4.28-4.35 (m, 2H), 5.38 (s, 2H), 6.95-7.03 (m, 3H), 7.15-7.29 (m, 3H), 7.47-7.51 (m, 1H), 7.51-7.63 (m, 1H)	459 (MH ⁺)
24m		(CDCl ₃) δ 0.96 (d, J = 6.57 Hz, 6H), 1.25 (t, J = 7.05 Hz, 6H), 1.56 (m, 1H), 1.72 (m, 1H), 3.10 (d, J = 21.45 Hz, 2H), 3.99 (m, 4H), 4.29 (m, 2H), 4.59 (s, 2H), 5.40 (s, 2H), 7.05-7.37 (m, 9H), 7.46 (d, J = 8.19 Hz, 2H), 7.73 (m, 1H), 8.83 (s, 1H)	618 (MH ⁺)

a, prepared using EDC as coupling reagent.


















Table 4- Acids were prepared by hydrolysis of the corresponding ester using NaOH/MeOH as previously described for compound **8**.

#	R ₂	¹ H-NMR Data	MS Data
25a		(DMSO-d ₆) δ 0.87 (d, J = 6.5 Hz, 6H), 1.38-1.52 (m, 2H), 1.58-1.63 (m, 1H), 3.38-3.48 (m, 1H), 4.24-4.33 (m, 2H), 4.38 (s, 2H), 5.29 (s, 2H), 5.41 (d, J = 4.3 Hz, 2H), 6.89-7.00 (m, 2H), 7.06-7.10 (m, 2H), 7.12-7.24 (m, 5H), 7.46-7.58 (m, 3 H)	629 (MH ⁺)
25b		(DMSO-d ₆) δ 0.90 (d, J = 6.5 Hz, 6H), 0.97-1.06 (m, 2H), 1.14-1.29 (m, 2H), 1.46-1.53 (m, 3H), 1.62-1.69 (m, 1H), 1.80-1.98 (m, 4H), 2.09-2.17 (m, 1H), 3.13 (t, J = 6.2 Hz, 2H), 4.40 (t, J = 8.0 Hz, 2H), 5.22 (s, 2H), 5.56 (s, 2H), 7.00-7.09 (m, 4H), 7.28-7.38 (m, 5H), 7.46-7.49 (m, 1H), 7.68 (d, J = 7.8 Hz, 2H), 8.58 (t, J = 5.7 Hz, 1H)	608 (MH ⁺)
25c		(CD ₃ OD) δ 0.90 (d, J = 6.6 Hz), 1.36-1.43 (m, 2 H), 1.59-1.69 (m, 1 H), 1.99-2.18 (m, 2 H), 4.30-4.37 (m, 2), 4.46-4.57 (m, 1 H), 5.22 (s, 2 H), 5.49 (s, 2 H), 6.98-7.09 (m, 3 H), 7.15-7.19 (m, 1 H), 7.25-7.38 (m, 2 H), 7.42-7.51 (m, 3 H), 7.64-7.69 (m, 1 H), 7.89 (d, J = 8.4 Hz, 2 H)	664 (MH ⁺)
25d		(DMSO-d ₆) δ 0.91 (d, J = 6.6 Hz, 6H), 1.40-1.45 (m, 2H), 1.58-1.65 (m, 1H), 3.79 (s, 3H), 4.25-4.38 (m, 2H), 5.16 (s, 2H), 5.44 (s, 2H), 6.87 (d, J = 8.1 Hz, 1H), 7.02-7.12 (m, 2H), 7.16-7.30 (m, 4H), 7.52 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 8.1 Hz, 2H)	498 (MH ⁺)
25e		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.35-1.42 (m, 2H), 1.58-1.60 (m, 1H), 2.98 (s, 3H), 4.25-4.39 (m, 2H), 5.38 (s, 2H), 5.42 (s, 1H), 5.81 (s, 2H), 6.95 -7.12 (m, 2H), 7.12-7.32 (m, 3H), 7.35-7.73 (m, 3H)	561 (MH ⁺)
25f		(CD ₃ OD) δ 0.91 (d, J = 6.6 Hz, 6H), 1.40-1.47 (m, 2H), 1.59-1.65 (m, 1H), 4.37 (t, J = 8.0 Hz, 2H), 5.27 (s, 2H), 5.52 (s, 2H), 7.01-7.14 (m, 3H), 7.18-7.20 (m, 1H), 7.28-7.33 (m, 2H), 7.48 (d, J = 7.5 Hz, 1H), 7.66-7.69 (m, 1H), 8.12 (s, 2H), 8.56 (d, J = 1.4 Hz, 1H)	513 (MH ⁺)
25g		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.32-1.48 (m, 2H), 1.51-1.71 (m, 1H), 4.27-4.35 (m, 2H), 4.78-4.85 (s, 2H), 5.27-5.45 (s, 2H), 6.92-7.05 (m, 2H), 7.10-7.28 (m, 4H), 7.50 (d, J = 7.9 Hz, 1H), 7.58-7.62 (m, 1H)	474 (MH ⁺)
25h		(DMSO-d ₆) δ 0.92 (d, J = 6.6 Hz, 6H), 1.35-1.51 (m, 4 H), 1.52-1.68 (m, 2H), 1.69-1.82 (m, 2H), 1.92-2.10 (m, 1H), 2.62-2.82 (m, 1H), 3.08-3.18 (m, 1H), 3.71-3.88 (m, 1H), 3.90-4.02 (m, 1H), 4.29-4.36 (m, 2H), 4.77-4.85 (m, 1H), 5.36 (s, 2H), 7.01-7.16 (m, 3H), 7.18-7.28 (m, 3H), 7.49 (d, J = 7.6 Hz, 1H), 7.61 (d, J = 7.3 Hz, 1H)	503 (MH ⁺)
25i		(DMSO-d ₆) δ 0.89-0.93 (m, 6H), 1.34-1.48 (m, 4H), 1.58-1.68 (m, 2H), 1.72-1.93 (m, 1H), 1.95-2.10 (m, 1H), 3.10-3.25 (m, 1H), 3.25-3.50 (m, 2H), 3.70-3.82 (m, 1H), 4.20-4.35 (m, 2H), 4.61-4.79 (m, 2H), 5.20-5.42 (m, 2H), 6.82-7.01 (m, 3H), 7.15-7.26 (m, 3H), 7.48 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.1 Hz, 1H)	503 (MH ⁺)

25j		(DMSO-d ₆) δ 0.90-0.93 (m, 6H), 1.23-1.65 (m, 8H), 2.27-2.32 (m, 1H), 2.51-2.71 (m, 1H), 4.02-4.15 (m, 2H), 4.28-4.38 (m, 2H), 4.50-4.59 (m, 1H), 4.76-4.83 (m, 1H), 5.36 (s, 2H), 6.96-6.99 (m, 2H), 7.08-7.26 (m, 3H), 7.49 (d, J = 7.4 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H), 7.82 (d, J = 7.4 Hz, 1H)	503 (MH ⁺)
25k		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.30-1.37 (m, 2H), 1.58-1.64 (m, 1H), 1.76-1.83 (m, 2H), 1.91 (t, J = 6.9 Hz, 2H), 3.85 (t, J = 7.2 Hz, 2H), 4.29 (t, J = 8.0 Hz, 2H), 5.36 (s, 2H), 6.95-7.06 (m, 2H), 7.15-7.26 (m, 3H), 7.34 (d, J = 7.4 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.61 (d, J = 7.4 Hz, 1H)	421 (MH ⁺)
25l		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.32-1.42 (m, 2H), 1.44-1.52 (m, 2H), 1.59-1.67 (m, 3H), 1.97 (t, J = 6.9 Hz, 2H), 3.35 (t, J = 6.2 Hz, 2H), 3.85 (t, J = 6.9 Hz, 2H), 4.26-4.32 (m, 2H), 5.36 (s, 2H), 6.96-7.07 (m, 2H), 7.15-7.26 (m, 4H), 7.48 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H)	435 (MH ⁺)
25m		(CD ₃ OD) δ 0.94 (d, J = 6.6 Hz, 6H), 1.31-1.51 (m, 4H), 1.64-1.74 (m, 3H), 1.78-1.88 (m, 2H), 2.19 (t, J = 7.6 Hz, 2H), 3.98 (t, J = 7.3 Hz, 2H), 4.34 (t, J = 8.2 Hz, 2H), 5.45 (s, 2H), 7.01-7.06 (m, 1H), 7.10-7.35 (m, 5H), 7.47 (dd, J = 1.7, 6.9 Hz, 1H), 7.67 (dd, J = 1.7, 6.8 Hz, 1H)	449 (MH ⁺)
25n		(CD ₃ OD) δ 0.94 (d, J = 6.3 Hz, 6H), 1.39-1.48 (m, 2H), 1.62-1.70 (m, 1H), 3.58-3.63 (m, 1H), 3.76 (s, 2H), 3.88 (t, J = 9.3 Hz, 1H), 4.19-4.23 (m, 1H), 4.29-4.41 (m, 2H), 4.91-5.02 (m, 2H), 5.44 (s, 2H), 7.03-7.16 (m, 3H), 7.26-7.33 (m, 2H), 7.37 (d, J = 7.5 Hz, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.63 (d, J = 7.2 Hz, 1H)	492 (MH ⁺)







Table 5- Phosponates.

#	R ₂	¹ H-NMR Data	MS Data
26a ^a		(DMSO-d ₆) δ 0.92 (d, J = 6.6 Hz, 6H), 1.15 (t, J = 7.0 Hz, 6H), 1.38-1.46 (m, 2H), 1.63-1.68 (m, 1H), 2.17-2.28 (m, 2H), 3.90-3.98 (m, 4H), 4.00-4.11 (m, 2H), 4.28-4.34 (m, 2H), 5.35 (s, 2H), 6.98-7.09 (m, 2H), 7.15-7.24 (m, 4H), 7.50 (d, J = 7.5 Hz, 1H), 7.59 (d, J = 7.4 Hz, 1H)	498 (MH ⁺)
26b ^b		(CDCl ₃) δ 0.96 (d, J = 6.7 Hz, 6H), 1.21 (d, J = 6.2 Hz, 6H), 1.27 (d, J = 6.2 Hz, 6H), 1.31-1.46 (m, 2H), 1.66-1.75 (m, 1H), 3.74 (d, J = 8.4 Hz, 2H), 3.92 (t, J = 5.4 Hz, 2H), 4.14 (t, J = 5.4	557 (MH ⁺)

		Hz, 2H), 4.33 (t, J = 8.2 Hz, 2H), 4.60-4.71 (m, 2H), 5.43 (s, 2H), 7.02-7.16 (m, 3H), 7.29-7.32 (m, 3H), 7.44 (d, J = 7.3 Hz, 1H), 7.80-7.84 (m, 1H)	
--	--	---	--


a, prepared by 1,4-addition to diethylvinyl phosphonate; **b**, alkylation using methanesulfonic acid 2-(diisopropoxy-phosphorylmethoxy)-ethyl ester.



5

Table 5- Phosphonate esters were cleaved with TMSBr.

#	R ₂	¹ H-NMR Data	MS Data
27a		(CDCl ₃) δ 0.80 (d, J = 6.6 Hz, 6H), 1.12-1.22 (m, 2H), 1.47-1.53 (m, 2H), 1.54-1.70 (m, 2H), 3.90-4.05 (m, 2H), 4.19-4.24 (m, 2H), 5.31 (s, 2H), 6.95 (t, J = 8.5 Hz, 1H), 7.05 (t, J = 7.7 Hz, 1H), 7.12-7.31 (m, 4H), 7.43 (d, J = 7.2 Hz, 1H), 7.58 (d, J = 7.2 Hz, 1H)	442 (MH ⁺)
27b		(CD ₃ OD) δ 0.95 (d, J = 6.7 Hz, 6H), 1.36-1.44 (m, 2H), 1.62-1.74 (m, 1H), 3.56 (d, J = 8.9 Hz, 2H), 3.88 (t, J = 5.3 Hz, 2H), 4.23 (t, J = 5.4 Hz, 2H), 4.35 (t, J = 8.1 Hz, 2H), 5.47 (s, 2H), 6.97-7.05 (m, 1H), 7.08-7.17 (m, 2H), 7.23-7.34 (m, 3H), 7.47 (d, J = 7.3 Hz, 1H), 7.63-7.68 (m, 1H)	473 (MH ⁺)

Compound 28


Compound 6 (4.01 g, 12 mmol) in CH_2Cl_2 (60 mL) was slowly added to a
5 suspension of α,α' -dibromo-p-xylene (15.84, 60 mmol) and BTTP (9.9 g, 18 mmol)
in a mixture of methylene chloride and THF (120 mL, 1:1). The resulting mixture
was stirred at room temperature for 1 h. The solvent was evaporated and the residue
was purified by flash chromatography (EtOAc: hexane = 1: 4 to 2:1) to give a
product which was triturated in EtOAc/ Et_2O to provide 4.12 g (66% yield) of the
10 compound **28** as a white solid:

^1H NMR ($\text{DMSO}-d_6$) δ 0.91 (d, J = 6.6 Hz, 6H), 1.41-1.49 (m, 2H), 1.60-1.67 (m,
1H), 4.32 (t, J = 7.5 Hz, 2H), 4.68 (s, 2H), 5.12 (s, 2H), 5.43 (s, 2H), 7.00-7.04 (m,
2H), 7.15-7.22 (m, 4H), 7.35 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.52 (d, J =
15 7.8 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H);

MS m/e 519, 517 (MH^+);

Anal. Calcd for $\text{C}_{28}\text{H}_{29}\text{BrN}_4\text{O}$: C, 64.99; H, 5.65; N, 10.83

Found: C, 64.97; H, 5.50; N, 10.57


Compound 29

Bromide **28** (103 mg, 0.2 mmol) and N-methylaminoethanol (75 mg, 1 mmol)
25 were stirred in methanol (3 mL) overnight. The solvent was evaporated. The residue
was diluted with EtOAc, washed with water, dried over MgSO_4 , and evaporated. To
the resulting residue in methanol (2 mL) was added 1N HCl in ether (2 mL). The

solvent was evaporated and the residue was dried in vacuum. The solid was triturated in Et₂O to give 99 mg (80% yield) of compound **29** as white powder:

¹H NMR (DMSO-d₆) δ 0.90 (d, J = 6.5 Hz, 6 H), 1.22-1.38 (m, 2 H), 1.49-1.71 (m, 1 H), 2.66 (d, J = 4.8 Hz, 2 H), 2.97-3.08 (m, 2 H), 3.74 (t, J = 5.6 Hz, 2 H), 4.24 (dd, J = 5.4, 13.0 Hz, 1 H), 4.34 (dd, J = 5.1, 13.0 Hz, 1 H), 4.46 (bt, J = 7.8 Hz, 2 H), 5.15 (s, 2 H), 5.66 (s, 2 H), 7.03-7.09 (m, 2 H), 7.16-7.21 (m, 1 H), 7.35-7.52 (m, 5 H), 7.57 (d, J = 8.1 Hz, 2 H), 7.74 (d, J = 7.2 Hz, 1 H), 7.81 (d, J = 7.7 Hz, 1 H);
IR (KBr, cm⁻¹) 3307, 2955, 2594, 1706, 1613, 1492, 1461, 1405, 750;
MS m/e 512 (MH⁺);

Anal. Calcd for C₃₂H₄₀N₅O₂ • 2HCl • H₂O C, 62.23; H, 7.18; N, 11.34
Found: C, 61.96; H, 6.91; N, 11.48.



15


A mixture of bromide **28** (160 mg, 0.31 mmol) and triethyl phosphite (536 mg, 3.88 mmol) were stirred at 135 °C for 30 minutes. The mixture was cooled to room temperature, diluted with Et₂O, washed with water, dried over MgSO₄, and evaporated. The product was initially an oil that slowly crystallized on standing.

The solid was filtered and rinsed with Et₂O to give 160 mg (90% yield) of compound **30**:

¹H NMR (CDCl₃) δ 0.95 (d, J = 6.6 Hz, 6H), 1.21 (t, J = 7.2 Hz, 6H), 1.41-1.49 (m, 2H), 1.66-1.75 (m, 1H), 3.11 (d, J = 21.3 Hz, 2H), 3.93-4.04 (m, 4H), 4.33 (t, J = 8.1 Hz, 2H), 5.08 (s, 2H), 5.45 (s, 2H), 6.82 (dd, J = 2.1, 6.6 Hz, 1H), 6.94-7.03 (m, 2H), 7.29-7.33 (m, 2H), 7.43-7.46 (m, 1H), 7.79-7.82 (m, 1H)
MS m/e 575 (MH⁺).

25

Compound 31



Uracil (5.0 g, 44.6 mmol) and potassium carbonate (7.4 g, 53.5 mmol) were suspended in DMF. *t*-butyl bromoacetate (9.1 g, 46.8 mmol) was added and the reaction mixture was stirred at 40-50 °C for 18 hours. The solvent was evaporated.

- 5 The white residue was taken up in water and extracted with EtOAc and CHCl₃. The organic extracts were dried over MgSO₄ and evaporated. Column chromatography (gradient 2:1 EtOAc/hexanes to 10:1 EtOAc/MeOH) of the residue gave 8.1g (80% yield) of compound **31** as a white solid:


- 10 ¹H NMR (CDCl₃) δ 1.49 (s, 9 H), 4.37 (s, 2 H), 5.75 (dd, J = 7.9, 2.0 Hz, 1 H), 7.11 (d, J = 7.9 Hz, 1 H), 9.22 (s, 1 H);

IR (KBr, cm⁻¹) 3051, 1745, 1715, 1681, 1460, 1234, 1151;

MS m/e 325 (MH⁺).

Anal. Calcd for C₁₀H₁₄N₂O₄: C, 53.09; H, 6.24; N, 12.38


- 15 Found: C, 53.09; H, 6.26; N, 12.43.



- 20 To ester **31** (30g, 132.6 mmol) in THF (20 ml) was added 4 N HCl in dioxane (250 mL). The resulting slurry was stirred for 1 day. The solvent was evaporated and the residue was triturated in Et₂O to give 21.81 g (97% yield) of compound **32** as a white solid:


- 25 ¹H NMR (DMSO-d₆) δ 4.41 (s, 2 H), 5.59 (d, J = 7.8 Hz, 1 H), 7.61 (d, J = 7.8 Hz, 1 H);

MS m/e 171 (MH⁺).

Compound 33

5 Compound 33 was prepared using the same procedure as for compound 16 with 32 and di-*t*-butyl aspartate:


¹H NMR (CDCl₃) δ 1.26 (s, 18H), 2.53 (dd, J = 4.2, 17.4 Hz, 1H), 2.71 (dd, J = 4.8, 17.4 Hz, 1H), 4.20 (d, J = 15.9 Hz, 1H), 4.32 (d, J = 15.9 Hz, 1H), 4.48-4.50 (m, 1H),
10 5.55 (dd, J = 1.5, 8.1 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 8.70 (bs, 1H);
MS m/e 398 (MH⁺).

Compound 34**34**

15


A mixture of 33 (39.0 g, 98.1 mmol), α, α'-dibromo-*p*-xylene (77.8 g, 294 mmol) and BTPP (36.8 g, 118 mmol) in THF (1 L) was stirred at room temperature for 1 h. After removal of the solvent, the residue was taken up in EtOAc (500 ml),
20 washed with water, 1 N HCl and brine, dried over MgSO₄, and evaporated. The residue was purified by column chromatography eluted with EtOAc-hexanes (25% to 75%) to give 38.7 g (68% yield) of compound 34 as a white solid:

¹H NMR (DMSO-*d*₆) δ 1.39 (s, 9H), 1.40 (s, 9H), 2.58-2.70 (m, 2H), 4.38 (s, 2H),
25 4.48-4.55 (m, 1H), 4.69 (s, 2H), 4.96 (s, 2H), 5.78-5.80 (m, 1H), 7.20-7.24 (m, 2H), 7.38-7.40 (m, 2H), 7.64-7.66 (d, J = 7.5 Hz, 2H), 8.64-8.66 (d, J = 7.5 Hz, 2H);
MS m/e 580/582 (MH⁺); 468/470 [M-(*t*-Bu)₂]⁺.

Compound 35

5 Compound 35 was prepared as described for compound 7 above.

¹H NMR (CDCl₃) δ 0.96 (d, J = 6.7 Hz, 6H), 1.44 (s, 9H), 1.51-1.74 (m, 3H), 4.32 (s, 2H), 4.43-4.49 (m, 2H), 5.06 (s, 2H), 5.08 (s, 2H), 5.71 (bs, 2H), 5.78 (d, J = 7.9 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.99-7.09 (m, 2H), 7.05 (d, J = 7.9 Hz, 1H),
10 7.24-7.28 (m, 4H), 7.39-7.44 (m, 4H), 7.95-8.01 (m, 1H);
MS m/e 663 (MH⁺).

Compound 36

15

Compound 36 was prepared in 49% yield using the same procedure of compound 19 with compound 7 and bromide 34:

20 ¹H NMR (CDCl₃) δ 0.92 (d, J = 6.7 Hz, 6H), 1.30-1.44 (m, 2H), 1.43 (s, 9H), 1.44 (s, 9H), 1.60-1.65 (m, 1H), 2.69 (dd, J = 4.3 Hz, 17.1 Hz, 1H), 2.89 (dd, J = 4.3, 17.1 Hz), 4.29 (d, J = 15.8 Hz, 1H), 4.27-4.35 (m, 2H), 4.43 (d, J = 15.8 Hz, 1H), 4.63-4.66 (m, 1H), 5.05 (s, 2H), 5.06 (s, 2H), 5.49 (s, 2H), 5.49 (s, 2H), 5.77 (d, J = 7.8 Hz, 1H), 6.85-6.97 (m, 1H), 6.86-7.00 (m, 1H), 7.14 (d, J = 7.8 Hz, 1H), 7.24-7.35 (m, 6H),
25 7.39 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 7.3 Hz, 1H), 7.82-7.84 (m, 1H);
MS m/e 834 (MH⁺).





















Table 7- Compounds listed below were prepared by treating compound 28 with a nucleophile as described for compound 29.

#	R ₂	¹ H-NMR Data	MS Data
37a		(DMSO-d ₆) δ 0.93 (d, J = 6.5 Hz, 6H), 1.48-1.53 (m, 2H), 1.63-1.69 (m, 1H), 3.40-3.50 (m, 2H), 4.13-4.19 (m, 3H), 4.32-4.38 (m, 3H), 5.13 (s, 2H), 5.30 (b, 3H), 5.44 (s, 2H), 6.99-7.02 (m, 2H), 7.12-7.15 (m, 1H), 7.18-7.30 (m, 3H), 7.39-7.46 (m, 4H), 7.54-7.60 (m, 2H), 8.38-8.42 (m, 2 H)	558 (MH ⁺)
37b		(CD ₃ OD) δ 0.99 (d, J = 6.2 Hz, 6H), 1.42 (t, J = 7.0 Hz, 9H), 1.65-1.77 (m, 3H), 3.21-3.29 (m, 6H), 4.48 (s, 2H), 4.58 (t, J = 7.6 Hz, 2H), 5.25 (s, 2H), 5.76 (s, 2H), 7.17-7.18 (m, 3H), 7.30-7.33 (m, 1H), 7.56-67 (m, 6H), 7.76-7.87 (m, 2H)	538 (MH ⁺)
37c		(DMSO-d ₆) δ 0.91 (d, J = 6.6 Hz, 6H), 1.43-1.50 (m, 2H), 1.60-1.67 (m, 1H), 2.97 (s, 6H), 3.34-3.40 (m, 2H), 3.84-3.93 (m, 2H), 4.32 (t, J = 8.0 Hz, 2H), 4.54 (s, 2H), 5.17 (s, 2H), 5.31 (t, J = 4.8 Hz, 1H), 5.42 (s, 2H), 7.00-7.05 (m, 2H), 7.15-7.27 (m, 4H), 7.47-7.59 (m, 4H)	526 (MH ⁺)
37d		(DMSO-d ₆) δ 0.92 (d, J = 6.6 Hz, 6H), 1.44-1.51 (m, 2H), 1.61-1.70 (m, 1H), 3.01 (s, 3H), 3.23-3.28 (m, 2H), 3.43-3.55 (m, 2H), 3.83-4.01 (m, 4H), 4.33 (t, J = 8.0 Hz, 2H), 4.64 (s, 2H), 5.18 (s, 2H), 5.42 (s, 2H), 7.00-7.05 (m, 2H), 7.16-7.28 (m, 4H), 7.47-7.59 (m, 6H)	
37e		(DMSO-d ₆) δ 0.92 (d, J = 6.6 Hz, 6H), 1.45-1.53 (m, 2H), 1.59-1.70 (m, 1H), 3.56-3.62 (m, 8H), 3.84-3.90 (m, 2H), 3.97-4.01 (m, 2H), 4.35 (t, J = 7.9 Hz, 2H), 4.70 (s, 2H), 5.19 (s, 2H), 5.45 (s, 2H), 7.01-7.05 (m, 2H), 7.18-7.29 (m, 4H), 7.49-7.60 (m, 6H), 8.15 (bs, 2H)	567 (MH ⁺)
37f		(DMSO-d ₆) δ 0.16 (d, J = 6.6 Hz, 6H), 0.73-0.84 (m, 2H), 0.86-0.98 (m, 1H), 3.52 (s, 3H), 3.61-3.69 (m, 2H), 4.07 (s, 4H), 4.15 (bs, 2H), 4.43 (bs, 2H), 4.81 (bs, 2H), 6.28-6.38 (m, 3H), 6.43-6.50 (m, 1H), 6.62-6.80 (m, 6H), 6.84-6.95 (m, 2H)	584 (MH ⁺)
		(DMSO-d ₆) δ 0.88 (d, J = 6.6 Hz, 6H),	516 (MH ⁺)

37g		1.40-1.48 (m, 2H), 1.58-1.67 (m, 1H), 4.31 (t, J = 8.0 Hz, 2H), 5.11 (s, 2H), 5.41 (s, 2H), 5.81 (s, 2H), 6.98-7.02 (m, 2H), 7.11-7.27 (m, 4H), 7.41-7.58 (m, 6H), 8.12-8.17 (m, 2H), 8.60 (t, J = 7.8 Hz, 1H), 9.17 (d, J = 5.4 Hz, 2H)	
37h		(CD ₃ OD) δ 0.93 (d, J = 6.6 Hz, 6H), 1.40-1.48 (m, 2H), 1.60-1.72 (m, 1H), 2.38-2.50 (m, 4H), 2.84 (t, J = 5.0 Hz, 4H), 3.50 (s, 2H), 4.33-4.39 (m, 2H), 5.16 (s, 2H), 5.49 (s, 2H), 6.99-7.11 (m, 3H), 7.16-7.21 (m, 1H), 7.26-7.39 (m, 6H), 7.48 (dd, J = 1.3, 6.8 Hz, 1H), 7.65-7.68 (m, 1H)	523 (MH ⁺)
37i		(CDCl ₃) δ 0.95 (d, J = 6.6 Hz, 6H), 1.41-1.49 (m, 2H), 1.46 (s, 9H), 1.66-1.75 (m, 1H), 2.45-2.90 (m, 8H), 3.13 (s, 2H), 4.32 (t, J = 8.1 Hz, 2H), 5.10 (s, 2H), 5.44 (s, 2H), 6.86-6.89 (m, 1H), 6.98-7.04 (m, 2H), 7.25-7.34 (m, 2H), 7.43-7.46 (m, 1H), 7.77-7.82 (m, 1H)	637 (MH ⁺)
37j		(CDCl ₃) δ 0.95 (d, J = 6.6 Hz, 6H), 1.25 (t, J = 7.1 Hz, 3H), 1.41-1.49 (m, 2H), 1.61-1.87 (m, 7H), 2.21-2.34 (m, 1H), 2.79-2.90 (m, 2H), 3.43-3.54 (m, 2H), 4.13 (q, J = 7.1 Hz, 2H), 4.32 (t, J = 8.1 Hz, 2H), 5.09 (s, 2H), 5.44 (s, 2H), 6.87-6.90 (m, 1H), 6.97-7.02 (m, 1H), 7.26-7.34 (m, 8H), 7.43-7.47 (m, 1H), 7.77-7.82 (m, 1H)	594 (MH ⁺)
37k		(CD ₃ OD) δ 0.99 (d, J = 6.2 Hz, 6H), 1.72-1.74 (m, 3H), 3.31-3.47 (m, 8H), 3.79 (s, 3H), 3.86 (s, 2H), 4.39 (s, 2H), 4.62 (t, J = 6.7 Hz, 2H), 5.23 (s, 2H), 5.83 (s, 2H), 7.20-7.21 (m, 3H), 7.34-7.36 (m, 1H), 7.53-7.61 (m, 4H), 7.68-7.73 (m, 2H), 7.78-7.82 (m, 1H), 7.94-7.97 (m, 1H)	595 (MH ⁺)
37l		(CDCl ₃) δ 0.95 (d, J = 6.5 Hz, 6H), 1.26 (t, J = 7.1 Hz, 3H), 1.41-1.49 (m, 3H), 1.68-1.77 (m, 5H), 1.94-2.05 (m, 2H), 2.23 (d, J = 6.9 Hz, 2H), 2.79-2.92 (m, 2H), 3.47-3.58 (m, 2H), 4.14 (q, J = 7.1 Hz, 2H), 4.29-4.35 (m, 2H), 5.10 (s, 2H), 5.45 (s, 2H), 6.88-6.91 (m, 1H), 6.99-7.02 (m, 2H), 7.28-7.45 (m, 7H), 7.80-7.83 (m, 1H), 8.52-8.54 (m, 1H)	608 (MH ⁺)
37m		(DMSO-d ₆) δ 0.90 (d, J = 6.5 Hz, 6H), 1.48-1.53 (m, 2H), 1.63-1.69 (m, 1H), 3.38-3.48 (m, 4H), 4.28-4.33 (m, 2H), 4.42 (s, 2H), 4.57 (t, J = 5.4 Hz, 2H), 5.10 (s, 2H), 5.41 (s, 2H), 6.98-7.01 (m, 2H), 7.12-7.24 (m, 4H), 7.39-7.46 (m, 4H), 7.50-7.54 (m, 2H), 7.57-7.59 (m, 2H), 8.99 (b, 4H)	513 (MH ⁺)
37n		(DMSO-d ₆) δ 0.91 (d, J = 6.6 Hz, 6H), 1.42-1.47 (m, 2H), 1.61-1.67 (m, 1H), 3.20 (s, 2H), 3.57 (s, 3H), 3.77 (s, 2H), 4.30-4.34 (m, 2H), 5.10 (s, 2H), 5.42 (s, 2H), 6.98-7.01 (m, 2H), 7.14-7.18 (m, 2H), 7.20-7.27 (m, 4H), 7.31-7.33 (m, 2H), 7.51 (d, J = 4.8, 1H), 7.60 (d, J = 4.7, 1H)	543 (MH ⁺)

37o		(DMSO-d ₆) δ 0.91 (d, J = 3.9, 6H), 1.42-1.46 (m, 2H), 1.61-1.69 (m, 1H), 2.78 (s, 3H), 2.91 (s, 3H), 3.73 (s, 2H), 4.31-4.33 (m, 2H), 5.09 (s, 2H), 5.42 (s, 2H), 6.99-7.01 (m, 2H), 7.14-7.33 (m, 8H), 7.51 (d, J = 4.8, 1H), 7.60 (d, J = 4.7, 1H)	556 (MH ⁺)
37p		(CD ₃ OD) δ 0.91 (d, J = 6.5 Hz), 1.37-1.44 (m, 2H), 1.59-1.71 (m, 1H), 2.46-2.55 (m, 1H), 2.79-2.87 (m, 1H), 3.68 (t, J = 7.4 Hz, 1H), 3.88 (s, 2H), 4.34 (t, J = 8.0 Hz, 2H), 5.14 (s, 2H), 5.49 (s, 2H), 7.01-7.09 (m, 3H), 7.16-7.19 (m, 1H), 7.28-7.38 (m, 6H), 7.45-7.49 (m, 1H), 7.65-7.68 (m, 1H)	587 (MH ⁺)
37q		(CD ₃ OD) δ 0.95 (d, J = 6.6 Hz, 6H), 1.44-1.52 (m, 2H), 1.65-1.73 (m, 1H), 4.21 (s, 3H), 4.38 (t, J = 8.2 Hz, 2H), 4.71 (s, 2H), 5.19 (s, 2H), 5.51 (s, 2H), 7.04-7.09 (m, 3H), 7.17-7.22 (m, 1H), 7.28-7.37 (m, 2H), 7.45 (d, J = 8.2 Hz, 2H), 7.50-7.55 (m, 3H), 7.65-7.73 (m, 2H), 8.05 (d, J = 8.3 Hz, 1H), 8.31 (t, J = 8.1 Hz, 1H), 8.79 (d, J = 5.8 Hz, 1H)	562 (MH ⁺)
37r		(DMSO-d ₆) δ 0.90 (d, J = 6.5 Hz, 6H), 1.51-1.58 (m, 2H), 1.63-1.69 (m, 1H), 3.11-3.24 (m, 2H), 3.27-3.40 (m, 2H), 3.75-3.83 (m, 2H), 4.20-4.29 (m, 2H), 4.41-4.47 (m, 2H), 5.14 (s, 2H), 5.63 (s, 2H), 7.05-7.07 (m, 2H), 7.18-7.21 (m, 1H), 7.31-7.35 (m, 1H), 7.42-7.51 (m, 4H), 7.56 (d, J = 7.4 Hz, 2H), 7.72 (d, J = 7.6 Hz, 1H), 7.77 (d, J = 6.9 Hz, 1H)	581 (MH ⁺)
37s		(CD ₃ OD) δ 0.93 (d, J = 6.5 Hz, 6H), 1.40-1.48 (m, 2H), 1.62-1.71 (m, 1H), 2.54-2.70 (m, 10H), 2.92-3.10 (m, 2H), 3.53 (s, 2H), 4.36 (t, J = 8.1 Hz, 2H), 4.53 (t, J = 6.8 Hz, 1H), 5.17 (s, 2H), 5.50 (s, 2H), 7.00-7.10 (m, 3H), 7.17-7.20 (m, 1H), 7.26-7.40 (m, 6H), 7.47-7.50 (m, 1H), 7.66-7.68 (m, 1H)	696 (MH ⁺)
37t		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.42-2.30 (10H), 2.64-2.75 (m, 2H), 3.31-3.45 (m, 2H), 4.31 (t, J = 8.0 Hz, 2H), 5.10 (bs, 2H), 5.41 (s, 2H), 6.98-7.01 (m, 2H), 7.14-7.26 (m, 8H), 7.50 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 7.5 Hz, 1H)	566 (MH ⁺)
37u		(CD ₃ OD) δ 0.92 (d, J = 6.6 Hz, 6H), 1.38-1.47 (m, 2H), 1.63-1.68 (m, 1H), 1.70-1.83 (m, 4H), 2.00-2.10 (m, 2H), 2.16-2.25 (m, 1H), 2.66 (d, J = 6.0 Hz, 2H), 2.84-2.93 (m, 2H), 3.50 (bs, 2H), 4.36 (t, J = 8.3 Hz, 2H), 4.47 (t, J = 5.8 Hz, 1H), 5.17 (s, 2H), 5.50 (s, 2H), 7.03-7.09 (m, 3H), 7.17-7.20 (m, 1H), 7.29-7.38 (m, 6H), 7.48 (d, J = 7.2 Hz, 1H), 7.67 (d, J = 7.1 Hz, 1H)	681 (MH ⁺)
37v		(DMSO-d ₆) δ 0.89 (d, J = 6.6 Hz, 6H), 1.07-1.23 (m, 2H), 1.40-1.47 (m, 2H), 1.58-1.69 (m, 4H), 1.80-1.94 (m, 2H), 2.11 (d, J = 6.2 Hz, 2H), 2.67-2.75 (m, 2H), 3.32-3.38 (m, 2H), 4.31 (t, J = 7.9 Hz, 2H), 5.09 (s, 2H), 5.41 (s, 2H)	580 (MH ⁺)

		6.98-7.01 (m, 2H), 7.14-7.32 (m, 8H), 7.50 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H)	
--	--	--	--

Compound 38


5

The t-butyl groups of ester **35** were removed with 4N HCl in dioxane using the procedure described for **32**. The acid was then treated with 2 equivalents of 1 N NaOH in MeOH to provide a di-sodium salt of **38**:


- 10 ^1H NMR (CD_3OD) δ 0.82 (d, J = 6.6 Hz, 6H), 1.29-1.37 (m, 2H), 1.51-1.57 (m, 1H), 2.60-2.63 (m, 2H), 4.23-4.28 (m, 2H), 4.40-4.53 (m, 3H), 5.00 (s, 2H), 5.06 (s, 2H), 5.40 (s, 2H), 5.67 (d, J = 8.1 Hz, 1H), 6.93-7.10 (m, 4H), 7.07-7.10 (m, 1H), 7.18-7.30 (m, 6H), 7.40 (d, J = 6.9 Hz, 1H), 7.49 (d, J = 7.5 Hz, 1H), 7.59 (d, J = 6.9 Hz, 1H);
- 15 IR (KBr, cm^{-1}) 3422, 2957, 1705, 1662, 1612, 1493, 1456, 1407, 747;
MS m/e 722 (MH^+).

Compound 39


20



- 25 Mercaptoethanol (3 g, 38.39 mmol) and K_2CO_3 (6.36 g, 46.01 mmol) were suspended in acetone (50 ml). Ethylbromoacetate (7.05 g, 42.21 mmol) was added. The resulting mixture was stirred at room temperature overnight. It was filtered and the filtrate was evaporated to give 6 g (95 % yield) of compound **39** as a yellow oil.


Compound 40

- 5 DEAD (506.77 mg, 2.9 mmol) was added to a stirred mixture of 2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester (500 mg 2.42 mmol) (Meanwell et al, *J.Org. Chem.* **1995**, 60, 1565-1582.), PPh₃ (763.21 mg, 2.90 mmol), and (2-hydroxy-ethylsulfanyl)-acetic acid ethyl ester (497.75 mg, 3.03 mmol) in dry THF (20 ml) at room temperature. The mixture was stirred for 48 hours. The solvent was removed
10 and the residue purified by column chromatography (25 % EtOAc/Hexane) to give 422 mg (49% yield) of the desired compound **40**.

Compound 41

15

Compound **40** (400 mg, 1.13 mmol) in THF (5 ml) was stirred with 21%NaOEt in EtOH (23.15 mg, 0.43 mmol) at room temperature overnight. The mixture was evaporated to give 284 mg (89 % yield) of compound **41**.


Compound 42

- 5 Compound 42 was prepared as with [2-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-ethylsulfanyl]-acetic acid ethyl ester and compound 6 as described for compound 7.

¹H NMR (DMSO-d₆) δ 0.90 (d, J = 6.6, 6 H), 1.18 (t, J = 7.1, 3 H), 1.37-1.44 (m, 2 H), 1.59-1.65 (m, 1 H), 2.94 (t, J = 6.8, 2 H), 3.45 (s, 2 H), 4.01-4.13 (m, 4 H), 4.26-4.32 (m, 2 H), 5.36 (s, 2 H), 6.98-7.08 (m, 2 H), 7.14-7.28 (m, 4H), 7.48 (d, J = 7.4, 2H), 7.59 (d, J = 7.4, 2H);
10 MS m/e 481 (MH⁺).


Compound 43

15




- Compound 42 (110 mg, 0.23 mmol) was dissolved in MeOH (10 ml). 1N NaOH (13.73 mg, 0.34 mmol) was added. The reaction was stirred overnight then the
20 solvent was removed. The residue was adjusted to pH 5 with 1N HCl. The white precipitate was filtered, washed with water and dried under vacuum to give 54 mg (52% yield) of compound 43 as a white solid.

¹H NMR (DMSO-d₆) δ 0.89 (d, J = 6.6, 6H), 1.34-1.39 (m, 2H), 1.59-1.65 (m, 1H),
25 2.81 (t, J = 7.1, 2H), 3.01 (s, 2H), 4.08 (t, J = 6.8, 2H), 4.28 (t, J = 8.0, 2H), 5.35 (s, 2H), 6.95-7.05 (m, 2H), 7.14-7.25 (m, 3H), 7.38 (d, J = 6.9, 1H), 7.48 (d, J = 7.6, 1H), 7.59 (d, J = 7.4, 1H);
MS m/e 453 (MH⁺).

Compound 44

- 5 Compound 43 (100 mg, 0.22 mmol) was dissolved in acetic acid (7 ml). Sodium perborate tetrahydrate (37.39 mg, 0.24 mmol) was added. The mixture was heated at 50°C overnight. Then the acetic acid was removed. The residue was taken into water and acidified with 1N HCl to pH 5. The product was extracted with EtOAc. The combined organic extracts were dried over Na₂SO₄, and evaporated to give 63 mg (61% yield) of the compound 44.

¹H NMR (DMSO-d₆) δ 0.88 (d, J = 6.6, 6 H), 1.23 (t, J = 7.1, 2 H), 1.32-1.39 (m, 2 H), 1.56-1.65 (m, 2 H), 3.16 (s, 1 H), 3.88-3.95 (m, 1 H), 4.25-4.32 (m, 2 H), 5.35 (s, 2 H), 6.97-7.08 (m, 2 H), 7.14-7.29 (m, 4 H), 7.48 (d, J = 7.4, 1H), 7.59 (d, J = 7.0, 1H);
15 MS m/e 469 (MH⁺).
MS m/e 469 (MH⁺).


Compound 45

20

- Compound 44 (110 mg, 0.24 mmol) was dissolved in acetic acid (7 ml). Sodium perborate tetrahydrate (149.58 mg, 0.97 mmol) was added and the mixture heated at 55 °C overnight. Acetic acid was removed and the residue taken into water and acidified with 1N HCl to pH 5. The aqueous layer was extracted with EtOAc. The combined organic extracts were dried over Na₂SO₄, and evaporated to give 63 mg (53% yield) of compound 45 as a white solid.

^1H NMR ($\text{DMSO}-d_6$) δ 0.90 (d, $J = 5.0$, 6H), 1.35-1.51 (m, 2H), 1.56 (s, 2H), 1.60-1.70 (m, 2H), 3.70-3.75 (m, 2H), 4.28-4.33 (m, 3H), 5.35 (s, 2H), 6.98-7.06 (m, 2H), 7.13-7.26 (m, 4H), 7.47-7.51 (m, 1H), 7.56-7.62 (m, 2H);
MS m/e 485 (MH^+).

5

Compound 46

A solution of compound 6 (50 mg, 0.15 mmol) and triethylamine (15 mg, 0.15 mmol) in DMF (2 mL) was cooled to 0°C . To this solution was added ethyl isocyanate (11 mg, 0.15 mmol) and the resulting mixture was stirred at 0°C for 4 hours. The reaction mixture was diluted with EtOAc, washed with H_2O , and dried over MgSO_4 . Purification by flash column chromatography (straight EtOAc) gave 30 mg (49% yield) of compound 46:

15

^1H NMR (CDCl_3) δ 0.93 (d, $J = 6.7$ Hz, 6H), 1.28 (t, $J = 7.3$ Hz, 3H), 1.32-1.40 (m, 2H), 1.63-1.72 (m, 1H), 3.44-3.54 (m, 2H), 4.24-4.30 (m, 2H), 5.46 (s, 2H), 7.13-7.18 (m, 2H), 7.31-7.32 (m, 3H), 7.45-7.54 (m, 1H), 7.80-7.83 (m, 1H), 8.18-8.21 (m, 1H), 8.63-8.70 (m, 1H);










20 MS m/e 406 (MH^+).

Table 8 - The compounds were prepared from compound 6 and commercially available isocyanates using the method above.


#	R ₂	¹ H-NMR Data	MS Data
47a		(CDCl ₃) δ 0.98 (d, J = 6.8 Hz, 6H), 1.42-1.50 (m, 2H), 1.67-1.78 (m, 1H), 4.29-4.35 (m, 2H), 5.48 (s, 2H), 7.18-7.23 (m, 3H), 7.29-7.36 (m, 3H), 7.43 (t, J = 7.9 Hz, 2H), 7.52-7.55 (m, 1H), 7.63-7.68 (m, 2H), 7.80-7.84 (m, 1H), 8.27-8.33 (m, 1H), 10.88 (s, 1H)	No data
47b		(CDCl ₃) δ 0.87 (d, J = 6.6 Hz, 6H), 1.29-1.38 (m, 2H), 1.58-1.69 (m, 1H), 4.19-4.25 (m, 2H), 4.65 (d, J = 5.8 Hz, 2H), 5.39 (s, 2H), 7.12-7.16 (m, 2H), 7.27-7.38 (m, 8H), 7.42-7.46 (m, 1H), 7.77-7.80 (m, 1H), 8.20-8.23 (m, 1H), 9.11-9.16 (m, 1H)	468 (MH ⁺)
47c		(CDCl ₃) δ 0.97 (d, J = 6.7 Hz, 6H), 1.42 (t, J = 7.1 Hz, 3H), 1.43-1.51 (m, 2H), 1.68-1.77 (m, 1H), 4.28-4.34 (m, 2H), 4.40 (q, J = 7.1 Hz, 2H), 5.46 (s, 2H), 7.20-7.25 (m, 2H), 7.28-7.33 (m, 3H), 7.53-7.56 (m, 1H), 7.73 (d, J = 8.7 Hz, 2H), 7.78-7.82 (m, 1H), 8.10 (d, J = 8.7 Hz, 2H), 8.26-8.29 (m, 1H), 11.14 (s, 1H)	526 (MH ⁺)
47d		(CDCl ₃) δ 0.96 (d, J = 6.6 Hz, 6H), 1.33 (t, J = 7.1 Hz, 3H), 1.39-1.47 (m, 2H), 1.64-1.75 (m, 1H), 4.00 (d, J = 5.3 Hz, 1H), 4.18-4.32 (m, 5H), 5.42 (s, 2H), 7.13-7.19 (m, 2H), 7.28-7.35 (m, 3H), 7.46-7.52 (m, 1H), 7.77-7.81 (m, 1H), 8.14-8.20 (m, 1H), 9.30 (t, J = 5.3 Hz, 1H)	464 (MH ⁺)
47e		(DMSO-d ₆) δ 0.98 (d, J = 6.2 Hz, 6H), 1.67-1.77 (m, 3H), 4.51 (t, J = 7.9 Hz, 2H), 5.75 (s, 2H), 7.20-7.28 (m, 2H), 7.33-7.40 (m, 1H), 7.46-7.56 (m, 2H), 7.71 (d, J = 7.3 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 8.09-8.14 (m, 1H), 10.18 (s, 1H)	456 (MH ⁺)
47f		(DMSO-d ₆) δ 0.91 (d, J = 6.6 Hz, 6H), 1.41-1.48 (m, 2H), 1.63-1.67 (m, 1H), 4.34 (t, J = 7.7 Hz, 2H), 5.05 (s, 2H), 5.46 (s, 2H), 6.87 (s, 1H), 7.01 (t, J = 3.7 Hz, 2H), 7.15-7.33 (m, 5H), 7.42 (d, J = 8.6 Hz, 2H), 7.52-7.64 (m, 4H), 7.85 (d, J = 8.7 Hz, 2H), 8.96 (s, 1H), 9.20 (s, 1H)	603 (MH ⁺)
47g ^a		(CD ₃ OD) δ 0.90 (d, J = 6.6 Hz, 6H), 1.36-1.48 (m, 2H), 1.57-1.69 (m, 1H), 2.73-2.88 (m, 2H), 4.27-4.42 (m, 2H), 4.61-4.74 (m, 1H), 5.11 (s, 2H), 5.47 (s, 2H), 7.00-7.14 (m, 4H), 7.26-7.32 (m, 4H), 7.35-7.52 (m, 5H), 7.63-7.66 (m, 1H), 7.83 (d, J = 8.7 Hz, 2H)	718 (MH ⁺)
47h ^b		(DMSO-d ₆) δ 0.91 (d, J = 6.5 Hz, 6H), 1.41-1.48 (m, 2H), 1.60-1.67 (m, 1H), 2.77-2.98 (m, 2H), 3.61 (s, 3H), 3.64 (s, 3H), 4.32 (t, J = 7.8 Hz, 2H), 4.78-4.85 (m, 1H), 5.05 (s, 2H), 5.42 (s, 2H), 6.99-7.02 (m, 2H), 7.15-7.24 (m, 4H), 7.31 (d, J = 8.6 Hz, 2H), 7.42 (d, J = 8.6 Hz,	746 (MH ⁺)

		2H), 7.52 (d, J = 8.9 Hz, 3H), 7.60 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.7 Hz, 2H), 8.74-8.77 (m, 2H), 8.94 (s, 1H)	
--	--	--	--

a, hydrolysis of 47a as described for compound 8; b, amide bond formation as described for compound 9.

Compound 48


5



Compound 47e (100 mg, 0.22 mmol) was heated at 100 °C for 2 hours in a mixture of DMF (10 ml) and H₂O (30 mL). The aqueous reaction mixture was extracted with EtOAc. The organic extracts were dried over MgSO₄, evaporated, and purified by flash column chromatography (straight EtOAc) to give 18 mg (22% yield) of compound 48:

¹H NMR (CDCl₃) δ 0.98 (d, J = 6.8 Hz, 6H), 1.38-1.46 (m, 2H), 1.68-1.76 (m, 1H), 4.28-4.33 (m, 2H), 5.49 (m, 2H), 7.17-7.28 (m, 2H), 7.33-7.35 (m, 2H), 7.53-7.56 (m, 1H), 7.82-7.86 (m, 1H), 8.18-8.21 (m, 1H), 8.63 (bs, 1H).

Compound 49



20

Compound 49 was prepared from compound 2 and (2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-acetic acid methyl ester (Meanwell et al, *J.Org. Chem.* 1995, 60, 1565-1582.) as described for compound 3 without treatment with tetrabutylammonium fluoride hydrate.

25


¹H NMR (CDCl₃) δ 3.41 (s, 3H), .77 (s, 3H), 4.65 (s, 2H), 5.57 (s, 2H), 6.92-7.11 (m, 1H), 7.11-7.27 (m, 3H), 7.32-7.46 (m, 3H), 7.66 (d, J = 9.0 Hz, 1H), 7.67-7.83 (m, 1H), 7.88 (d, J = 9.0 Hz, 1H);

MS m/e 414 (MH⁺);

Anal. Calcd for C₁₉H₁₈N₄O₅S: C, 55.07; H, 4.38; N, 13.52

Found: C, 55.38; H, 4.58; 13.64.


5 **Compound 49a**



10 Compound **49** (3 g, 7.23 mmol) and tetrabutylammonium fluoride (1.89 g, 7.23 mmol) were refluxed in THF (300 ml) for 3 hours. After cooling, the solvent was evaporated. The residue was diluted with water and extracted with diethyl ether and EtOAc. The combined organic extracts were dried over Na₂SO₄, and evaporated to give 2.3 g (96% yield) of the desired compound **49a** as a yellow solid.

15 ¹H NMR (DMSO-d₆) δ 3.61 (s, 3H), 4.79 (s, 2H), 5.29 (s, 2H), 7.00-7.21 (m, 6H), 7.43 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H).
MS m/e 336 (MH⁺).

20 **Compound 49a and 49b**




To compound **49a** (300 mg, 1.02 mmol) in DMF (10 ml) was added NaH (60% in mineral oil, 45.2 mg, 1.13 mmol) at room temperature. After stirring for 1
25 hour, 1-bromo-3-methyl-2-butene (168.42 mg, 1.13 mmol) was added and the mixture was stirred overnight. The mixture was diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na₂SO₄ and evaporated. The residue was purified by column chromatography (hexane/EtOAc = 4:1) to afford 76 mg (18% yield) of compound **49b** and 120 mg
30 (25% yield) of compound **49c** both as a white solids.

Compound 49b:

^1H NMR (DMSO- d_6) δ 1.65 (s, 3H), 1.86 (s, 3H), 3.70 (s, 3H), 4.80 (s, 2H), 4.95-4.98 (m, 2H), 5.03-5.05 (m, 1H), 5.38 (s, 2H), 7.01-7.08 (m, 2H), 7.15-7.25 (m, 4H), 7.43 (d, $J = 7.5$, 1H), 7.59 (d, $J = 7.4$, 1H);

5 MS m/e 405 (MH^+).

Compound 50

10 To compound 3 (1.5 g, 4.929 mmol) suspended in CH_3CN (30 ml) was added acrylonitrile (523 mg, 9.858 mmol) followed by MTBD (38 mg, 0.246 mmol). The reaction mixture was heated at 50-60 $^\circ\text{C}$ for 16 hours. The solution became transparent. The solvent was stripped. The yellow oil residue was taken up in ether and triturated to give 1.67 g of compound 50 as a pale yellow solid:

15


^1H NMR (CDCl_3) δ 2.26 (s, 3H), 2.75 (t, $J = 6.7$ Hz, 2H), 4.82 (t, $J = 6.7$ Hz, 2H), 5.24 (s, 1H), 5.41 (s, 1H), 5.45 (s, 2H), 7.11-7.16 (m, 3H), 7.31-7.37 (m, 3H), 7.57-7.60 (m, 1H), 7.81-7.85 (m, 1H);

IR (KBr, cm^{-1}) 3005, 1686, 1655, 1615, 1508, 1487, 1427, 1400, 745;

20 MS m/e 358 (MH^+);

Anal. Calcd for $\text{C}_{21}\text{H}_{19}\text{N}_5\text{O}$: C, 70.57; H, 5.36; N, 19.59


Found: C, 70.42; H, 5.51; N, 19.61

Compound 51

5 Compound **51** was prepared as described for compound **6**.

¹H NMR (DMSO-d₆) δ 3.20 (t, J = 6.7 Hz, 2H), 4.89 (t, J = 6.8 Hz, 2H), 5.60 (s, 2H), 6.97-7.08 (m, 3H), 7.27 (d, J = 6.6 Hz, 1H), 7.39-7.50 (m, 2H), 7.69 (d, J = 7.5 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 11.20 (s, 1H).

10 **Compound 52**



Nitrile **50** (9.19 g, 25.71 mmol), ammonium chloride (4.13 g, 77.13 mmol) and
15 sodium azide (5.01 g, 77.13 mmol) were stirred in DMF (100 mL) at 100 °C for two days.
The solvent was evaporated and the residue diluted with water and the pH was adjusted to 5
with concentrated HCl and the solid was filtered. The collected solid was triturated with hot
methanol to give 8.85 g (86% yield) of compound **52** as a solid. To the suspension of the
tetrazole (6.30 g) in methanol was added 1 equivalent of 1 N NaOH. The suspension was
20 then heated to dissolve the solid and solvent was evaporated. The residue was dried in
vacuum and triturated in ether to give 6.36 g of the sodium salt of compound **52**:

¹H NMR (DMSO-d₆) δ 2.15 (s, 3H), 3.43 (t, J = 7.1 Hz, 2H), 4.84 (t, J = 7.1 Hz, 2H),
5.20 (s, 1H), 5.38 (s, 2H), 5.40 (d, J = 1.2 Hz, 1H), 7.04-7.09 (m, 2H), 7.16-7.26 (m,
25 4H), 7.53-7.58 (m, 2H);


IR (KBr, cm⁻¹) 3407, 2484, 2115, 1701, 1656, 1613, 1487, 1396, 1156, 751.

MS m/e 401 (MH⁺);

Anal. Calcd for C₂₁H₂₀N₈O: C, 62.99; H, 5.03; N, 27.98

Found: C, 59.91; H, 5.20; N, 28.30

5 **Compound 53**




10 Compound 53 was prepared as described for compound 52 except 1-methyl-2-benzimidazolone was used in the coupling step.

¹H NMR (CD₃OD) δ 3.33 (t, J = 6.9Hz, 2H), 3.46 (s, 3H), 4.79 (t, J = 6.9 Hz, 2H), 5.21 (s, 2H), 6.99 (d, J = 7.0Hz, 1H), 7.07-7.31 (m, 5H), 7.50-7.54 (m, 2H);

MS m/e 375 (MH⁺);

15

Compound 54



20 To a solution of compound 52 (2.0 g, 4.99 mmol) and 1 N NaOH (4.99 mmol) in methanol (20 mL) was added 10% Pd/C (0.5 g). The mixture was hydrogenated on a Parr shaker for 3 days. The catalyst was removed by filtration. The filtrate was evaporated, and the residue was purified using C18 column chromatography (H₂O: MeOH(1% TFA) = 10:1 to 10 :6 as eluant) to give 1.52 g (72% yield) of compound 54 as a white solid:

^1H NMR (CDCl_3) δ 1.46 (d, $J = 7.0$ Hz, 6 H), 3.10 (t, $J = 6.6$ Hz, 2 H), 4.58-4.71 (m, 1 H), 4.68 (t, $J = 6.6$ Hz, 2 H), 5.13 (s, 2 H), 6.94-7.22 (m, 5 H), 7.31 (d, $J = 7.9$ Hz, 1 H), 7.49 (t, $J = 8.6$ Hz, 2 H);


5 IR (KBr, cm^{-1}) 3384, 1696, 1490, 1410, 751.

MS m/e 403 (MH^+);

Anal. Calcd for $\text{C}_{21}\text{H}_{22}\text{N}_8\text{O}\cdot\text{H}_2\text{O}$ C, 57.01; H, 5.24; N, 25.33

Found: C, 56.78; H, 5.62; N, 24.93

10 **Compound 55**




Compound 55 was prepared from compound 52 as described for compound 6.

15

^1H NMR (CD_3OD) δ 3.78 (t, $J = 6.6$ Hz, 2H), 5.19 (t, $J = 6.6$ Hz, 2H), 5.89 (s, 2H), 7.14-7.21 (m, 3H), 7.31-7.35 (m, 1H), 7.62-7.74 (m, 3H), 7.98 (dd, $J = 1.6, 7.0$ Hz, 1H);

MS m/e 361 (MH^+).

20

Compound 56

5 Compound **55** (31.3 g, 86.85mmol), triethylamine (13.19 mmol) and trityl chloride (26.64 mmol) were mixed in DMF (0.5 mL) and were stirred at 70 °C for 16 hours. To the mixture additional triethylamine (13.19 g) and trityl chloride (9.52 g) were added and the resulting mixture was stirred for an additional 2 hours. The solvent was evaporated, and the residue was triturated in 1 N NaOH solution and filtered. The solid collected was triturated
10 in hot methanol, cooled to room temperature and filtered to give 44.0 g (84% yield) of compound **56** as a white powder. The filtrate was concentrated to give additional 4.1 g (8% yield) of compound **56**.


¹H NMR (DMSO-d₆) δ 3.46 (t, J = 6.3 Hz, 2H), 4.82 (t, J = 6.3 Hz, 2H), 5.15 (s, 2H), 6.81-
15 7.14 (m, 12H), 7.27-7.37 (m, 10H), 7.56 (dd, J = 1.5, 6.7 Hz, 1H);

MS m/e 625 (MH⁺);

Anal. Calcd for C₃₇H₃₀N₈O: C, 73.74; H, 5.02; N, 18.59

Found: C, 73.46; H, 5.07; N, 18.31.

20 **Compound 57 (General Method)**



Compound **56** (500 mg, 0.83 mmol) was suspended in THF (15 mL) or
25 THF/DMF (10 mL / 2 mL) and the base BTPP (518 mg, 1.66 mmol, 2 eq) was added

at room temperature. This solution was allowed to stir for 15-30 minutes at which time the alkyl or benzyl halide (0.91 mmol, 1.1 eq) was added. The reaction was stirred 16 hours at room temperature under N₂ atmosphere. The solvent was evaporated and the resulting residue was taken up in water and extracted with ether, ethyl acetate, or methylene chloride. The combined organic extracts were dried over MgSO₄, filtered, and evaporated. The crude product was purified by flash chromatography on silica gel using a mixture of solvents such as ethyl acetate, hexanes, methylene chloride and methanol.














Table 9 – Alkylation of compound 56 with alkyl halide as described above.

#	R ₂	¹ H-NMR Data	MS Data
57a	CH ₂ CH ₂ CO ₂ Et	(DMSO-d ₆) 2.56 (t, J = 6.9 Hz, 2 H), 3.41 (t, J = 6.3 Hz, 2 H), 4.07 (t, J = 6.6 Hz, 2 H), 4.19 (d, J = 5.9 Hz, 2 H), 4.79 (t, J = 6.7 Hz, 2 H), 5.20 (s, 2 H), 6.82-6.93 (m, 7 H), 6.99-7.22 (m, 9 H), 7.27-7.36 (m, 11 H), 7.56-7.58 (m, 1 H), 8.49 (t, J = 5.8 Hz, 1 H)	764 (MH ⁺)
57b		(DMSO-d ₆) 2.56 (t, J = 6.9 Hz, 2 H), 3.41 (t, J = 6.3 Hz, 2 H), 4.07 (t, J = 6.6 Hz, 2 H), 4.19 (d, J = 5.9 Hz, 2 H), 4.79 (t, J = 6.7 Hz, 2 H), 5.20 (s, 2 H), 6.82-6.93 (m, 7 H), 6.99-7.22 (m, 9 H), 7.27-7.36 (m, 11 H), 7.56-7.58 (m, 1 H), 8.49 (t, J = 5.8 Hz, 1 H)	764 (MH ⁺)
57c	CH ₂ OCH ₃	(DMSO-d ₆) 3.23 (s, 3 H), 3.45 (t, J = 6.6 Hz, 2 H), 4.82 (t, J = 6.6 Hz, 2 H), 5.22 (s, 2 H), 5.26 (s, 2 H), 6.82-6.85 (m, 6 H), 6.97 (dd, J = 1.1, 7.7 Hz, 1 H), 7.02-7.16 (m, 3 H), 7.22-7.35 (m, 12 H), 7.55 (dd, J = 2.4, 7.6 Hz, 1 H)	647 (MH ⁺)
57d		(CDCl ₃) 3.26 (t, J = 6.9 Hz, 2 H), 4.56 (d, J = 6.0 Hz, 2 H), 4.82 (t, J = 6.9 Hz, 2 H), 5.27 (s, 2 H), 6.15-6.25 (m, 1 H), 6.53, 6.58 (bs, 1 H), 6.90-6.99 (m, 9 H), 7.12-7.39 (m, 18 H), 7.76 (d, J = 7.9 Hz, 1 H)	719 (MH ⁺)
57e		(CDCl ₃) 1.77-1.94 (m, 4 H), 3.27 (t, J = 6.8 Hz, 2 H), 3.88 (t, J = 6.9 Hz, 2 H), 3.94 (t, J = 6.0 Hz, 2 H), 4.80 (t, J = 6.8 Hz, 2 H), 5.24 (s, 2 H), 6.83 (dd, J = 1.0, 8.7 Hz, 2 H), 6.90-7.01 (m, 11 H), 7.12-7.37 (m, 14 H), 7.75 (d, J = 8.0 Hz, 1 H)	

57f		(CDCl ₃) 3.28 (t, J = 6.8 Hz, 2 H), 3.83 (s, 3 H), 4.76 (t, J = 6.9 Hz, 2 H), 5.20 (s, 2 H), 5.30 (s, 2 H), 6.76-6.77 (m, 1 H), 6.90-7.00 (m, 8 H), 7.14-7.38 (m, 15 H), 7.49-7.60 (m, 2 H), 7.77 (d, J = 8.0 Hz, 1 H)	751 (MH ⁺)
57g		(CDCl ₃) 3.27 (t, J = 7.0 Hz, 2 H), 4.83 (t, J = 7.0 Hz, 2 H), 5.02 (s, 2 H), 5.30 (s, 2 H), 6.77-6.79 (m, 1 H), 6.94-7.00 (m, 8 H), 7.18-7.39 (m, 12 H), 7.41-7.47 (m, 2 H), 7.58 (d, J = 7.4 Hz, 1 H), 7.77 (d, J = 7.9 Hz, 1 H), 8.09-8.12 (m, 2 H)	738 (MH ⁺)
57h		(CDCl ₃) 0.02 (s, 9 H), 0.91 (t, J = 8.1 Hz, 2 H), 3.30 (t, J = 6.8 Hz, 2 H), 3.59 (t, J = 8.3 Hz, 2 H), 4.82 (t, J = 6.9 Hz, 2 H), 5.22 (s, 2 H), 5.26 (s, 2 H), 6.93-6.97 (m, 6 H), 7.02-7.23 (m, 6 H), 7.29-7.35 (m, 9 H), 7.39 (d, J = 10.5 Hz, 1 H), 7.78 (d, J = 7.8 Hz, 1 H)	733 (MH ⁺)
57i		(CDCl ₃) 3.42 (t, J = 6.6 Hz, 2 H), 4.58 (d, J = 5.8 Hz, 2 H), 4.81 (t, J = 6.6 Hz, 2 H), 5.16 (s, 2 H), 6.93-6.96 (m, 6 H), 7.11-7.44 (m, 20 H), 7.75-7.78 (m, 1 H), 8.19-8.22 (m, 1 H), 9.06 (t, J = 5.9 Hz, 1 H)	736 (MH ⁺)
57j		(DMSO-d ₆) 3.57 (t, J = 7.0 Hz, 2 H), 4.57 (d, J = 5.9 Hz, 2 H), 4.94 (t, J = 7.0 Hz, 2 H), 5.56 (s, 2 H), 7.18-7.41 (m, 10 H), 7.61 (d, J = 7.6 Hz, 1 H), 7.75 (d, J = 8.0 Hz, 1 H), 8.09-8.12 (m, 1 H), 9.07 (t, J = 5.9 Hz, 1 H)	494 (MH ⁺)
57k		(CDCl ₃) 2.74 (t, J = 6.8 Hz, 2 H), 3.21 (d, J = 7.4 Hz, 2 H), 4.07 (d, J = 6.8 Hz, 2 H), 4.79 (d, J = 7.4 Hz, 2 H), 5.28 (s, 2 H), 6.07-7.42 (m, 22 H), 7.79 (d, J = 8.2 Hz, 1 H)	656 (MH ⁺)
57l	CH ₂ OCH ₂ CH ₂ OCH ₃	(CDCl ₃) 3.30 (t, J = 6.9 Hz, 2 H), 3.31 (s, 3 H), 3.45-3.48 (m, 2 H), 3.64-3.67 (m, 2 H), 4.82 (t, J = 6.9 Hz, 2 H), 5.27 (s, 2 H), 5.31 (s, 2 H), 6.94-6.97 (m, 6 H), 7.02-7.07 (m, 2 H), 7.14-7.23 (m, 4 H), 7.27-7.35 (m, 10 H), 7.78 (d, J = 7.8 Hz, 1 H)	691 (MH ⁺)
57m	CH ₂ CH ₂ CH ₂ CH ₂ CN	(CD ₃ OD) 3.34 (t, J = 6.9 Hz, 2 H), 4.80 (t, J = 6.9 Hz, 2 H), 5.03 (s, 2 H), 5.26 (s, 2 H), 6.73 (dd, J = 2.0, 6.5 Hz, 2 H), 6.97-7.01 (m, 1 H), 7.04-7.05 (m, 3 H), 7.20-7.31 (m, 4 H), 7.47 (d, J = 7.5 Hz, 1 H), 7.55 (d, J = 7.1 Hz, 1 H)	467 (MH ⁺)

Compound 58 (General Method)

5 The trityl protected tetrazole (75 mg, 0.12 mmol) compound was suspended in MeOH (5 mL) and to this solution was added conc. HCl (0.25 mL). The reaction was stirred for 1-2 hours at room temperature. The solvent was evaporated and the residue was dried under vacuum. The residue was then triturated with diethyl ether or methylene chloride to give the HCl salt.

10 The HCl salt was treated with exactly 2 eq 1N NaOH in methanol (one to remove the HCl and one to make the sodium salt of the tetrazole). The solvent was evaporated and the sodium salt was triturated with ether.

15 Method 2: The trityl protected tetrazole compound was treated with exactly 1 eq 1N NaOH in methanol. The reaction was heated at reflux and monitored by TLC and LC/MS for the completion of deprotection. The solvent was then evaporated and the residue was triturated with ether and/or methylene chloride to remove the trityl side product and filtration gave the final sodium salt product.













Table 10 – The trityl group was removed as described above for compound 58.

#	R ₂	¹ H-NMR Data	MS Data
58a	CH ₂ CH ₂ CO ₂ Me	(CD ₃ OD) δ 2.87 (t, J = 6.9Hz, 2H), 3.65 (s, 3H), 3.76 (t, J = 6.6Hz, 2H), 4.28 (t, J = 6.9 Hz, 2H), 5.17 (t, J = 6.6Hz, 2H), 5.89 (s, 2H), 7.18-7.29 (m, 2H), 7.38 (d, J = 8.7Hz, 2H), 7.61-7.73 (m, 3H), 7.97 (dd, J = 1.6, 6.9 Hz, 1H)	447 (MH ⁺)
58b		(DMSO-d ₆) δ 3.27 (t under DMSO, 2 H), 4.66 (d, J = 5.0 Hz, 2 H), 4.87 (t, J = 6.9 Hz, 2 H), 5.45 (s, 2 H), 6.35-6.46 (m, 1 H), 6.60, 6.66 (s, 1 H), 7.03-7.08 (m, 2 H), 7.22-7.32 (m, 4 H), 7.40 (d, J = 7.0 Hz, 1 H), 7.55-7.60 (m, 1 H)	477 (MH ⁺)
58c		(DMSO-d ₆) δ 1.69-1.87 (m, 4 H), 3.27 (t under DMSO, 2 H), 3.92-4.00 (m, 4 H), 4.89 (t, J = 6.9 Hz, 2 H), 5.51 (s, 2 H), 6.87-6.92 (m, 3 H), 7.01-7.12 (m, 2 H), 7.22-7.33 (m, 6 H), 7.59 (d, J = 7.4 Hz, 1 H), 7.66 (d, J = 8.2 Hz, 1 H)	509 (MH ⁺)
58d		(DMSO-d ₆) δ 3.27 (t under DMSO, 2 H), 3.83 (s, 3 H), 4.86 (t, J = 6.9 Hz, 2 H), 5.49 (s, 2 H), 5.54 (s, 2 H), 7.02-7.05 (m, 2 H), 7.15-7.30 (m, 5 H), 7.49-7.61 (m, 4 H), 7.69 (d, J = 8.0 Hz, 1 H)	509 (MH ⁺)
58e		(DMSO-d ₆) δ 3.27 (t under DMSO, 2 H), 4.92 (t, J = 7.1 Hz, 2 H), 5.27 (s, 2 H), 5.60 (s, 2 H), 7.04-7.07 (m, 2 H), 7.23-7.38 (m, 2 H), 7.60-7.71 (m, 3 H), 7.82 (d, J = 8.0 Hz, 1 H), 8.13-8.16 (m, 1 H), 8.26 (s, 1 H)	496 (MH ⁺)
58f	CH ₂ OCH ₃	(CD ₃ OD) δ 3.23 (s, 3 H), 3.37 (t, J = 6.9 Hz, 2 H), 4.80 (t, J = 6.9 Hz, 2 H), 5.22 (s, 2 H), 5.33 (s, 2 H), 6.99-7.03 (m, 1 H), 7.09-7.20 (m, 2 H), 7.22-7.32 (m, 3 H), 7.50-7.55 (m, 2 H)	405 (MH ⁺)
58g		(DMSO-d ₆) δ 0.08 (s, 9 H), 0.85 (t, J = 8.0 Hz, 2 H), 3.14 (t, J = 6.6 Hz, 2 H), 3.56 (t, J = 8.1 Hz, 2 H), 4.67 (t, J = 6.6 Hz, 2 H), 5.18 (s, 2 H), 5.27 (s, 2 H), 6.98-7.13 (m, 4 H), 7.16-7.35 (m, 2H), 7.42 (d, J = 7.5 Hz, 1 H), 7.53 (d, J = 7.8 Hz, 1 H)	491 (MH ⁺)
58h	CH ₂ CO ₂ Me	(DMSO-d ₆) δ 3.40 (t, J = 6.8 Hz, 2 H), 3.68 (s, 3 H), 4.79 (s, 2 H), 4.81 (t, J = 6.8 Hz, 2 H), 5.39 (s, 2 H), 7.04-7.07 (m, 2 H), 7.14-7.24 (m, 4 H), 7.50 (d, J = 7.9 Hz, 1 H), 7.56 (d, J = 7.6 Hz, 1 H)	433 (MH ⁺)
58i	CH ₂ CO ₂ H	(DMSO-d ₆) δ 3.41 (t, J = 7.2 Hz, 2 H), 4.65 (s, 2 H), 4.81 (t, J = 7.0 Hz, 2 H), 5.38 (s, 2 H), 7.01-7.08 (m, 2 H), 7.14-7.24 (m, 4 H), 7.49 (d, J = 7.5 Hz, 1 H), 7.56 (d, J = 7.4 Hz, 1 H)	419 (MH ⁺)
58j		(CD ₃ OD) δ 3.34 (t, J = 6.9 Hz, 2 H), 4.80 (t, J = 6.9 Hz, 2 H), 5.03 (s, 2 H), 5.26 (s, 2 H), 6.73 (dd, J = 2.0, 6.5 Hz, 2 H), 6.97-7.01 (m, 1 H), 7.04-7.05 (m, 3 H), 7.20-7.31 (m, 4 H), 7.47 (d, J = 7.5 Hz, 1 H), 7.55 (d, J = 7.1 Hz, 1 H)	467 (MH ⁺)
58k		(CDCl ₃) δ 3.76 (t, J = 6.6 Hz, 2 H), 3.90 (s, 3 H), 5.18 (t, J = 6.6 Hz, 2 H), 5.27 (s, 2 H), 5.93 (s, 2 H), 7.17-7.23 (m, 3 H), 7.38-7.40 (m, 1H), 7.54 (d, J = 8.3 Hz, 2 H), 7.60-7.74 (m, 3 H), 7.96 (dd, J = 6.7, 1.6 Hz, 1 H), 8.02 (dd, J = 6.5, 1.8 Hz, 2 H)	509 (MH ⁺)

581		(DMSO-d ₆) δ 3.45 (t, J = 7.0 Hz, 2 H), 4.84 (t, J = 7.0 Hz, 2 H), 5.17 (s, 2 H), 5.43 (s, 2 H), 6.98-7.05 (m, 2 H), 7.09-7.25 (m, 4H), 7.44 (d, J = 8.3 Hz, 2 H), 7.53 (t, J = 6.9 Hz, 2 H), 7.89 (d, J = 8.3 Hz, 2 H)	495 (MH ⁺)
-----	---	--	------------------------

Compounds 59 and 60

5

To a solution of compound **52** (2.5 g, 6.24 mmol) and BTPP (2.92 g, 9.36 mmol) in THF (20 mL) was added iodomethane (1.06 g, 1.2 mmol). The reaction mixture was stirred for 3 hours at room temperature. The solvent was evaporated and the residue was purified by flash column chromatography (gradient, EtOAc/hexanes, 2:1 to EtOAc/MeOH, 10:1) to give 2-methyl tetrazole product **59** (1.62 g, 63% yield) and 1-methyltetrazole product **60** (715 mg, 28% yield).

10

Compound 59

¹H NMR (CDCl₃) δ 2.23 (s, 3H), 3.26 (t, J = 7.3 Hz, 2H), 4.16 (s, 3H), 4.88 (t, J = 7.3 Hz, 2H), 5.25 (s, 1H), 7.38 (d, J = 1.3 Hz, 1H), 5.46 (s, 2H), 7.07-7.10 (m, 3H), 7.29-7.35 (m, 3H), 7.53-7.54 (m, 1H), 7.80-7.83 (m, 1H);

MS m/e 415 (MH⁺);Anal. Calcd for C₂₂H₂₂N₈O: C, 63.75; H, 5.35; N, 27.02

20


Found: C, 63.46; H, 5.61; N, 26.74.

Compound 60

¹H NMR (CDCl₃) δ 2.21 (s, 3 H), 3.22 (t, J = 6.8 Hz, 2 H), 3.42 (s, 3 H), 4.89 (t, J = 6.8 Hz, 2 H), 5.31 (s, 1 H), 5.39 (d, J = 1.3 Hz, 1 H), 5.44 (s, 2 H), 7.06-7.13 (m, 3 H), 7.23-7.32 (m, 3 H), 7.55-7.61 (m, 1 H), 7.80 (d, J = 7.2 Hz, 1 H);


25

MS m/e 415 (MH⁺).

Compound 61

5 Compound **61** was prepared according to the same procedure as described for compound **6**.

¹H NMR (DMSO-d₆) δ 3.34 (t over water, J = 6.9 Hz, 2H), 4.24 (s, 3H), 4.79 (t, J = 6.9 Hz, 2H), 5.23 (s, 2H), 6.91-7.00 (m, 3H), 7.09-7.23 (m, 3H), 7.48 (d, J = 7.6 Hz, 1H), 7.52 (d, J = 7.5 Hz, 1H);
10 MS m/e 375 (MH⁺).


Compound 62

15 Compound **61** (1.00 g, 2.67 mmol) was suspended in THF / DMF (30 mL / 5 mL) and BTPP (1.67 g, 5.32 mmol) was added at room temperature. The solution was allowed to stir for 15-30 minutes at which time methyl 4-(bromomethyl)-
20 benzoate (0.73 g, 3.20 mmol) was added. The reaction was stirred 16 hours at room temperature under nitrogen atmosphere. The solvent was removed and the resulting residue partitioned between water and EtOAc. The combined organic extracts were dried over magnesium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel using a mixture of ethyl acetate in
25 hexanes to give compound **62**.

^1H NMR (CDCl_3) δ 3.24 (t, $J = 7.3\text{ Hz}$, 2H), 3.90 (s, 3H), 4.17 (s, 3H), 4.88 (t, $J = 7.3\text{ Hz}$, 2H), 5.17 (s, 2H), 5.54 (s, 2H), 6.83 (dd, $J = 7.7, 1.0\text{ Hz}$, 1H), 6.99-7.10 (m, 2H), 7.31-7.41 (m, 5H), 7.56 (d, $J = 6.7\text{ Hz}$, 1H), 7.82-7.85 (m, 1H), 7.99 (dd, $J = 6.6, 1.8\text{ Hz}$, 1H);

5 MS m/e 523 (MH^+).










Compound 63









10


Table 11- Prepared as described for compound 62.

#	R_2	^1H -NMR Data	MS Data
63a ^x		(DMSO- d_6) δ 3.36 (t, $J = 6.8\text{ Hz}$, 2H), 4.25 (s, 3H), 4.80 (t, $J = 6.8\text{ Hz}$, 2H), 5.14 (s, 2H), 5.36 (s, 2H), 6.98-7.03 (m, 2H), 7.09-7.23 (m, 4H), 7.39 (d, $J = 8.2\text{ Hz}$, 2H), 7.48-7.55 (m, 2H), 7.86 (d, $J = 8.2\text{ Hz}$, 2H)	509 (MH^+)
63b		(CDCl_3) δ 3.25 (t, $J = 7.4\text{ Hz}$, 2H), 4.17 (s, 3H), 4.90 (t, $J = 7.4\text{ Hz}$, 2H), 5.21 (s, 2H), 5.57 (s, 2H), 6.84 (d, $J = 7.5\text{ Hz}$, 1H), 7.05-7.14 (m, 2H), 7.34-7.43 (m, 3H), 7.50 (d, $J = 8.9\text{ Hz}$, 2H), 7.64 (bd, $J = 7.5\text{ Hz}$, 1H), 7.85-7.88 (m, 1H), 8.19 (d, $J = 8.9\text{ Hz}$, 2H)	510 (MH^+)
63c ^b		(DMSO- d_6) δ 3.50 (t, $J = 6.7\text{ Hz}$, 2H), 4.24 (s, 3H), 4.96 (t, $J = 6.7\text{ Hz}$, 2H), 5.12 (s, 2H), 5.61 (s, 2H), 7.04-7.08 (m, 2H), 7.15-7.19 (m, 1H), 7.30-7.49 (m, 7H), 7.69 (d, $J = 7.1\text{ Hz}$, 1H), 7.83 (d, $J = 7.7\text{ Hz}$, 1H)	480 (MH^+)
63f ^c		(CD_3OD) δ 3.37 (t, $J = 6.8\text{ Hz}$, 2H), 4.14 (s, 3H), 4.87 (t, $J = 6.9\text{ Hz}$, 2H), 5.20 (s, 2H), 5.44 (s, 2H), 5.84 (s, 2H), 7.06-7.09 (m, 3H), 7.18-7.21 (m, 1H), 7.24-7.34 (m, 2H), 7.46-7.53 (m, 5H), 7.60 (dd, $J = 1.6, 7.0\text{ Hz}$, 1H), 8.12 (t, $J = 6.8\text{ Hz}$, 2H), 8.62 (t, $J = 7.9\text{ Hz}$, 1H), 9.06 (d, $J = 5.8\text{ Hz}$, 2H)	556 (MH^+)
63g		(CD_3OD) δ 3.68-3.74 (m, 4H), 4.02 (bs, 4H), 4.25 (s, 3H), 4.49 (t, $J = 5.7\text{ Hz}$, 2H), 5.13 (t, $J = 6.5\text{ Hz}$, 2H), 5.78 (s, 2H), 7.19-7.31 (m, 3H), 7.42 (d, $J = 7.4\text{ Hz}$, 1H), 7.61-7.70 (m, 2H), 7.78 (dd, $J = 2.4, 6.8\text{ Hz}$, 1H), 8.00 (d, $J = 8.4\text{ Hz}$, 1H)	488 (MH^+)
63h		(CD_3OD) δ 1.86-1.98 (m, 4H), 2.89 (t, $J = 7.3\text{ Hz}$, 2H), 3.32 (t, $J = 7.0\text{ Hz}$, 2H), 4.01	511 (MH^+)

		(t, J = 6.7 Hz, 2 H), 4.17 (s, 3 H), 4.85 (t, J = 7.0 Hz, 2 H), 5.41 (s, 2 H), 7.02-7.20 (m, 3 H), 7.25-7.33 (m, 3 H), 7.50 (dd, J = 2.0, 6.7 Hz, 1 H), 7.63 (dd, J = 2.0, 6.6 Hz, 1 H)	
63i		(CDCl ₃) δ 1.27 (t, J = 7.1 Hz, 3 H), 2.05-2.14 (m, 2 H), 2.41 (t, 7.3 Hz, 2 H), 3.18 (t, J = 7.6 Hz, 2 H), 3.98 (t, J = 8.7 Hz, 2 H), 4.12 (q, J = 7.1 Hz, 2 H), 4.81 (t, J = 7.3 Hz, 2 H), 5.42 (s, 2 H), 7.02-7.12 (m, 3 H), 7.23-7.34 (m, 3 H), 7.43-7.46 (m, 1 H), 7.77-7.80 (m, 1 H)	489 (MH ⁺)
63j ^a		(DMSO-d ₆) δ 1.70-1.82 (m, 2 H), 1.89 (t, J = 7.6 Hz, 2 H), 3.31 (t, J = 6.9 Hz, 2 H), 3.83 (t, J = 7.3 Hz, 2 H), 4.25 (s, 3 H), 4.79 (t, J = 6.9 Hz, 2 H), 5.29 (s, 2 H), 6.97-7.07 (m, 2 H), 7.13-7.23 (m, 3 H), 7.33 (d, J = 7.2 Hz, 1 H), 7.52 (d, J = 7.3 Hz, 1 H), 7.55 (d, J = 7.4 Hz, 1 H)	460 (MH ⁺)
63k		(CDCl ₃) δ 2.38 (t, J = 7.1 Hz, 2 H), 3.20 (t, J = 7.3 Hz, 2 H), 3.65 (s, 3 H), 3.93 (t, J = 6.9 Hz, 2 H), 4.18 (s, 3 H), 4.83 (t, J = 7.4 Hz, 2 H), 5.45 (s, 2 H), 6.98-7.01 (m, 1 H), 7.05-7.09 (m, 2 H), 7.29-7.35 (m, 3 H), 7.48-7.50 (m, 1 H), 7.79-7.82 (m, 1 H)	489 (MH ⁺)
63l		(DMSO-d ₆) δ 1.14 (t, J = 7.1 Hz, 3 H), 1.52-1.71 (m, 2 H), 2.34 (t, J = 7.4 Hz, 2 H), 3.12 (t over water, 2 H), 3.87 (t, J = 6.8 Hz, 2 H), 4.01 (q, J = 7.1 Hz, 2 H), 4.79 (t, J = 6.8 Hz, 2 H), 5.31 (s, 2 H), 6.99-7.09 (m, 2 H), 7.13-7.24 (m, 4 H), 7.49 (d, J = 7.5 Hz, 1 H), 7.54 (d, J = 7.6 Hz, 1 H)	
63m ^a		(DMSO-d ₆) δ 1.35-1.48 (m, 2 H), 1.56-1.64 (m, 2 H), 1.90 (t, J = 7.3 Hz, 2 H), 3.31 (t, J = 6.8 Hz, 2 H), 3.81 (t, J = 7.1 Hz, 2 H), 4.24 (s, 3 H), 4.78 (t, J = 6.8 Hz, 2 H), 5.29 (s, 2 H), 6.96-7.07 (m, 2 H), 7.11-7.22 (m, 4 H), 7.47 (d, J = 7.3 Hz, 1 H), 7.53 (d, J = 7.5 Hz, 1 H)	475 (MH ⁺)
63n		(CDCl ₃) δ 1.24 (t, J = 7.1 Hz, 3 H), 1.37-1.53 (m, 2 H), 1.62-1.93 (m, 4 H), 2.30 (t, J = 7.5 Hz, 2 H), 3.42 (t, J = 6.8 Hz, 2 H), 4.10 (q, J = 7.1 Hz, 2 H), 4.19 (s, 3 H), 4.81 (t, J = 7.2 Hz, 2 H), 5.42 (s, 2 H), 6.97-7.12 (m, 3 H), 7.23-7.33 (m, 3 H), 7.43-7.46 (m, 1 H), 7.76-7.82 (m, 1 H)	517 (MH ⁺)
63o ^a		(DMSO-d ₆) δ 1.20-1.30 (m, 2 H), 1.39-1.48 (m, 2 H), 1.50-1.66 (m, 2 H), 1.82 (t, J = 7.2 Hz, 2 H), 3.31 (t, J = 6.8 Hz, 2 H), 4.25 (s, 3 H), 4.79 (t, J = 7.0 Hz, 2 H), 5.30 (s, 2 H), 6.98-7.23 (m, 6 H), 7.48 (d, J = 7.4 Hz, 1 H), 7.55 (d, J = 7.4 Hz, 1 H)	488 (MH ⁺)
63p		(CDCl ₃) δ 2.94 (t, J = 7.0 Hz, 2 H), 3.16 (t, J = 6.9 Hz, 2 H), 4.16 (s, 3 H), 4.26 (t, J = 7.0 Hz, 2 H), 4.77 (t, J = 6.9 Hz, 2 H), 5.42 (s, 2 H), 7.06-7.17 (m, 3 H), 7.27-7.33 (m, 2 H), 7.35-7.39 (m, 1 H), 7.44-7.47 (m, 1 H), 7.78-7.83 (m, 1 H)	428 (MH ⁺)
63q		(CD ₃ OD) δ 3.08 (s, 6 H), 3.68-3.72 (m, 4 H), 4.23 (s, 2 H), 4.45 (t, J = 5.7 Hz, 2 H), 5.11 (t, J = 6.5 Hz, 2 H), 5.74 (s, 2 H), 7.19-7.32 (m, 3 H), 7.41 (d, J = 7.4 Hz, 1 H), 7.58-7.68 (m, 2 H), 7.74 (d, J = 7.4 Hz, 1 H), 7.97 (d, J = 7.4 Hz, 1 H)	446 (MH ⁺)

63r		(CDCl ₃) δ 1.70-1.80 (m, 2 H), 1.92-2.02 (m, 2 H), 2.46 (t, J = 7.0 Hz, 2 H), 3.20 (t, J = 7.4 Hz, 2 H), 3.98 (t, J = 6.7 Hz, 2 H), 4.18 (s, 3 H), 4.82 (t, J = 7.4 Hz, 2 H), 5.44 (s, 2 H), 6.98-7.07 (m, 1 H), 7.07-7.12 (m, 2 H), 7.28-7.37 (m, 3 H), 7.48-7.51 (m, 1 H), 7.78-7.84 (m, 1 H)	456 (MH ⁺)
63s		(CDCl ₃) δ 2.10-2.24 (m, 2 H), 2.49 (t, J = 7.1 Hz, 2 H), 3.22 (t, J = 7.4 Hz, 2 H), 4.07 (t, J = 6.6 Hz, 2 H), 4.16 (s, 3 H), 4.87 (t, J = 7.4 Hz, 2 H), 5.51 (s, 2 H), 7.04-7.07 (m, 1 H), 7.11-7.15 (m, 2 H), 7.34-7.43 (m, 3 H), 7.56-7.64 (m, 1 H), 7.87-7.87 (m, 1 H)	442 (MH ⁺)
63t ^d		(DMSO-d ₆) δ 1.82-1.93 (m, 2 H), 2.09 (t, J = 7.4 Hz, 2 H), 3.29-3.33 (m, 2 H), 3.85 (t, J = 6.9 Hz, 2 H), 4.24 (s, 3 H), 4.78 (t, J = 6.9 Hz, 2 H), 5.29 (s, 2 H), 6.16 (bs, 2 H), 6.99-7.08 (m, 2 H), 7.12-7.24 (m, 4 H), 7.48 (d, J = 7.5 Hz, 1 H), 7.53 (d, J = 7.4 Hz, 1 H), 9.09 (bs, 1 H)	475 (MH ⁺)
63u		(CDCl ₃) δ 3.21 (t, J = 7.4 Hz, 2 H), 4.14 (s, 3 H), 4.84 (t, J = 7.4 Hz, 2 H), 5.12 (s, 2 H), 5.47 (s, 2 H), 6.87-6.92 (m, 1 H), 6.97-7.04 (m, 2 H), 7.24-7.35 (m, 8 H), 7.44-7.47 (m, 1 H), 7.77-7.83 (m, 1 H)	465 (MH ⁺)
63v		(DMSO-d ₆) δ 3.36 (t, J = 6.7 Hz, 2 H), 3.66 (s, 3 H), 4.25 (s, 3H), 4.74 (s, 3H), 4.80 (t, J = 6.9 Hz, 2 H), 5.00 (s, 2 H), 5.33 (s, 2 H), 6.87 (d, J = 8.7 Hz, 2 H), 6.98-7.01 (m, 2 H), 7.13-7.23 (m, 4 H), 7.30 (d, J = 8.7 Hz, 2 H), 7.51 (dd, J = 7.7, 12.9 Hz, 2 H)	553 (MH ⁺)
63w ^a		(DMSO-d ₆) δ 3.34 (t, J = 6.9 Hz, 2 H), 4.01 (s, 2 H), 4.27 (s, 3 H), 4.81 (t, J = 6.9 Hz, 2 H), 4.98 (s, 2 H), 5.34 (s, 2 H), 6.73 (d, J = 8.6 Hz, 2 H), 6.98-7.01 (m, 2 H), 7.13-7.25 (m, 6 H), 7.50 (d, J = 7.5 Hz, 1 H), 7.55 (d, J = 7.3 Hz, 1 H)	539 (MH ⁺)

a, saponification of ester as described for compound **8**; **b**, catalytic hydrogenation as described for compound **123**; **c**, alkylation with 1,4-di(bromomethyl)benzene followed by addition of pyridine to form a pyridinium salt as described for **37g**; **d**, prepared as described for compound **119**.

Compound 64

5 The general coupling method used for compound **63a** was applied using 4-benzyloxybenzyl chloride and BTPP in tetrahydrofuran to give the product benzyl ether. The benzyl ether (600 mg, 1.05 mmol) and 10% palladium hydroxide on carbon (160 mg) in 2:1 methanol/ tetrahydrofuran (50 mL / 25 mL) was agitated under hydrogen at 55 psi for 48 hours. The reaction mixture was filtered through a
10 pad of Celite and then subjected to column chromatography (2:1 EtOAc/CH₂Cl₂) to give compound **64** as a white solid (262 mg, 52% yield).

¹H NMR (DMSO-d₆) δ 3.35 (t, J = 6.8 Hz, 2H), 4.25 (s, 3H), 4.80 (t, J = 6.8 Hz, 2H), 4.94 (s, 2H), 5.33 (s, 2H), 6.68 (d, J = 8.5 Hz, 2H), 6.95-7.02 (m, 2H), 7.09-7.23 (m, 6H), 7.47-7.54 (m, 2H), 9.39 (s, 1H);
15


IR (KBr, cm⁻¹) 3247, 2944, 1664, 1613, 1597, 1515, 1491, 1445, 1413, 747;

MS m/e 481 (MH⁺);

Anal. Calcd for C₂₆H₂₄N₈O₂: C, 64.99; H, 5.03; N, 23.32

Found: C, 64.79; H, 4.98; N, 23.38.

20


Compound 65

A mixture of compound **63c**, (100 mg, 0.18 mmol) and triethylamine (55 mg, 0.54 mmol) in methylene chloride (5 mL) was cooled to 0 °C. Methanesulfonyl
25 chloride (21 mg, 0.18 mmol) was added and the reaction mixture was allowed to

warm gradually to room temperature. After stirring for 5.5 hours under nitrogen atmosphere, the organic material was washed with dilute aqueous sodium bicarbonate solution (10 mL). The aqueous layer was then extracted with methylene chloride (2 x 20 mL). The combined organic extracts were dried over magnesium sulfate, filtered and evaporated. Trituration with anhydrous diethyl ether followed by filtration gave compound **65** as a yellow solid (92 mg, 91% yield):

^1H NMR (CD_3OD) δ 2.95 (s, 3H), 3.07 (s, 1H), 3.68 (t, $J = 6.5$ Hz, 2H), 4.26 (s, 3H), 5.14 (t, $J = 6.7$ Hz, 2H), 5.15 (s, 2H), 5.81 (s, 2H), 7.16-7.28 (m, 6H), 7.43 (d, $J = 8.6$ Hz, 2H), 7.63-7.75 (m, 3H), 7.99-8.02 (m, 1H);
IR (KBr, cm^{-1}): 3435, 2929, 1708, 1615, 1513, 1493, 1404, 1329, 1152, 752.
MS m/e 558 (MH^+).

Compound 66



A mixture of compound **63c** (100 mg, 0.18 mmol) and triethylamine (55 mg, 0.54 mmol) in methylene chloride (4 mL) was cooled to 0 °C. Acetyl chloride (18 mg, 0.23 mmol) was added followed by DMAP (5 mg, catalytic quantity). The reaction mixture was allowed to warm to room temperature gradually and stirring was continued for 16 hours at room temperature under nitrogen atmosphere. A white precipitate was observed. The organic material was washed with dilute aqueous sodium bicarbonate solution (10 mL). The aqueous layer was then extracted with methylene chloride (2 x 20 mL). The combined organic extracts were dried over magnesium sulfate, filtered and evaporated to give a white solid. The solid was triturated with anhydrous diethyl ether and filtered to give the compound **66** as a white solid (50 mg, 53 % yield).

^1H NMR (DMSO- d_6) δ 2.00 (s, 3 H), 3.36 (t, $J = 6.9$ Hz, 2 H), 4.25 (s, 3 H), 4.80 (t, $J = 6.9$ Hz, 2 H), 5.14 (s, 2 H), 5.34 (s, 2 H), 6.97-7.02 (m, 2 H), 7.07-7.23 (m, 6 H), 7.28 (d, $J = 8.5$ Hz, 2 H), 7.48-7.54 (m, 4 H), 9.92 (s, 1H).

IR (KBr, cm^{-1}): 3308, 2929, 1694, 1610, 1516, 1495, 1407, 1311, 749.

5 MS m/e 522 (MH^+).

Anal. Calcd for


$\text{C}_{28}\text{H}_{27}\text{N}_9\text{O}_2$:

C, 64.48; H, 5.22; N, 24.17

Found:

C, 64.13; H, 5.32; N, 23.86

Compound 67



10

To a solution of compound 63q (32 mg, 0.07 mmol) in acetone (1 mL) was added iodomethane (20 mg, 0.14 mmol). The reaction mixture was stirred at 50 °C for 2 hours and then stirred at room temperature overnight. The resulting precipitate was filtered and triturated with CH_2Cl_2 and Et_2O to give 18 mg (55% yield) of compound 67.


15

^1H NMR (DMSO- d_6) δ 3.19 (s, 9H), 3.51 (t, $J = 7.0$ Hz, 2H), 3.74 (t, $J = 6.7$ Hz, 2H), 4.39 (t, $J = 6.7$ Hz, 2H), 4.91 (t, $J = 7.0$ Hz, 2 H), 5.57 (bs, 2H), 7.08-7.19 (m, 2H), 7.27-7.28 (m, 3H), 7.41 (d, $J = 7.2$ Hz, 1H), 7.57 (d, $J = 7.7$ Hz, 1 H), 7.73 (d, $J = 7.7$ Hz, 1H);

20

MS (m/e) 446 (MH^+).

Compound 68




25

To a solution of 2-hydroxymethylbenzimidazole (29.63 g, 200 mmol) in a mixture of DMF/THF (150 mL, 1:1) was added sodium hydride (60% in mineral oil, 8.4 g, 210 mmol) in several portions at room temperature. After stirring for 1 hour, 4-bromobutyronitrile (29.6 g, 200 mmol) was added and the resulting solution was stirred at 80 °C for 16 hours. The solvent was evaporated and the residue diluted with water and extracted with EtOAc. The combined extracts were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (gradient, EtOAc/hexane, 1:1 to 2:1, then EtOAc/MeOH, 10:1) to give 22.11 g (51% yield) 4-(2-hydroxymethyl-benzoimidazol-1-yl)-butyronitrile, **68** as a white solid.

10

¹H NMR (CDCl₃) δ 2.27-2.32 (m, 2H), 2.41 (t, J = 6.0 Hz, 2H), 4.41 (t, J = 7.2 Hz, 2H), 7.26-7.38 (m, 3H), 7.67-7.70 (m, 1H);
MS m/e 216 (MH⁺).


15 **Compound 69**

To 4-(2-hydroxymethyl-benzoimidazol-1-yl)-butyronitrile, **68**, (22 g, 102.2 mmol) suspended in CH₂Cl₂ (100 mL), thionyl chloride (15.81 g, 132.9 mmol) was slowly added with ice-water bath cooling. The ice bath was removed. The solution was stirred at room temperature for 1 hour and then evaporated. The residue was triturated with EtOAc to give a nearly quantitative yield of 4-(2-chloromethyl-benzoimidazol-1-yl)-butyronitrile, **69**, as light gray powder.

25 ¹H NMR (CDCl₃) δ 2.32-2.38 (m, 2 H), 2.70 (t, J = 7.3 Hz, 2 H), 4.69 (t, J = 7.6 Hz, 2 H), 5.33 (s, 2 H), 7.69-7.74 (m, 2 H), 7.85-7.87 (m, 1 H), 8.00-8.02 (m, 1 H);
MS m/e 234 (MH⁺).

Anal. Calcd for C₁₂H₁₂N₃•HCl•0.25 H₂O: C, 52.48; H, 4.95; N, 15.30


Found: C, 52.52; H, 4.88; N, 15.26

Compound 70

5 Compound **70** was prepared as described for **4**.

^1H NMR (CDCl_3) δ 1.93-2.06 (m, 2H), 2.29 (s, 3H), 7.65 (t, $J = 7.6$ Hz, 2H), 4.50 (t, $J = 7.7$ Hz, 2H), 5.22 (s, 1H), 5.40 (s, 2H), 5.42 (s, 1H), 7.10-7.17 (m, 3H), 7.30-7.38 (m, 3H), 7.53-7.57 (m, 1H), 7.79-7.83 (m, 1H);

10 MS m/e 372 (MH^+).

Compound 71


15

Compound **71** prepared as described for compound **52**.

^1H NMR (CD_3OD) δ 2.12-2.20 (m, 2H), 2.23 (s, 3H), 2.94 (t, $J = 7.4$ Hz, 2 H), 4.46 (t, $J = 7.8$ Hz, 2H), 4.92 (s, 2H), 5.23 (s, 1H), 5.45 (s, 2H), 7.05-7.33 (m, 6H), 7.45 (dd, $J = 1.3, 6.8$ Hz, 1H), 7.61 (dd, $J = 1.7, 6.9$ Hz, 1H);


20

MS m/e 415 (MH^+).

Compound 72

- 5 **Table 12-** Prepared by treatment of compound 71 as described for compound 6 followed by alkylation as described for compound 7 using Cs_2CO_3 instead of BTTP.

#	R ₂	¹ H-NMR Data	MS Data
72a		(DMSO-d ₆) 2.87 (s, 3 H), 2.96 (s, 3 H), 3.13 (t, J = 6.7 Hz, 2 H), 4.76 (t, J = 6.7 Hz, 2 H), 5.16 (s, 2 H), 5.50 (s, 2 H), 7.02-7.04 (m, 2 H), 7.16-7.21 (m, 2 H), 7.25-7.30 (m, 2 H), 7.37-7.42 (m, 4 H), 7.58 (d, J = 7.9 Hz, 1 H), 7.70 (d, J = 8.1 Hz, 1 H)	479 (MH ⁺)
72b		(CDCl ₃) 2.74 (t, J = 6.7 Hz, 2 H), 3.92 (s, 3 H), 4.82 (t, J = 6.7 Hz, 2 H), 5.17 (s, 2 H), 5.51 (s, 2 H), 6.87 (d, J = 7.3 Hz, 1 H), 7.03-7.12 (m, 1 H), 7.33-7.43 (m, 6 H), 7.60 (d, J = 7.2 Hz, 1 H), 7.83-7.86 (m, 1 H), 8.02 (d, J = 8.3 Hz, 2 H)	466 (MH ⁺)
72c		(DMSO-d ₆) δ 1.59-1.62 (m, 2 H), 1.76-1.79 (m, 2 H), 1.99-2.02 (m, 2 H), 2.54-2.63 (m, 4 H), 3.93 (t, J = 4.1, 2 H), 4.41 (t, J = 4.5, 2 H), 5.41 (s, 2 H), 6.99-7.19 (m, 4 H), 7.24-7.28 (m, 2 H), 7.56-7.60 (m, 2H);	413 (MH ⁺)

Compound 73

10


- Compound 3 (2.00 g, 6.57 mmol) was suspended in acetonitrile (100 mL) and methyl vinyl sulfone (2.09 g, 19.72 mmol) was added followed by MTBD (50 mg, 0.33 mmol). The reaction mixture was heated at 50-60 °C for 16 hours. The solution became transparent. The solvent was evaporated and the residue was purified by
- 15 flash column chromatography on silica gel (10:1 ethyl acetate/hexanes) to give 2.50g (93% yield) of compound 73 as a yellow-orange solid:

¹H NMR (CDCl₃) δ 2.25 (s, 3 H), 3.07 (s, 3H), 3.39 (t, J = 7.6 Hz, 2H), 4.96 (t, J = 7.3 Hz, 2 H), 5.25 (s, 1 H), 5.42 (s, 1 H), 5.50 (s, 2H), 7.12-7.28 (m, 3H), 7.36-7.47 (m, 3H), 7.63 (d, J = 4.6 Hz, 1H), 7.83-7.86 (m, 1H);

5 IR (KBr, cm⁻¹) 1698, 1489, 1397, 1306, 1137, 745;

MS m/e 411 (MH⁺).

Compound 74



10

Compound **73** (2.2 g, 5.36 mmol) was suspended in MeOH (100 ml) and concentrated hydrochloric acid (10 mL). The mixture was heated at reflux for 3.5 hours and then stirred overnight at room temperature. The solvent was stripped, repeatedly evaporated with hexanes and/or diethyl ether, and dried under vacuum to


15

¹H NMR (DMSO-d₆) δ 3.17 (s, 3H), 4.02 (t, J = 6.1 Hz, 2H), 5.24 (t, J = 6.1 Hz, 2H), 5.93 (s, 2H), 7.09-7.20 (m, 2H), 7.29 (bd, J = 8.0 Hz, 1H), 7.65-7.73 (m, 2H), 8.06 (bd, J = 8.0 Hz, 1H);

20 IR (KBr, cm⁻¹) 1687, 1461, 1399, 1305, 1127, 751;

MS m/e 317 (MH⁺).

Compound 75




25

Compound **75** prepared as described for compound **7**.

¹H NMR (CDCl₃) δ 1.72-1.78 (m, 2H), 1.92-1.98 (m, 2H), 2.14-2.20 (m, 2H), 2.46 (t, J = 7.1 Hz, 2H), 2.85 (s, 3H), 3.07 (t, J = 7.6 Hz, 2H), 3.98 (t, J = 6.9 Hz, 2H), 4.54

(t, $J = 7.7$ Hz, 2H), 5.42 (s, 2H), 6.98-7.00 (m, 1H), 7.08-7.12 (m, 2H), 7.31-7.34 (m, 2H), 7.39-7.41 (m, 1H), 7.53-7.55 (m, 1H), 7.81 (dd, $J = 3.1, 5.9$ Hz, 1H); MS (m/e) 466 (MH^+).

5 Compound 76




Compound 76 prepared as described for compound 121.

10

1H NMR (CD_3OD) δ 1.73-1.78 (m, 2H), 1.86-1.90 (m, 2H), 2.15-2.19 (m, 2H), 2.61 (t, $J = 7.5$ Hz, 2H), 2.94 (s, 3H), 3.20 (t, $J = 7.6$ Hz, 2H), 4.03 (t, $J = 6.9$ Hz, 2H), 4.55 (t, $J = 7.7$ Hz, 2H), 5.47 (s, 2H), 7.07 (t, $J = 7.7$ Hz, 1H), 7.14 (t, $J = 7.2$ Hz, 1H), 7.21-7.34 (m, 4H), 7.59 (d, $J = 8.0$ Hz, 1H), 7.63 (d, $J = 8.0$ Hz, 1H);

15 MS (m/e) 525 (MH^+).

Compound 77




20 Compound 74 (2.20 g, 5.36 mmol) was suspended in anhydrous THF (70 mL). Upon addition of BTTP (6.70 g, 21.44 mmol), the reaction mixture became a clear solution. After stirring for 20 minutes, methyl 4-(bromomethyl)benzoate (1.47 g, 6.43 mmol) was added and the mixture was allowed to stir at room temperature under a nitrogen atmosphere for 16 hours. The solvent was evaporated. The brown
25 residue was taken up in water (75 mL) and extracted with methylene chloride (3 x 300 mL). The organic extracts were dried over anhydrous $MgSO_4$, and evaporated. The product was purified by flash column chromatography (gradient with EtOAc/hexanes 2:1 to 5:1 as eluant) to give 1.2 g (43% yield) of compound 77:

¹H NMR (CDCl₃) δ 2.99 (s, 3H), 3.43 (t, J = 7.3 Hz, 2H), 3.94 (s, 3H), 4.95 (t, J = 7.3 Hz, 2H), 5.17 (s, 2H), 5.55 (s, 2H), 6.86 (d, J = 7.7 Hz, 1H), 7.03-7.15 (m, 2H), 7.36-7.747 (m, 4 H), 7.55 (d, J = 4.8 Hz, 1H), 7.65-7.86 (m, 1H), 8.02 (d, J = 8.1 Hz, 2H); IR (KBr, cm⁻¹) 1707, 1493, 1438, 1408, 1282, 1135, 750;

5 MS m/e 519 (MH⁺).

Compound 78



10


Ester **77** (1.2 g, 2.31 mmol) was suspended in a solution of methanol (75 mL) and 1 N NaOH (4.6 mL, 4.63 mmol). The reaction mixture was heated at reflux for 3 hours. The methanol was evaporated and the residue was taken up in water (75 mL). The aqueous solution was acidified to pH 6 with 1 N HCl. An unfilterable gelatinous precipitate came out of solution. A large amount of sodium chloride was added to the aqueous material to create a saturated solution which was then extracted with THF (400 mL x 3). The organic extracts were dried over anhydrous magnesium sulfate, filtered, and evaporated to give 894 mg (81% yield) of compound **78** as a free acid.

20

The acid (500 mg, 0.99 mmol) was suspended in a mixture of methanol and THF (50%, 70 mL), and 1 N NaOH (0.99 mL, 0.99 mmol) was added. The solvent was evaporated and the solid was dried under vacuum. The solid was triturated with diethyl ether to give 464 mg (89% yield) of compound **78** as a sodium salt.

25

¹H NMR (DMSO-d₆) δ 3.10 (s, 3H), 3.78 (t, J = 6.5 Hz, 2H), 4.86 (t, J = 6.5 Hz, 2H), 5.09 (s, 2H), 5.52 (s, 2H), 6.97-7.29 (m, 8H), 7.57 (d, J = 7.6 Hz, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.79 (d, J = 8.1 Hz, 2H); IR (KBr, cm⁻¹) 3398, 2926, 1698, 1597, 1554, 1493, 1392, 1293, 1132, 750; MS m/e 505 (MH⁺).


Compound 79

5 Acid 78 (400 mg, 0.79 mmol), dimethylamine hydrochloric acid salt (97 mg, 1.19 mmol), and N,N-diisopropylethylamine (307 mg, 2.38 mmol) were stirred in DMF (10 mL). To this solution was added PyBroP (433 mg, 0.95 mmol). The reaction was allowed to stir under nitrogen atmosphere at room temperature for 48 hours. The solvent was evaporated. The residue was taken up in water (20 mL) and
10 extracted with ethyl acetate (3 x 150 mL). The organic extracts were dried over anhydrous MgSO₄, and evaporated. Column chromatography (methylene chloride /methanol = 20:1) followed by preparative high pressure liquid chromatography (reverse phase) gave 110 mg (26% yield) of compound 79:

15 ¹H NMR (CD₃OD) δ 2.96, 3.05, 3.08 (s, 3H each), 3.83(t, J = 3.8 Hz, 2H), 5.07 (t, J = 3.8 Hz, 2H), 5.21 (s, 2H), 5.77 (s, 2H), 7.08 (bs, 3H), 7.28-7.30 (m, 1 H), 7.41 (d, J = 4.9 Hz, 2H), 7.44-7.53 (m, 4H), 7.65 (d, J = 4.9 Hz, 1H), 7.79 (d, J = 4.9 Hz, 1H);
IR (KBr, cm⁻¹) 3441, 1702, 1621, 1493, 1406, 1133, 750;
MS m/e 532 (MH⁺);

20 Anal. Calcd for C₂₈H₂₉N₅O₄S • 2H₂O: C, 59.24; H, 5.86; N, 12.34

Found: C, 59.00; H, 5.15; N, 12.17.


Compound 80

Compound **80** was prepared as described for **50** except ethyl vinylphosphinate was used in place of acrylonitrile.

¹H NMR (DMSO-d₆) δ 1.10 (t, *J* = 7.1, 6H), 2.11 (s, 3H), 2.29-2.40 (m, 2H), 3.85-3.95 (m, 4H), 4.54-4.64 (m, 2H), 5.20 (s, 1H), 5.40 (s, 1H), 5.45 (s, 2H), 7.02-7.09 (m, 2H), 7.14-7.32 (m, 4H), 7.50-7.57 (m, 2H);
MS (m/e) 469 (MH⁺).

Compound 81

10




The isopropenyl group of compound **80** was reduced to give compound **81** as described for compound **54**.

15

¹H NMR (DMSO-d₆) δ 1.10 (t, *J* = 7.0, 6H), 1.46 (d, *J* = 7.0, 6H), 2.24-2.35 (m, 2H), 3.85-3.95 (m, 4H), 4.53-4.70 (m, 3H), 5.41 (s, 2H), 6.96-7.06 (m, 2H), 7.14-7.34 (m, 4H), 7.48-7.57 (m, 2H);
MS (m/e) 471 (MH⁺).

20


Compound 82



25 Compound **82** was prepared as described for compound **7** using [1,2]oxathiolane 2,2-dioxide as the alkylating agent.


¹H NMR (DMSO-d₆) δ 1.10 (t, *J* = 7.0, 6H), 1.90-2.0 (m, 2H), 2.28-2.47 (m, 4H), 3.85-3.98 (m, 6H), 4.52-5.62 (m, 2H), 5.44 (s, 2 H), 6.96-7.08 (m, 2H), 7.12-7.29 (m, 4H), 7.48-7.57 (m, 2H);
MS (m/e) 551 (MH⁺).

5

Compound 83

10 Compound 83 was prepared as described for compound 7.


¹H NMR (DMSO-d₆) δ 1.09 (t, *J* = 7.1, 6H), 2.32-2.43 (m, 2H), 3.82 (s, 3H), 3.84-3.94 (m, 4H), 4.55-4.64 (m, 2H), 5.20 (s, 2H), 5.51 (s, 2H), 6.97-7.04 (m, 2H), 7.09-7.31 (m, 4H), 7.46-7.56 (m, 4H), 7.93 (d, *J* = 8.3, 2H);
15 MS (m/e) 577 (MH⁺).

Compound 84

20

Compound 84 was prepared as described for compound 4.


¹H NMR (DMSO-d₆) δ 1.09 (t, *J* = 7.1, 6H), 7.38-2.44 (m, 2H), 3.86-3.95 (m, 4H), 4.61-4.69 (m, 2H), 5.20 (s, 2H), 5.62 (s, 2H), 7.01-7.04 (m, 2H), 7.25-7.37 (m, 2H),
25 7.46 (d, *J* = 8.2, 2H), 7.59-7.66 (m, 2H), 7.90 (s, 2H);
MS (m/e) 563 (MH⁺).

Compound 85

5 Compound **85** was prepared as described for **50** using methyl vinyl ketone.

¹H NMR (CDCl₃) δ 2.09 (s, 3H), 2.45 (s, 3H), 2.84 (t, J = 6.8 Hz, 2H), 4.64 (t, J = 6.8 Hz, 2H), 5.21 (s, 1H), 5.38 (d, J = 1.3 Hz, 1H), 5.51 (s, 2H), 7.06-7.10 (m, 3H), 7.28-7.31 (m, 2H), 7.34-7.38 (m, 1H), 7.49-7.52 (m, 1H), 7.77-7.80 (m, 1H);


10 MS m/e 375 (MH⁺).

Compound 86

15 Compound **86** was prepared as described for compound **6**.

¹H NMR (CDCl₃) 2.09 (s, 3H), 2.82 (t, J = 6.8 Hz, 2H), 3.50 (s, 1H), 4.63 (t, J = 6.9 Hz, 2H), 5.51 (s, 2H), 7.04-7.07 (m, 3H), 7.29-7.37 (m, 2H), 7.44-7.45 (m, 1H), 7.78-7.81 (m, 1H), 8.64 (s, 1H);


20 MS m/e 335 (MH⁺).

Compound 87

Compound 87 was prepared as described for compound 7 using 2-bromo-propionic acid ethyl ester.

¹H NMR (CDCl₃) δ 1.09 (t, J = 7.1 Hz, 3H), 1.57 (d, J = 7.4 Hz, 3H), 2.08 (s, 3H),
5 2.77 (t, J = 6.9 Hz, 2H), 4.21 (q, J = 7.1 Hz, 2H), 4.60 (t, J = 6.9 Hz, 2H), 5.27 (q, J =
7.4 Hz, 1H), 5.51 (q, J = 12.4 Hz, 2H), 6.93-6.96 (m, 1H), 7.09-7.09 (m, 2H), 7.28-
7.32 (m, 2H), 7.34-7.38 (m, 1 H), 7.48-7.51 (m, 1H), 7.77-7.81 (m, 1H);
MS m/e 435 (MH⁺).

10 **Compound 88**




To compound 3 (1.62 g, 5.32 mmol) in anhydrous DMF (20 mL) was added
15 NaH (60% in mineral oil, 510 mg, 12.77 mmol), followed by 2-chloroethyl
dimethylamine hydrochloride (843 mg, 5.85 mmol). The mixture was stirred at 65°C
overnight. The solution was poured into saturated sodium bicarbonate and extracted
with EtOAc. The combined extracts were dried over MgSO₄ and evaporated. The
residue was purified by chromatography (EtOAc:MeOH, 10:1) to give 1.72g (86%
20 yield) of compound 88 as a solid:

¹H NMR (CDCl₃) δ 2.23 (s, 3H), 2.25 (s, 6H), 2.48 (t, J = 6.7 Hz, 2H), 4.45 (t, J = 6.7
Hz, 2H), 5.21 (s, 1H), 5.37 (s, 1H), 5.39 (s, 2H), 7.03-7.09 (m, 3H), 7.24-7.34 (m,
3H), 7.49-7.52 (m, 1H), 7.75-7.79 (m, 1H);
25 IR (KBr, cm⁻¹) 2941, 2830, 2774, 1693, 1396, 1157, 747, 732;
MS m/e 376 (MH⁺);

Anal. Calcd for C₂₂H₂₅N₅O: C, 70.38; H, 6.71; N, 18.65


Found: C, 70.29; H, 6.78; N, 18.76.

Compound 89**89**

5

Compound **89** was prepared as described for compound **6**.


¹H NMR (CDCl₃) δ 2.29 (s, 6H), 2.50 (t, J = 7.2Hz, 2H), 4.45 (t, J = 7.2Hz, 2H), 5.40 (s, 2H), 7.00-7.05 (m, 3H), 7.27-7.30 (m, 2H), 7.35-7.37 (m, 1H), 7.42-7.44 (m, 1H),
10 7.77-7.80 (m, 1H), 8.41 (bs, 1H);
MS m/e 336 (MH⁺).

Compound 90

15

The isopropenyl group of compound **88** was reduced to the isopropyl group as described for compound **115**.

20 ¹H NMR (CDCl₃) δ 1.54 (d, J = 7.0 Hz, 6H), 2.27 (s, 6H), 2.47 (t, J = 6.8Hz, 2H),
4.44 (t, J = 6.8Hz, 2H), 4.72-4.82 (m, 1H), 5.39 (s, 2H), 6.98-7.06 (m, 2H), 7.07-7.13 (m, 1H), 7.24-7.33 (m, 3H), 7.48-7.52 (m, 1H), 7.75-7.79 (m, 1H);
MS m/e 413 (MH⁺).


4-Bromomethyl-N,N-dimethyl-benzamide

5 4-bromomethylbenzoic acid (25 g, 116.25 mmol) was dissolved in CH_2Cl_2 (200 ml) and treated with oxalyl chloride (12.2 ml, 139.5 mmol). DMF (0.45 ml) was added slowly then stirred for 1 h. The solvent was removed to give the 4-bromomethylbenzoyl chloride as a white solid.

10 A mixture of 4-bromomethyl-benzoyl chloride (7.0 g, 30.24 mmol), polyvinyl pyridine (9.6 g, 90.7 mmol) and dimethyl amine (15.9 ml, 31.8 mmol, 2.0 M in THF) was stirred at 23°C for 15 h. The solution was filtered and the solvent removed to give 7.3 g (99% yield) of 4-bromomethyl-N,N-dimethyl-benzamide as a yellow solid.

15

^1H NMR (CDCl_3) δ 2.98 (s, 3H), 3.10 (s, 3H), 4.49 (s, 2H), 7.37-7.43 (m, 4H).
MS m/e 242 (MH^+).












20

Table 13- Compounds in the table below were prepared by alkylation of compound 89 as described for compound 7.

#	R_2	^1H -NMR Data	MS Data
91a		(CD_3OD) 2.36 (s, 3H), 2.39 (s, 3H), 3.10 (s, 6H), 3.87 (t, $J = 7.9\text{Hz}$, 2H), 5.19 (t, $J = 7.9\text{Hz}$, 2H), 5.19 s, 2H), 5.46 (s, 2H), 5.90 (s, 2H), 6.37 (s, 1H), 7.16-7.23 (m, 5H), 7.45 (d, $J = 8.2\text{Hz}$, 3H), 7.68-7.79 (m, 3H), 8.12 (d, $J = 8.5\text{Hz}$, 1H)	534 (MH^+)
91b		(CD_3OD) δ 3.12 (s, 6 H), 3.85 (t, $J = 7.4\text{ Hz}$, 2 H), 3.91 (s, 3 H), 5.17-5.24 (m, 2 H), 5.21 (s, 2 H), 5.78 (s, 2 H), 5.90 (s, 2 H), 7.06-7.25 (m, 3 H), 7.38 (d, $J = 7.9\text{ Hz}$, 2 H), 7.46 (d, $J = 8.3\text{ Hz}$, 3 H), 7.65-7.79 (m, 3 H), 8.10 (d, $J = 8.3\text{ Hz}$, 1 H), 8.31 (s, 1 H), 9.23 (s, 1 H)	564 (MH^+)


91c		(DMSO-d6) δ 2.21 (s, 6 H), 2.56 (t, J = 6.5 Hz, 2 H), 4.39 (t, J = 6.4 Hz, 2 H), 5.08 (s, 2 H), 5.43 (s, 2 H), 5.51 (s, 2 H), 6.98-6.99 (m, 2 H), 7.10 (d, J = 8.1 Hz, 2 H), 7.14-7.25 (m, 4 H), 7.31 (d, J = 8.2 Hz, 2 H), 7.54-7.56 (m, 4 H), 8.00 (bs, 1 H)	550 (MH+)
91d		(CDCl3) 2.30 (s, 6H), 2.52-2.63 (m, 2H), 3.38 (s, 3H), 4.47-4.59 (m, 2H), 5.08 (s, 2H), 5.10 (s, 4H), 5.45 (s, 2H), 5.81 (d, J = 7.9Hz, 1H), 6.87-6.90 (m, 1H), 7.00-7.04 (m, 2H), 7.23-7.30 (m, 5H), 7.42 (d, J = 8.0 Hz, 3H), 7.49-7.52 (m, 1H), 7.78-7.81 (m, 1H)	594 (MH+)
91e		(CD3OD) 3.03 (s, 6H), 3.73 (s, 3H), 3.74-3.80 (m, 2H), 4.56 (s, 2H), 5.07 (s, 2H), 5.12 (s, 2H), 5.12-5.20 (m, 2H), 5.76 (d, J = 7.5Hz, 1H), 5.87 (s, 2H), 7.17-7.20 (m, 3H), 7.28-7.33 (m, 4H), 7.44-7.46 (m, 1H), 7.54 (d, J = 7.8Hz, 1H), 7.63-7.78 (m, 3H), 8.11 (d, J = 8.1Hz, 1H)	622 (MH+)
91f		(DMSO-d6) 1.33 (s, 9H), 2.88 (s, 3H), 2.89 (s, 3H), 3.67-3.41 (m, 2H), 4.44 (s, 2H), 4.94 (s, 2H), 4.96-5.01 (m, 2H), 5.09 (s, 2H), 5.68 (s, 2H), 5.78 (d, J = 7.9Hz, 1H), 7.04-7.07 (m, 2H), 7.16-7.19 (m, 1H), 7.21 (d, J = 8.2Hz, 2H), 7.32 (d, J = 8.2Hz, 2H), 7.39-7.47 (m, 3H), 7.69 (t, J = 8.3Hz, 2H), 7.99 (d, J = 8.0 Hz, 1H)	664 (MH+)
91g		(CDCl3) 2.26 (s, 6H), 2.52 (t, J = 6.9Hz, 2H), 2.82 (dd, J = 4.5, 17.4Hz, 1H), 3.00 (dd, J = 4.5, 17.1Hz, 1H), 3.65 (s, 3H), 3.70 (s, 3H), 4.37 (d, J = 5.1Hz, 2H), 4.47 (t, J = 7.1Hz, 2H), 4.80-4.84 (m, 1H), 5.04 (s, 4H), 5.44 (s, 2H), 5.76 (d, J = 7.8Hz, 1H), 6.85-6.88 (m, 1H), 6.97-7.00 (m, 2H), 7.14 (d, J = 8.1Hz, 1H), 7.19-7.29 (m, 4H), 7.35-7.47 (m, 4H), 7.75-7.78 (m, 1H)	751 (MH+)
91h		(DMSO-d6) δ 1.22 (t, J = 7.1Hz, 3H), 2.36 (s, 6H), 2.71-2.82 (s, 2H), 4.16 (q, J = 7.1Hz, 2H), 4.52 (t, J = 6.4Hz, 2H), 4.79 (s, 2H), 5.43 (s, 2H), 7.00-7.10 (m, 2H), 7.10-7.30 (m, 4H), 7.61-7.72 (m, 2H)	421 (MH+)
91i		(CD3OD) 1.66-1.72 (m, 2H), 1.83-1.88 (m, 2H), 2.41 (t, J = 7.2Hz, 2H), 3.14 (s, 6H), 3.62 (s, 3H), 3.87 (t, J = 8.0 Hz, 2H), 4.02 (t, J = 6.8Hz, 2H), 5.19 (t, J = 7.8Hz, 2H), 5.86 (s, 2H), 7.22-7.34 (m, 3H), 7.45-7.48 (m, 1H), 7.67-7.79 (m, 3H), 8.11 (d, J = 8.0 Hz, 1H)	450 (MH+)
91j		(CDCl3) 1.21-1.29 (m, 3 H), 1.36-1.46 (m, 2 H), 1.64-1.84 (m, 6 H), 2.29-2.33 (m, 6 H), 2.52 (m, 2 H), 3.88-3.93 (m, 2 H), 4.07-4.14 (m, 2 H), 4.43-4.48 (m, 2 H), 5.42 (s, 2 H), 6.91-7.50 (m, 6 H), 7.75-7.81 (m, 2 H)	478 (MH+)
91k		(CD3OD) 3.11 (s, 6 H), 3.77 (t, J = 7.8 Hz, 2 H), 5.05 (t, J = 7.8 Hz, 2 H), 5.53 (s, 2 H), 5.72 (s, 2 H), 7.13-7.25 (m, 3 H), 7.72 (d, J = 7.8 Hz, 1 H),	427 (MH+)

		7.85 (d, J = 8.1 Hz, 1 H), 8.03-8.06 (m, 2 H), 8.83 (bs, 2 H)	
91l		(CD ₃ OD) 3.11 (s, 6 H), 3.77 (t, J = 7.9 Hz, 2 H), 5.02 (t, J = 7.9 Hz, 2 H), 5.52 (s, 2 H), 5.68 (s, 2 H), 7.07 (d, J = 8.4 Hz, 1 H), 7.32 (dd, J = 1.6, 8.4 Hz, 1 H), 7.43-7.55 (m, 2 H), 7.70-7.73 (m, 2 H), 7.83 (d, J = 7.9 Hz, 1 H), 8.03 (d, J = 6.3 Hz, 2 H), 8.83 (d, J = 6.0 Hz, 2 H)	505, 507 (MH ⁺)
91m		(CD ₃ OD) 3.09 (s, 6 H), 3.82-3.95 (m, 2 H), 5.13 (s, 2 H), 5.20-5.24 (m, 2 H), 5.94 (s, 2 H), 7.17-7.24 (m, 3 H), 7.30-7.38 (m, 2 H), 7.47-7.52 (m, 3 H), 7.65-7.78 (m, 3 H), 8.18 (d, J = 8.0 Hz, 1 H)	506 (MH ⁺)
91n		(CDCl ₃) 2.31 (s, 6 H), 2.57 (t, J = 6.6 Hz, 2 H), 4.53 (t, J = 6.7 Hz, 2 H), 5.04 (s, 2 H), 5.06 (s, 2 H), 5.46 (s, 2 H), 6.92-6.95 (m, 3 H), 7.01-7.04 (m, 2 H), 7.27-7.43 (m, 10 H), 7.49-7.52 (m, 1 H), 7.79-7.83 (m, 1 H)	532 (MH ⁺)
91o		(CD ₃ OD) 3.13 (s, 6 H), 3.87 (t, J = 7.9 Hz, 2 H), 5.20 (t, J = 7.7 Hz, 2 H), 5.34 (s, 2 H), 5.91 (s, 2 H), 7.19-7.24 (m, 3 H), 7.48-7.52 (m, 1 H), 7.63-7.77 (m, 5 H), 8.09-8.12 (m, 1 H), 8.22-8.26 (m, 2 H)	505 (M-H ⁻)
91p		(CD ₃ OD) 3.12 (s, 6 H), 3.89 (t, J = 7.9 Hz, 2 H), 5.24 (t, J = 7.9 Hz, 2 H), 5.29 (s, 2 H), 5.96 (s, 2 H), 7.19-7.24 (m, 3 H), 7.50-7.53 (m, 1 H), 7.60 (d, J = 8.3 Hz, 1 H), 7.67 (d, J = 7.5 Hz, 1 H), 7.71-7.80 (m, 5 H), 8.17 (d, J = 8.1 Hz, 1 H)	494 (MH ⁺)
91q		(CD ₃ OD) 2.02-2.33 (m, 4 H), 3.22-3.33 (m, 2 H), 3.78-3.89 (m, 2 H), 3.90 (s, 3 H), 3.94 (t, J = 7.9 Hz, 2 H), 5.21 (t, J = 7.2 Hz, 2 H), 5.27 (s, 2 H), 5.94 (s, 2 H), 7.17-7.25 (m, 3 H), 7.49-7.53 (m, 3 H), 7.69-7.81 (m, 3 H), 8.02 (d, J = 8.2 Hz, 2 H), 8.16 (d, J = 7.9 Hz, 1 H)	510 (MH ⁺)
91r		(DMSO-d ₆) 1.27 (t, J = 6.9 Hz, 6 H), 3.29 (s, 6 H), 3.81 (t, J = 7.6 Hz, 2 H), 4.06-4.12 (m, 4 H), 5.19 (t, J = 7.6 Hz, 2 H), 5.26 (s, 2 H), 5.88 (s, 2 H), 7.16-7.21 (m, 3 H), 7.46-7.79 (m, 8 H), 8.09 (d, J = 7.8 Hz, 1 H)	562 (MH ⁺)
91s		(CDCl ₃) 2.79 (s, 6 H), 3.41-3.69 (m, 2 H), 3.52 (s, 3 H), 3.62 (s, 6 H), 4.82 (bs, 2 H), 5.22-5.36 (m, 2 H), 5.77 (bs, 2 H), 6.32 (s, 2 H), 6.77 (d, J = 7.8 Hz, 1 H), 6.85-7.03 (m, 2 H), 7.18-7.29 (m, 1 H), 7.35-7.51 (m, 2 H), 7.82-7.92 (m, 1 H), 8.10-8.25 (m, 1 H)	516 (MH ⁺)

Compound 92

To a solution of compound **89** (502 mg, 1.5 mmol), 4-N,N-dimethylaminobenzyl
5 alcohol (prepared as described by Swami, S. S. et al, Synth Commun., 29(12), 2129-
2131, 1999) (272 mg, 1.8 mmol), and 1,1'-(azodicarbonyl)dipiperidine (453 mg, 1.8
mmol) in THF was added tributylphosphine (364 mg, 1.8 mmol) at 0°C. The final
solution was allowed to warm to room temperature and stirred for 12 h. The solvent
is evaporated and the residue purified by preparative reverse phase HPLC to yield
10 420 mg (60%) of compound **92** as a viscous oil.

¹H NMR (DMSO-d₆) δ 3.06 (s, 6H), 3.16 (s, 6H), 3.67 (t, J = 7.5 Hz, 2H), 4.99 (t, J =
7.5 Hz, 2H), 5.18 (s, 2H), 5.61 (s, 2H), 7.09-7.18 (m, 3H), 7.37-7.53 (m, 7H), 7.66-
7.78 (m, 2H);
15 MS m/e 469 (MH⁺).


Compound 93

20 A mixture of compound **91i** (50 mg, 0.10 mmol), N-methylpiperidine (12 mg, 0.12
mmol), sodium t-butoxide (14 mg, 0.15 mmol), dipalladium (0) (9 mg, 0.01 mmol)
and (R)-(+)-BINAP (19 mg, 0.03 mmol) in toluene (2 ml) was heated to 100°C for 2
h. The solvent is evaporated and the residue purified by preparative reverse phase-
HPLC to yield 54 mg (100%) of compound **93** as a white solid.

25

^1H NMR (CD_3OD) δ 2.93 (s, 3H), 3.05 (s, 6H), 3.18-3.24 (m, 2H), 3.57-3.69 (m, 4H), 3.78-3.82 (m, 2H), 4.92-4.98 (m, 2H), 5.09 (s, 2 H), 5.56 (s, 2H), 6.98-6.99 (m, 2H), 7.06-7.09 (m, 3 H), 7.28-7.34 (m, 2H), 7.38-7.47 (m, 3H), 7.66-7.72 (m, 2H); MS m/e 524 (MH^+).

5


Compound 94

Compound 94 was prepared using the same procedure as compound 88 with
10 N-(2-chloroethyl) pyrrolidine hydrochloride in 82% yield:

^1H NMR (CDCl_3) δ 1.70 (bs, 4H), 2.23 (s, 3H), 2.50 (bs, 4H), 2.66 (t, $J = 7.0$ Hz, 2H), 4.48 (t, $J = 7.0$ Hz, 2H), 5.20 (s, 1H), 5.37 (s, 1H), 5.39 (s, 2H), 7.02-7.09 (m, 3H), 7.24-7.35 (m, 2H), 7.35-7.40 (m, 1H), 7.47-7.50 (m, 1H), 7.75-7.80 (m, 1H);
15 IR (KBr, cm^{-1}) 2956, 2796, 1701, 1489, 1395, 1332, 1153, 743;
MS m/e 402 (MH^+);

Anal. Calcd for $\text{C}_{24}\text{H}_{27}\text{N}_5\text{O}$: C, 71.79; H, 6.78; N, 17.44

Found: C, 71.55; H, 6.84; N, 17.37


20 **Compound 95**

Compound 95 was prepared as described for compound 6.

25

¹H NMR (CDCl₃) 1.62-1.80 (m, 4H), 2.46-2.59 (m, 4H), 2.67 (t, J = 7.2Hz, 2H), 4.47 (t, J = 7.4Hz, 2H), 5.40 (s, 2H), 7.00-7.04 (m, 3H), 7.25-7.29 (m, 2H), 7.36-7.43 (m, 2H), 7.76-7.93 (m, 1H), 8.68 (bs, 1H);
MS m/e 362 (MH⁺).


5

Compound 96

Compound 96 was prepared as described for compound 7.

10

¹H NMR (CD₃OD) δ 2.02-2.33 (m, 4H), 3.22-3.33 (m, 2H), 3.78-3.89 (m, 2H), 3.90 (s, 3H), 3.94 (t, J = 7.9Hz, 2H), 5.21 (t, J = 7.2 Hz, 2H), 5.27 (s, 2H), 5.94 (s, 2H), 7.17-7.25 (m, 3H), 7.49-7.53 (m, 3H), 7.69-7.81 (m, 3H), 8.02 (d, J = 8.2Hz, 2 H), 8.16 (d, J = 7.9 Hz, 1H);

15 MS m/e 362 (MH⁺).**Compound 97**


20

Compound 97 was prepared as described for compound 88 using 2-chloropropyltrimethylamine hydrochloride.

¹H NMR (CDCl₃) δ 1.74-1.84 (m, 2H), 2.13 (s, 6H), 2.17 (t, J = 6.9 Hz, 2H), 2.23 (s, 3H), 4.41 (t, J = 7.1 Hz, 2H), 5.20 (s, 1H), 5.37 (d, J = 1.4 Hz, 1H), 5.44 (s, 2H),
25 6.98-7.08 (m, 3H), 7.22-7.28 (m, 2 H), 7.35-7.41 (m, 1H), 7.46-7.52 (m, 1H), 7.75-7.80 (m, 1H);

MS m/e 390 (MH⁺).

Compound 98



5


Compound 98 was prepared as described for compound 6.

¹H NMR (CDCl₃) δ 1.76-1.85 (m, 2H), 2.23 (s, 6H), 2.33 (t, J = 7.1 Hz, 2H), 4.38 (t, J = 7.3 Hz, 2H), 5.43 (s, 2H), 6.99-7.02 (m, 3H), 7.25-7.29 (m, 2H), 7.35-7.42 (m, 2H), 7.75-7.80 (m, 1H);

10

MS m/e 350 (MH⁺).

Compound 99



15


N-methylethanolamine was treated with benzylchloroformate to give (2-hydroxy-ethyl)-methyl-carbamic acid benzyl ester. The product was treated with methanesulfonyl chloride and Et₃N in CH₂Cl₂ to give methanesulfonic acid 2-(benzyloxycarbonyl-methyl-amino)-ethyl ester. The resulting mesylate is used to alkylate 3 as described for the preparation of 4. The isopropenyl group is removed with acid as described for 6. The product is alkylated as described for compound 7 and the benzyloxy group was removed with catalytic hydrogenation (Pd/C) to give compound 99.

20

¹H NMR (CD₃OD) δ 2.86 (s, 3H), 3.79 (t, J = 6.7Hz, 2H), 3.90 (s, 3H), 5.16 (t, J = 6.7Hz, 2H), 5.26 (s, 2H), 5.96 (s, 2H), 7.19-7.26 (m, 3H), 7.51 (d, J = 8.3Hz, 3H), 7.68-7.80 (m, 3H), 8.01 (d, J = 8.3Hz, 2H), 8.14 (d, J = 8.2Hz, 1H);
MS m/e 470 (MH⁺).


5

Compound 100 (Scheme I)



10 To a solution of 1-ethyl-2-benzimidazolone (0.5 g, 3.39 mmol) in DMF (10 mL) was added to NaH (136 mg, 3.39 mmol) and the mixture was stirred for 1 hr. 1-Methylsulfonyl-2-iodomethylbenzimidazole (2) (1.14 g, 3.39 mmol) was added and the mixture was stirred for 12 h. The reaction was diluted with saturated sodium bicarbonate and extracted with ethyl acetate. The organic extracts were combined,
15 dried over sodium sulfate, filtered and evaporated. The residue was purified by silica gel chromatography, eluted with 50 % ethyl acetate in hexanes to give 767 mg (61% yield) of the N-methanesulfonylated derivative of **100a**. A mixture of the N-methanesulfonylated derivative of **100** (760 mg, 2.0 mmol) and hydrazine hydrate (0.9 ml) in methanol was heated to reflux for 12h, then cooled and concentrated. The
20 residue was diluted with water and extracted with ethyl acetate. The combined extracts were dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel with 50% ethyl acetate in hexanes as eluant to give 250 mg (28%) of compound **100** as a white solid.

25 ¹H NMR (DMSO-d₆) δ 1.26 (t, J = 7.1 Hz, 3H), 3.93 (q, J = 7.1 Hz, 2H), 5.27 (s, 2H), 6.99 (t, J = 7.4 Hz, 1H), 7.05-7.06 (m, 2H), 7.07-7.08 (m, 2H), 7.24 (d, J = 8.3 Hz, 1H), 7.40-7.60 (m, 2H);
MS m/e 292 (MH⁺).

Compound 101

5 Compound **100** (500 mg, 1.71 mmol) in DMF (2 mL) was added to a slurry of sodium hydride (60% in mineral oil, 75 mg, 3.14 mmol) in DMF (10 ml) and stirred for 1 h. 2-Bromoacetophenone (375 mg, 1.88 mmol) was added and the mixture was stirred for 48 h. The reaction was diluted with water and extracted with ethyl acetate. The organic extracts were combined, dried over sodium sulfate and concentrated.

10 The residue was purified by silica gel chromatography with 50% ethyl acetate in hexanes as eluant to give 474 mg (68% yield) of compound **101** as a white solid:

¹H NMR (DMSO-d₆) δ 1.05 (t, J = 7.1 Hz, 3 H), 3.65 (q, J = 7.1 Hz, 2 H), 5.28 (s, 2 H), 6.15 (s, 2 H), 7.00-7.05 (m, 2 H), 7.13-7.20 (m, 3 H), 7.24-7.27 (m, 1 H), 7.44-7.49 (m, 1 H), 7.60-7.65 (m, 3 H), 7.73-7.95 (m, 1 H), 8.03 (d, J = 8.4 Hz, 2 H);


15 IR (KBr, cm⁻¹) 2956, 1706, 1686, 1497, 1219, 744;

 MS m/e 411 (MH⁺);

Anal. Calcd for C₂₅H₂₂N₄O₂•0.4 H₂O: C, 72.20; H, 5.48; N, 13.47

 Found: C, 72.04; H, 5.45; N, 13.66.

20

Compound 102


To a 0°C solution of compound **101** (350 mg, 0.85 mmol) in MeOH (10 ml)

25 was added NaBH₄ (323 mg, 8.53 mmol) and the mixture stirred for 2 h. The reaction was warmed to 23°C and stirred for 12 h. The solvent was evaporated and the residue dissolved in EtOAc and washed with water. The organic layer is dried over Na₂SO₄

and concentrated. The residue was purified by flash chromatography with 50% EtOAc in hexanes to give 264 mg (75%) of compound **102** as a white solid.

¹H NMR (DMSO-d₆) δ 1.22 (t, J = 7.1 Hz, 3H), 3.91 (q, J = 6.9 Hz, 2H), 4.42-4.61 (m, 2H), 4.90-4.91 (m, 1H), 5.26-5.31 (m, 1H), 5.40-5.46 (m, 1H), 5.82-5.83 (m, 2H), 6.97-7.08 (m, 2H), 7.15-7.29 (m, 4H), 7.32-7.42 (m, 3H), 7.39-7.61 (m, 4H);
5 IR (KBr, cm⁻¹) 3200, 1701, 733;
MS m/e 412 (MH⁺);

Anal. Calcd for C₂₅H₂₄N₄O₂•0.16 H₂O: C, 72.29; H, 5.90; N, 13.49
Found: C, 72.27; H, 5.72; N, 13.33.

Compound 103

- 5 To a stirred solution of compound **100** (150 mg, 0.51 mmol) in DMF (10 ml) was added sodium hydride (22.6 mg, 0.55 mmol) and the mixture stirred for 1 hour. R-(+)-styrene oxide (123 mg, 1.02 mmol) was added and the mixture heated to 110°C for 2 h. The mixture was cooled, diluted with water and extracted with EtOAc. The combined organic extracts are dried over Na₂SO₄ and concentrated. The residue is
- 10 purified by flash chromatography to give compound **103** (34 mg, 16%) as a white solid.

¹H NMR (DMSO-d₆) δ 1.22 (t, J = 7.1 Hz, 3H), 3.91 (q, J = 6.9 Hz, 2H), 4.43-4.61 (m, 2H), 4.90-4.93 (m, 1H), 5.16-5.31 (m, 1H), 5.33-5.46 (m, 1H), 5.82-5.83 (m, 2H), 6.97-7.08 (m, 2H), 7.15-7.29 (m, 4H), 7.32-7.42 (m, 3H), 7.39-7.61 (m, 4H);


- 15 [α]_D²⁵ = -44.76 (25°C, c = 0.714, CH₂Cl₂)

MS m/e 412 (MH⁺);

Anal. Calcd for C₂₅H₂₄N₄O₂: C, 72.80; H, 5.86; N, 13.58

Found: C, 72.50; H, 6.21; N, 12.52.


20 **Compound 104**



- Compound **104** was prepared by alkylation of compound **100** with 1-
- 25 methanesulfonyl-4-chloromethyl-benzene as previously described for compound **101**.

¹H NMR (DMSO-d₆) δ 1.96 (s, 3 H), 3.12 (s, 3 H), 4.94 (s, 1 H), 5.19 (s, 1 H), 5.42 (s, 2 H), 5.77 (s, 2 H), 6.95 (d, *J* = 5.0, 2 H), 7.02-7.07 (m, 3 H), 7.20-7.25 (m, 3 H), 7.61-7.63 (m, 2H), 7.68-7.71 (m, 1H), 7.90-7.98 (m, 1H);
MS *m/e* 473 (MH⁺).

5

Compound 105


10 The isopropenyl group of compound 104 was removed as described for compound 6 and converted to compound 105 as described for compound 7 using 1-methanesulfonyl-4-chloromethylbenzene.

¹H NMR (DMSO-d₆) δ 3.17 (s, 6H), 4.99 (s, 2H), 5.47 (s, 2H), 5.79 (s, 2H), 6.98-7.03 (m, 3H), 7.07 (d, *J* = 5.0, 2H), 7.17 (d, *J* = 5.5, 1H), 7.25-7.27 (m, 2H), 7.47-7.53 (m, 1H), 7.51 (d, *J* = 4.1, 2H), 7.69-7.72 (m, 2H), 7.88 (d, *J* = 5.0, 2H);
MS *m/e* 600 (MH⁺).

15

Compound 106 (Scheme II)

20




To a solution of 2-hydroxymethylbenzimidazole (27.1 g, 182.9 mmol) in a 1:1 mixture of DMF/THF (200 mL) was added NaH (60% in mineral oil, 8.05 g, 201.2 mmol) at room temperature. After stirring for 1.5 h, 1-bromo-3-methylbutane (29 g, 192 mmol) was added and the mixture was stirred at 75 °C overnight. The mixture was adjusted to neutral pH with concentrated HCl and the solvent was evaporated. The residue was diluted with EtOAc, washed with water, dried over

25

MgSO₄, and evaporated. The residue was crystallized from EtOAc/hexane to give 29 g of compound **106** as white solid. The mother liquor was purified by flash chromatography (EtOAc:hexane= 1:1 to 2:1 and then EtOAc:MeOH = 10:0 to 10:1) to give additional 5.24 g (total 86% yield) of compound **106**.

5

Compound 107




10 To a solution of compound **106** (34.24g, 156.9 mmol) in CH₂Cl₂ (100 mL) was slowly added SOCl₂ (28 g, 235.4 mmol) with an ice-bath cooling. The resulting solution was stirred at room temperature for 1 h and evaporated. The residue was dried in vacuum and then triturated in a mixture of CH₂Cl₂/Et₂O to give 41.25 g (96% yield) of compound **107** as a white solid:

15

¹H NMR (DMSO-d₆) δ 0.99 (d, J = 6.3 Hz, 6H), 1.72-1.79 (m, 3H), 4.47-4.52 (m, 2H), 5.36 (s, 2H), 7.52-7.61 (m, 2H), 7.82-7.92 (m, 2H);
MS m/e 237 (MH⁺).

20 Compound 108



A mixture of **107** (200 mg, 0.84 mmol), N-methylbenzimidazole (128 mg, 0.76 mmol) and NaH (33.6 mg, 0.84 mmol) were stirred in acetonitrile (10 mL) for 1 h. The solvent was evaporated. The residue was diluted with water and extracted with CH₂Cl₂. The combined extracts were washed with water, brine, and dried over MgSO₄. The solvent was evaporated, and the residue was purified by chromatography to give 65.9 mg (25% yield) of compound **108**:

25

^1H NMR (CDCl_3) δ 0.92 (d, $J = 6.6$ Hz, 6 H), 1.28-1.36 (m, 2 H), 1.61-1.74 (m, 1 H), 3.45 (s, 3 H), 4.26-4.32 (m, 2 H), 5.42 (s, 2 H), 6.93-7.10 (m, 3 H), 7.27-7.32 (m, 3 H), 7.40 (d, $J = 7.4$ Hz, 1 H), 7.79-7.81 (m, 1 H);


5 IR (KBr, cm^{-1}) 3425, 3054, 1706, 1499, 1399, 743;

MS m/e 349 (MH^+);

Anal. Calcd for $\text{C}_{21}\text{H}_{24}\text{N}_4\text{O}_1 \cdot 0.65 \text{H}_2\text{O}$: C, 70.03; H, 7.08; N, 15.56.

Found: C, 70.05; H, 6.83; N, 15.45.


10 **Compound 109**




Compound 109 was prepared from the known 1-carboethoxy-
15 benzimidazolone (Meanwell et al J. Org. Chem. 1995, 60, 1565-1582) and 107 as described
above for the preparation of 108.

^1H NMR CDCl_3 δ 0.95 (d, $J = 6.6$ Hz, 6H), 1.37-1.45 (m, 2H), 1.50 (t, $J = 7.1$ Hz, 3H), 1.67-1.74 (m, 1H), 4.29-4.35 (m, 2H), 5.38 (s, 2H), 7.10-7.19 (m, 2H), 7.29-7.33 (m, 3H), 7.47-7.50 (m, 1H), 7.77-7.80 (m, 1H), 7.83-7.86 (m, 1H);

20 MS m/e 407 (MH^+).

Compound 110

- 5 ¹H NMR (CDCl₃) δ 0.94 (dd, J = 1.3, 6.6 Hz, 6H), 1.44-1.74 (m, 3H), 3.76 (s, 3H), 4.32-4.38 (m, 2H), 5.46 (s, 2H), 6.67 (d, J = 7.5 Hz, 1H), 6.97-7.09 (m, 3H), 7.27-7.43 (m, 5H), 7.54 (d, J = 7.6 Hz, 1H), 7.78-7.83 (m, 1H).

Compound 111

10

Compound 111 was prepared in 49% yield by the same procedure as described for compound 108 with chloride 107 and N-t-butoxycarbonyl-5-chlorobenzimidazolone (Meanwell et al J. Org. Chem. 1995, 60, 1565-1582):

15


¹H NMR (CDCl₃) δ 0.95 (d, J = 6.7 Hz, 6H), 1.39-1.45 (m, 2H), 1.66 (s, 9H), 1.64-1.77 (m, 1H), 4.29-4.35 (m, 2H), 5.37 (s, 2H), 7.07 (dd, J = 2.0, 8.6 Hz, 1H), 7.28-7.33 (m, 3H), 7.56 (bs, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.80-7.82 (m, 1H);
IR (KBr, cm⁻¹) 2871, 1791, 1752, 1489, 1378, 1323, 1253, 1149, 1113, 742.

20

MS m/e 469 (MH⁺);

Anal. Calcd for C₂₅H₂₉ClN₄O₃: C, 64.03; H, 6.23; N, 11.95

Found: C, 64.29; H, 6.02; N, 11.55.

Compound 112

5 Compound 111 (200 mg, 0.43 mmol) was dissolved in a mixture of
CH₂Cl₂:TFA (3:1, 4 mL). The mixture was stirred at ambient temperature for 5
minutes and then evaporated. The residue was dissolved in CH₂Cl₂, washed with
saturated NaHCO₃, water, and dried over MgSO₄. The residue was purified by
chromatography (EtOAc: hexane 1:1 to 2:1) to give compound 18 mg of the
10 compound 112 as a light yellow solid:


¹H NMR (DMSO-d₆) δ 0.94 (d, J = 6.6 Hz, 6H), 1.41-1.48 (m, 2H), 1.63-1.72 (m,
1H), 4.30 (bt, J = 8.1 Hz, 2H), 5.34 (s, 2H), 7.04 (s, 2H), 7.12-7.27 (m, 3H), 7.52 (d, J
= 7.9 Hz, 1H), 7.60 (d, J = 7.5 Hz, 1H);

15 IR (KBr, cm⁻¹) 2956, 1705, 1489, 1458, 1386, 741;
MS m/e 369 (MH⁺);

Anal. Calcd for C₂₀H₂₁ClN₄O•0.4 CF₃COOH: C, 60.28; H, 5.20; N, 13.52.

Found: C, 60.49; H, 5.58; N, 13.41.

20 **Compound 113**



Compound 113 was prepared using Michael addition conditions described by Popov,
25 I. I. in Khim Geterotskl. Soedin. 1996 (6), 781-792.


¹H NMR (CDCl₃) δ 3.08 (t, J = 6.8 Hz, 2H), 4.63 (t, J = 6.8 Hz, 2H), 4.77 (d, J = 5.7 Hz, 2H), 5.73 (t, J = 5.7 Hz, 1H), 7.17-7.28 (m, 2H), 7.64 (d, J = 1.2 Hz, 1H), 7.70 (d, J = 1.2 Hz, 1H);

MS m/e 202 (MH^+);

5 Anal. Calcd for $C_{11}H_{11}N_3O$: C 65.66; H, 5.51; N, 20.88.

Found: C, 65.94; H, 5.57; N, 21.08.

Compound 114



10

To a solution of alcohol **113** (20g, 99.4 mmol) in methylene chloride (50 mL) was slowly added SOCl₂ (15.4 g, 129.2 mmol). The solution was stirred at room temperature for 3 hours. The solvent was evaporated. The residue was diluted with water and neutralized with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The combined extracts were washed with water, dried over magnesium sulfate, and evaporated. The residue was triturated with Et₂O and hexane to give 19.78 g (91% yield) of compound **114** as a white solid:

20

¹H NMR (CDCl₃) δ 3.02 (t, J = 7.0Hz, 2H), 4.65 (t, J = 7.0 Hz, 2H), 4.99 (s, 2H), 7.34-7.44 (m, 3H), 7.79-7.82 (m, 1H);


MS m/e 220 (MH⁺);

Anal. Calcd for $C_{11}H_{10}ClN_3$: C, 60.09; H, 4.65; N, 19.13.

25

Found: C, 60.09; H, 4.65; N, 19.11.

Compound 115



A mixture of N-isopropenyl-2-benzimidazolone (6.90 g, 39.6 mmol) and 1 g of 10 % palladium on carbon in 30 mL of methanol was hydrogenated at 45-55 psi for one hour. The catalyst was filtered and the filtrate was evaporated to give quantitative yield of compound 115 as a white solid:

5

^1H NMR (CDCl_3) δ 1.57 (d, $J = 7.1$ Hz, 6H), 4.70-4.81 (m, 1H), 7.02-7.10 (m, 2H), 7.10-7.20 (m, 2H);


MS m/e 177 (MH^+);

Anal. Calcd for $\text{C}_{10}\text{H}_{12}\text{N}_2\text{O}$: C, 68.16; H, 6.86; N, 15.90

10

Found: C, 68.05; H, 6.63; N, 15.77.

Compound 116



15

To compound 115 (5.0 g, 28.37 mmol) and chloride 114 (6.23 g, 28.37 mmol) in THF (50 mL) was added BTPP (7.39 g, 42.6 mmol) at room temperature and stirred for 30 minutes. The solvent was evaporated and the residue was purified by flash chromatography (EtOAc : hexane 1:2 to 2:1) to give 7.62 g (75%) of compound 116 as a white solid:

20

^1H NMR (CDCl_3) δ 1.58 (d, $J = 7.0$ Hz, 6H), 2.68 (t, $J = 6.8$ Hz, 2H), 4.71-4.83 (m, 1H), 4.81 (t, $J = 6.8$ Hz, 2H), 5.40 (s, 2H), 7.06-7.27 (m, 3H), 7.34-7.40 (m, 3H), 7.57-7.61 (m, 1H), 7.82-7.87 (m, 1H);


25

IR (KBr, cm^{-1}) 2250, 1694, 1493, 1396, 745;


MS m/e 360 (MH^+);

Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{N}_5\text{O} \cdot 0.3 \text{H}_2\text{O}$: C, 69.14; H, 5.97; N, 19.20

Found: C, 69.07; H, 5.92; N, 19.40.


Compound 117

2-fluoronitrobenzene was treated with aniline in the presence of K_2CO_3 in CH_3CN and heated to reflux for 12 h. The solution is cooled, filtered and the solvent removed. The nitro group is reduced with catalytic hydrogenation and the diamine treated with CDI to give 1-phenyl-1,3-dihydro-benzoimidazol-2-one.

Compound 118

Compound 118 was prepared by alkylation of compound 117 with compound 114 as described for compound 7.

1H NMR ($CDCl_3$) δ 2.82 (t, $J = 6.5$ Hz, 2H), 4.86 (t, $J = 6.5$ Hz, 2H), 5.56 (s, 2H), 7.08-7.21 (m, 3H), 7.34-7.39 (m, 3H), 7.44-7.47 (m, 1H), 7.54-7.57 (m, 4H), 7.72 (d, $J = 7.8$ Hz, 1H), 7.85-7.89 (m, 1H);
MS m/e 393 (MH^+).

Compound 119


5 Nitrile **116** (4.6 g, 12.80 mmol), hydroxylamine hydrochloride (3.2 g, 46.07 mmol), and potassium carbonate (3.5 g, 25.60 mmol) were suspended in ethanol / water (100 mL/ 50 mL). This mixture was stirred at near reflux (60-80 °C) for 16 hours. The solvent was evaporated. To the residue, water was added to dissolve any inorganic salts. The white solid was filtered and washed with water. The solid was
10 triturated with EtOAc to give 5.0 g (quantitative yield) of compound **119** as a white solid.

¹H NMR (DMSO-d₆) δ 1.47 (d, J = 6.9 Hz, 6H), 2.39 (t, J = 6.8 Hz, 2H), 4.56 (t, J = 6.8 Hz, 2H), 4.61-4.70 (m, 1H), 5.35 (s, 2H), 6.61 (s, 2H), 6.98-7.06 (m, 2H), 7.12-
15 7.24 (m, 3H), 7.33 (d, J = 7.1 Hz, 1H), 7.54 (t, J = 8.4 Hz, 2H), 8.96 (s, 1H);
IR (KBr, cm⁻¹) 3470, 3332, 1698, 1680, 1663, 1491, 1430, 750;
MS m/e 393 (MH⁺);

Anal. Calcd for C₂₁H₂₄N₆O₂•2.75 H₂O: C, 57.07; H, 6.73; N, 19.01

Found: C, 57.43; H, 6.43; N, 18.79.

20

Compound 120

25 Amidoxime **119** (4.0 g, 10.19 mmol) was suspended in a toluene solution of phosgene (1.92M, 53 mL, 101.92 mmol). The reaction mixture was heated to reflux

(120 °C) for 8 hours under nitrogen. The solvent was evaporated. The residue was taken up in water and the pH was adjusted to 5 by addition of saturated sodium bicarbonate. The aqueous mixture was then extracted with CH₂Cl₂. The combined organic extracts were dried over MgSO₄, filtered and evaporated. Recrystallization of 4 g of the crude product in hot EtOAc (400-500 mL) gave compound **120** as fine white needles (3.0 g, 75% recovery, 71% yield from **119**):

To a solution of compound **120** (1.58 g, 3.77 mmol) in MeOH (10 mL) was added 1N NaOH (3.77 mL, 3.77 mmol) and evaporated. The residue was taken up in water and filtered. The filtrate was lyophilized to give the sodium salt of compound **120** as an amorphous fluffy white solid (1.56 g, 94% yield):

¹H NMR (DMSO-d₆) δ 1.46 (d, J = 7.0 Hz, 6H), 2.67 (t, J = 6.7 Hz, 2H), 4.59-4.68 (m, 3H), 5.35 (s, 2H), 6.94-7.05 (m, 2H), 7.14-7.23 (m, 3H), 7.32 (d, J = 7.9 Hz, 1H), 7.52 (t, J = 6.8 Hz, 2H);


IR (KBr, cm⁻¹) 3406, 2978, 1686, 1490, 1408, 750;

MS m/e 511 (MH⁺);

Anal. Calcd for C₂₂H₂₂N₆NaO₃: C, 59.86; H, 5.02; N, 19.04

Found: C, 59.68; H, 5.00; N, 18.78


Compound 121 (Scheme II)



To a mixture of 2-fluoronitrobenzene (16.8 g, 119 mmol) and sodium acetate (300 mg) was added N,N-dimethylethylenediamine (12.5 mL, 113 mmol). After heating to 80 °C for 1 h, the mixture was poured into water, and extracted with EtOAc. The combined organic layers were dried over MgSO₄ and evaporated. The crude material was purified by silica gel chromatography (gradient, 1:1 EtOAc:Hexanes to 5% MeOH in EtOAc) to provide 12.0 g (50% yield) of compound **121** as an orange oil.


¹H NMR (CDCl₃) δ 2.31 (s, 6H), 2.64 (t, J = 6.3 Hz, 2H), 3.35 (t, J = 6.3 Hz, 2H), 6.63 (t, J = 7.0 Hz, 1H), 6.83 (d, J = 8.5 Hz, 1H), 7.40-7.45 (m, 1H), 8.17 (d, J = 8.6 Hz, 1H), 8.29-8.39 (m, 1H);
MS m/e 209 (MH⁺).

5

Compound 122

A mixture of compound **121** (10.0 g, 47.7 mmol) and 10% Pd/C (500 mg) in
10 ethanol (100 mL) was hydrogenated at 50 psi for 1 h. The mixture was filtered
through a pad of celite and the filtrate was evaporated. The residue was recrystallized
from hexanes to give 7.52 g (88%) of a flaky brown solid of compound **122**.

¹H NMR (CDCl₃) δ 2.26 (s, 6H), 2.59 (t, J = 6.0 Hz, 2H), 3.15 (t, J = 6.0 Hz, 2H),
15 6.65-6.72 (m, 3H), 6.79-6.82 (m, 1H);
MS m/e 179 (MH⁺).

Compound 123

20

A mixture of ethyl 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylate (5 g,
24.3 mmol), K₂CO₃ (3.35 g, 24.3 mmol) and methyl 4-bromomethyl-benzoate (5.56
g, 24.3 mmol) was stirred in acetonitrile (100 mL) at reflux for 3 h. The mixture was
filtered and the filtrate was concentrated. The oily residue was dissolved in methanol
25 (50 mL), treated with sodium methoxide in methanol (1.0 mL, 0.5 M) and stirred for
12 h. The product precipitated from the solution was filtered to give 5.88 g (99%
yield) of compound **123** as white solid:

¹H NMR (DMSO-d₆) δ 3.82 (s, 3H), 5.09 (s, 2H), 6.95-6.99 (m, 4H), 7.42 (d, J = 8.4
30 Hz, 2H), 7.92 (d, J = 8.4 Hz, 2H);

IR (KBr, cm^{-1}) 3464(br), 1718, 1696;


MS m/e 283 (MH^+);

Anal. Calcd for $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_3$: C, 68.08; H, 5.00; N, 9.92.

Found: C, 67.85; H, 5.01; N, 9.84.

5


Compound 124



10 A mixture of **123** (5.8 g, 27.6 mmol), t-butyl bromoacetate (4.1 mL, 27.6 mmol) and potassium carbonate (3.8 g, 27.6 mmol) in acetonitrile (100 mL) was heated to reflux for 3 h. The mixture was cooled to room temperature, filtered and concentrated to give 9.58 g (88% yield) of compound **124** as a white solid:


15 ^1H NMR ($\text{DMSO}-d_6$) δ 1.41 (s, 9H), 3.83 (s, 3H), 4.66 (s, 2H), 5.17 (s, 2H), 7.02-7.18 (m, 4H), 7.42 (d, $J = 8.1$ Hz, 2H), 7.92 (d, $J = 8.1$ Hz, 2H);
IR (KBr, cm^{-1}) 1742, 1721, 1715;
MS m/e 397 (MH^+).

20 **4-(3-Isopropenyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-N,N-dimethylbenzamide**



25 4-(3-Isopropenyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-N,N-dimethylbenzamide was prepared from 1-isopropenyl-1,3-dihydro-benzoimidazol-2-one and compound **90** as described for compound **7**.


^1H NMR (CD_3OD) δ 2.21 (s, 3H), 2.96 (s, 3H), 3.07 (s, 3H), 5.15 (s, 2H), 5.23 (s, 1H), 5.45-5.46 (m, 1H), 7.05-7.12 (m, 3H), 7.17-7.18 (m, 1H), 7.39-7.43 (m, 4H);
30 MS m/e 336 (MH^+).

N,N-Dimethyl-4-(2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-benzamide

5

N,N-Dimethyl-4-(2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-benzamide was prepared as described for compound 6.

¹H NMR (DMSO-d₆) δ 2.86 (s, 3 H), 2.95 (s, 3H), 5.04 (s, 2H), 6.94-7.05 (m, 4H),
10 7.33-7.37 (m, 4H);
MS m/e 296 (MH⁺).

Compound 125

15


Ester 124 (5.4 g, 13.6 mmol) was stirred in trifluoroacetic acid (50 mL) at room temperature for 12 h. The mixture was evaporated to give 4.0 g (87% yield) of compound 125 as a light yellow solid:

20

¹H NMR (DMSO-d₆) δ 3.88 (s, 3H), 4.72 (s, 2H), 5.22 (s, 2H), 7.06-7.24 (m, 3H),
7.17-7.27 (m, 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.97 (d, J = 8.4 Hz, 2H);
IR (KBr, cm⁻¹) 3464(br), 1738, 1720, 1666;
MS m/e 341 (MH⁺);

25

Anal. Calcd for C₁₈H₁₆N₂O • 0.86 H₂O: C, 57.67; H, 4.69; N, 7.26.
Found: C, 57.67; H, 4.29; N, 6.95.

Compound 126

5 Compound 122 (1.32 g, 7.35 mmol) and benzimidazolone 125 (2.5 g, 7.35 mmol) were dissolved in DMF (8 mL). To the solution EDC (3.18 g, 16.2 mmol) was added and the resulting mixture was stirred for 18 h under nitrogen. The mixture was poured into water and extracted into EtOAc. The extracts were dried over MgSO₄ and evaporated. The gummy residue was dissolved in 20 mL of acetic acid
10 and the solution was heated to reflux for 6 h. The mixture was evaporated and the residue was diluted with EtOAc, washed with water, dried over MgSO₄ and evaporated. The gummy residue was triturated with EtOAc to produce 255 mg (7% yield) of compound 126. A portion of the material was converted to the HCl salt with excess HCl in dioxane and the volatile components were removed in vacuo:

15

¹H NMR (DMSO-d₆) δ 3.12, 3.33 (s, 6H), 4.00 (m, 2H), 4.25 (s, 3H), 5.39 (m, 2H), 5.65 (s, 2H), 6.10 (s, 2H), 7.49 (m, 2H), 7.57 (m, 1H), 7.81 (m, 4H), 7.92 (d, J = 8.1 Hz, 2H), 8.08 (d, J = 7.8 Hz, 1H), 8.36 (d, J = 8.1 Hz, 2H), 11.67 (s, 1H);
IR (KBr, cm⁻¹) 3421, 2952, 1708, 1491, 1407, 1280, 750;


20 MS m/e 484 (MH⁺);

Anal. Calcd for C₂₈H₂₉N₅O₃•2.25 HCl: C, 59.22; H, 5.56; N, 12.33.

Found: C, 59.22; H, 5.42; N, 12.01.

Compound 131


25



Sodium ethoxide was prepared by dissolving fresh cut sodium (0.2 g, 8.40 mmol) in anhydrous EtOH (10 mL). To a solution of methyl ester, compound 126, (1.2 g, 2.48 mmol) in anhydrous EtOH (300 mL) was added the ethanolic sodium ethoxide solution. The reaction mixture was stirred at reflux for 1 hour and the solution was adjusted to pH 1 with 4 N HCl in dioxane. The solvent was evaporated. The residue was purified by flash column chromatography (gradient, straight EtOAc to EtOAc/MeOH, 10:1) and treated with excess 4 N HCl in dioxane to give 1.07 g (87% yield) of compound 131 as the HCl salt:


¹H NMR (CDCl₃) δ 1.37 (t, J = 7.2 Hz, 3H), 2.26 (s, 6H), 2.51 (t, J = 6.9 Hz, 2H), 4.36 (q, J = 7.2 Hz, 2H), 4.45 (t, J = 6.9 Hz, 2H), 5.16 (s, 2H), 5.47 (s, 2H), 6.80 (d, J = 7.5 Hz, 1H), 6.98-7.04 (m, 2H), 7.28-7.35 (m, 2H), 7.28-7.35 (m, 4H), 7.38 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.78-7.81 (m, 1H), 8.00 (d, J = 8.1 Hz, 2H); MS m/e 498 (MH⁺).

Compound 132



As described for compound 131, the isopropyl derivative 132 was prepared from compound 126 using sodium isopropoxide.

¹H NMR (DMSO-d₆) δ 1.29 (d, J = 6.2 Hz, 6H), 2.89 (s, 3H), 2.91 (s, 3H), 4.93 (t, J = 7.8 Hz, 2H), 5.07-5.15 (m, 1H), 5.22 (s, 2H), 5.63 (s, 2H), 7.02-7.14 (m, 3H), 7.32-7.40 (m, 3H), 7.48 (d, J = 8.3 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.87-7.93 (m, 3H); MS m/e 512 (MH⁺).

Compound 133

5 Compound **133** was prepared as a white powder in 71% yield using the same procedure as compound **8**:

¹H NMR (DMSO-d₆) δ 2.18 (s, 6H), 3.30-3.50 (m, 2H), 4.43 (t, J = 6.3 Hz, 2H), 5.09 (s, 2H), 5.44 (s, 2H), 6.95-7.00 (m, 2H), 7.08-7.25 (m, 1H), 7.52-7.57 (m, 5H), 7.54 (t, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H).


IR (KBr, cm⁻¹) 3422, 1702, 1599, 1557, 1395, 750;

MS m/e 470 (MH⁺);

Anal. Calcd for C₂₇H₂₆N₃O₃Na•2.1NaOH•2.0 H₂O:

C, 52.88; H, 5.28; N, 11.42.

15 Found: C, 53.10; H, 4.88; N, 11.02.

Compound 134


20

Compound **134** was prepared from compound **133** using PyBroP and 2-aziridin-1-yl-ethanol. The aziridine ring was opened during preparative HPLC with MeOH/H₂O with 1% TFA as buffer.

25 ¹H NMR (DMSO-d₆) 2.90-2.92 (m, 6H), 3.08-3.08 (m, 2H), 3.37 (s, 2H), 3.63 (s, 2H), 3.71-3.76 (m, 2H), 4.54 (t, J = 4.8Hz, 2H), 5.02 (t, J = 7.4Hz, 2H), 5.25 (s, 2H),

5.72-5.77 (m, 2H), 7.06-7.15 (m, 3H), 7.38-7.770 (m, 5H), 7.70 (d, $J = 8.0$ Hz, 1H), 8.00 (d, $J = 8.0$ Hz, 1H), 8.10 (d, $J = 8.1$ Hz, 2H), 9.79 (m, 1H), 11.59 (m, 1H); MS m/e 557 (MH^+).


5 **Compound 135**



Compound 135 was prepared from compound 133 using PyBroP 1-methyl-3-hydroxypyrolidine.

1H NMR (CD_3OD) δ 2.28-2.81 (m, 2H), 3.02 (s, 2H), 3.07 (s, 1H), 3.12 (s, 6H), 3.86-3.91 (m, 4H), 5.23 (t, $J = 8.2$ Hz, 2H), 5.29 (s, 2H), 5.64-5.69 (m, 1H), 5.94 (s, 2H), 7.16-7.23 (m, 3H), 7.49-7.55 (m, 3H), 7.69-7.82 (m, 3H), 8.07-8.17 (m, 3H); MS m/e 553 (MH^+).

Compound 136



20

Compound 136 was prepared using the same procedure as compound 126:


1H NMR ($CDCl_3$) δ 2.31 (bs, 6H), 2.58 (bs, 2H), 3.97 (s, 3H), 4.52 (bs, 2H), 5.50 (s, 2H), 5.60 (s, 2H), 6.81 (d, $J = 6.8$ Hz, 1H), 6.98-7.09 (m, 3H), 7.28-7.42 (m, 5H), 7.80-7.83 (m, 1H), 8.07 (dd, $J = 1.4, 7.4$ Hz, 1H);

25

IR (KBr, cm^{-1}) 1717, 1702, 1497, 1417, 1261, 742;
MS m/e 484(MH^+).

Compound 137

5




Compound 137 was prepared using the same procedure as compound 133:

- 10 ^1H NMR (CD_3OD) δ 2.28 (s, 6 H), 2.59 (t, $J = 6.9$ Hz, 2 H), 4.50 (t, $J = 6.9$ Hz, 2 H), 5.20 (s, 2 H), 5.30 (s, 2 H), 6.98-7.08 (m, 4 H), 7.18-7.32 (m, 5 H), 7.64-7.68 (m, 2 H);
IR (KBr, cm^{-1}) 1699, 168, 1586, 1560, 1492, 1395, 742;
MS m/e 470 (MH^+);
15 Anal. Calcd for $\text{C}_{27}\text{H}_{27}\text{N}_5\text{NaO}_3 \cdot 0.75\text{H}_2\text{O}$: C, 64.09; H, 5.68; N, 13.84
Found: C, 63.96; H, 5.49; N, 13.74

Compound 138

20



- To a solution of acid 133 (704 mg, 1.5 mmol), N,N -dimethylamine hydrochloride salt (183 mg, 2.25 mmol), and diisopropylethylamine (386 mg, 3.0 mmol) in DMF (10 mL) was added PyBroP (769 mg, 1.65 mmol) in one portion at
25 the ambient temperature. After stirring overnight, the resulting solution was concentrated. The residue was purified by prep-HPLC to furnish 660 mg (89% yield)

of compound **138** as white solid. To a solution of this solid (660 mg, 1.33 mmol) in methanol (20 mL) was added 4 N HCl in 1,4-dioxane (0.66 mL, 2.66 mmol). The resulting hydrochloride salt precipitated out of solution and was collected by filtration to yield 650 mg (92% yield) of dihydrochloride salt of compound **138** as white crystals:

¹HNMR (CD₃OD) δ 2.99 (s, 3H), 3.10 (s, 3H), 3.12 (s, 6H), 3.87 (t, J = 7.5 Hz, 2H), 5.23 (t, J = 7.5 Hz, 2H), 5.24 (s, 2H), 5.94 (s, 2H), 7.20-7.23 (m, 3H), 7.43 (d, J = 8.2 Hz, 2H), 7.48-7.52 (m, 3H), 7.70-7.81 (m, 3H), 8.16 (d, J = 8.3 Hz, 1H);

IR (KBr, cm⁻¹) 3422, 1702, 1614, 1493, 1406, 1181, 753;


MS m/e 497 (MH⁺);

Anal. calcd for C₂₉H₃₃ClN₆O₂•2.0HCl•1.0TFA•1.5H₂O:

C, 52.40; H, 5.39; N, 11.83%;

Found: C, 52.21; H, 5.34; N, 11.83%

Compound 139



Compound **139** was prepared by the same procedure as compound **138** using N-methylpiperazine and acid **133**:


¹HNMR (CD₃OD) δ 2.92 (s, 3H), 3.06 (s, 6H), 3.65 (t, J = 8.0 Hz, 2H), 4.92 (t, J = 7.9 Hz, 2H), 5.22 (s, 2H), 5.54 (s, 2H), 7.09-7.14 (m, 3H), 7.34 (t, J = 8.0 Hz, 1H), 7.39-7.47 (m, 6H), 7.66-7.68 (m, 2H);

MS m/e 552 (MH⁺);

IR (KBr, cm⁻¹) 3442, 1685, 1638, 1494, 1412, 1202, 1131;


Anal. Calcd for C₃₂H₃₇N₇O₂•3TFA•2.5H₂O: C, 48.62; H, 4.83; N, 10.44

Found: C, 48.51; H, 4.44; N, 10.21.

Compound 140

5 A solution of the methyl ester 126 (484 mg, 1.0 mmol) and hydrazine (250 mg, 5.0 mmol) in MeOH (5 ml) was heated in a sealed tube at 90 °C for 4 h. After cooling, the precipitate formed was collected and washed with cold MeOH and dried to yield compound 140 (84 mg, 17%) as a white solid.



10 ¹H NMR (CD₃OD) δ 3.08 (s, 6H), 3.71-3.78 (m, 2H), 5.01-5.08 (m, 2H), 5.17 (s, 2H), 5.68 (s, 2H), 7.06-7.19 (m, 3H), 7.42-7.57 (m, 5H), 7.70-7.73 (m, 1H), 7.85-7.91 (m, 3H);
MS m/e 484 (MH⁺).


15 **Compound 141**

20 **Table 13A** - Compounds were prepared as described for compound 138 using acid 133 and a commercially available amine.

#	R ₂	¹ H-NMR Data	MS Data
141a		(DMSO-d ₆) δ 2.76 (d, J = 4.6Hz, 3H), 2.95 (s, 6H), 3.56-3.59 (m, 2H), 4.80 (t, J = 7.8Hz, 2H), 5.18 (s, 2H), 5.52 (s, 2H), 7.02-7.08 (m, 2H), 7.14-7.16 (m, 1H), 7.24-7.27 (m, 1H), 7.32-7.35 (m, 1H), 7.41 (d, J = 8.4Hz, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.2Hz, 1H), 7.78-7.80 (m, 2H), 8.39-8.41 (m, 1H), 9.99 (b, 1H)	483 (MH ⁺)


141b		(CD ₃ OD) δ 3.09 (s, 6H), 3.80-3.84 (m, 5H), 5.16-5.26 (m, 4H), 5.82 (s, 2H), 7.05-7.13 (m, 3H), 7.38-7.42 (m, 3H), 7.53-7.618 (m, 2H), 7.72-7.78 (m, 1H), 7.91-7.99 (m, 3H)	547 (MH ⁺)
141c		(CD ₃ OD) δ 3.03-3.13 (m, 9H), 3.38-3.91 (m, 6H), 5.24-5.29 (m, 4H), 5.97 (s, 2H), 7.16-7.26 (m, 3H), 7.44-7.52 (m, 5H), 7.67-7.80 (m, 3H), 8.19 (d, J = 8.2Hz, 1H)	527 (MH ⁺)
141d		(CD ₃ OD) δ 2.99 (s, 6H), 3.12 (s, 6H), 3.40 (t, J = 9.6Hz, 2H), 3.74-3.79 (m, 2H), 3.88 (t, J = 8.0 Hz, 2H), 5.21-5.27 (m, 4H), 5.97 (s, 2H), 7.15-7.25 (m, 3H), 7.49-7.54 (m, 3H), 7.67-7.82 (m, 3H), 7.91 (d, J = 8.3Hz, 2H), 8.17 (d, J = 8.3Hz, 1H)	540 (MH ⁺)
141e		(CD ₃ OD) δ 3.06-3.14 (m, 9H), 3.47-3.88 (m, 10H), 5.21-5.28 (m, 4H), 5.95-5.98 (m, 2H), 7.20-7.22 (m, 3H), 7.44-7.52 (m, 5H), 7.66-7.80 (m, 3H), 8.17 (d, J = 8.2Hz, 1H)	647 (MH ⁺)
141f		(CD ₃ OD) δ 3.10 (s, 6H), 3.88 (t, J = 7.9Hz, 2H), 5.24 (t, J = 7.9Hz, 2H), 5.31 (s, 2H), 5.97 (s, 2H), 7.17-7.24 (m, 3H), 7.44 (d, J = 4.0 Hz, 1H), 7.49 (d, J = 7.3Hz, 1H), 7.62 (d, J = 8.3Hz, 2H), 7.68-7.80 (m, 4H), 8.07 (d, J = 8.3Hz, 2H), 8.16 (d, J = 8.3Hz, 2H)	552 (MH ⁺)
141g		(CD ₃ OD) δ 1.75 (s, 6H), 2.24 (t, J = 7.8Hz, 2H), 3.58 (t, J = 7.5Hz, 2H), 3.72 (s, 2H), 4.26 (s, 2H), 5.60-5.64 (m, 4H), 5.91 (d, J = 7.5Hz, 2H), 5.98 (d, J = 8.0 Hz, 2H), 6.00-6.06 (m, 1H), 6.06-6.13 (m, 1H), 6.19 (d, J = 8.0 Hz, 1H), 6.40-6.46 (m, 3H)	535 (MH ⁺)
141h		(DMSO-d ₆) δ 2.35 (s, 6H), 2.74 (t, J = 6.2Hz, 2H), 4.52 (t, J = 6.4Hz, 2H), 5.23 (s, 2H), 5.76 (s, 2H), 7.01-7.04 (m, 2H), 7.14-7.27 (m, 4H), 7.52 (d, J = 8.1Hz, 2H), 7.57 (d, J = 8.6Hz, 2H), 8.06 (d, J = 8.0 Hz, 2H)	537 (MH ⁺)
141i		(CD ₃ OD) δ 3.10 (s, 6H), 3.84 (t, J = 8.2Hz, 2H), 5.18 (t, J = 7.9Hz, 2H), 5.30 (s, 2H), 5.90 (s, 2H), 7.15-7.22 (m, 3H), 7.48 (d, J = 7.6Hz, 1H), 7.59 (d, J = 8.9Hz, 2H), 7.63 (t, J = 7.3Hz, 1H), 7.69 (t, J = 7.3Hz, 1H), 7.77 (d, J = 8.2Hz, 1H), 8.04 (d, J = 8.9Hz, 2H), 8.07 (d, J = 8.2Hz, 1H), 8.39 (d, J = 7.6Hz, 2H), 8.66 (d, J = 7.6Hz, 2H)	546 (MH ⁺)
141j		(CD ₃ OD) δ 2.29 (s, 6H), 2.64 (t, J = 6.9Hz, 2H), 4.51 (t, J = 6.9Hz, 2H), 5.27 (s, 2H), 5.53 (s, 2H), 7.04-7.07 (m, 3H), 7.22-7.34 (m, 3H), 7.52-7.55 (m, 3H), 7.96 (d, J = 8.3Hz, 2H), 8.32 (dd, J = 1.1, 5.8Hz, 1H), 8.64 (d, J = 5.9Hz, 1H), 8.86 (s, 1H)	547 (MH ⁺)

141k		(CD ₃ OD) δ 3.04 (s, 6H), 3.74-3.79 (m, 2H), 5.08-5.13 (m, 2H), 5.21 (s, 2H), 5.81 (s, 2H), 7.08-7.15 (m, 4H), 7.40 (d, J = 6.6Hz, 1H), 7.47 (d, J = 8.4Hz, 1H), 7.53-7.64 (m, 2H), 7.70 (d, J = 8.1Hz, 1H), 7.86 (d, J = 8.4Hz, 2H), 7.98 (d, J = 6.6Hz, 3H), 8.73 (d, J = 6.9Hz, 2H)	561 (MH ⁺)
141l		(CD ₃ OD) δ 2.65 (s, 3H), 3.08 (s, 6H), 3.67-3.85 (m, 2H), 4.70 (s, 2H), 4.96 (s, 2H), 5.14-5.19 (m, 2H), 5.24 (s, 2H), 5.87 (s, 2H), 7.10-7.19 (m, 3H), 7.45-7.50 (m, 3H), 7.60-7.64 (m, 2H), 7.75 (d, J = 7.8Hz, 1H), 7.88 (d, J = 8.4Hz, 2H), 8.08 (d, J = 8.1Hz, 1H), 8.18 (s, 1H)	620 (MH ⁺)

Compound 142

Carbon disulfide (0.5 mL) was added dropwise to ethylenediamine (5 g, 83.20 mmol). To this solution was added the nitrile (0.55 g, 1.22 mmol) and the resulting solution was stirred at 110 °C for 4 hours (Pharmazie, 1992, (47), 11-14). The excess ethylenediamine was evaporated and the residue was purified by preparative HPLC to compound 142:

¹H NMR (CD₃OD) δ 3.09 (s, 6H), 3.77 (t, J = 7.9Hz, 2H), 4.08 (s, 4H), 5.09 (t, J = 7.7Hz, 2H), 5.29 (s, 2H), 5.75 (s, 2H), 7.07-7.18 (m, 3H), 7.42 (d, J = 7.7Hz, 1H), 7.51 (t, J = 7.6Hz, 1H), 7.57 (t, J = 7.8Hz, 1H), 7.61 (d, J = 7.9Hz, 2H), 7.72 (d, J = 8.1Hz, 1H), 7.85 (d, J = 8.2Hz, 2H), 7.91 (d, J = 8.0 Hz, 1H)
MS m/e 494 (MH⁺);

Compound 143


A mixture of compound **91m** (840 mg, 1.87 mmol), hydroxylamine hydrochloride (195 mg, 2.80 mmol) and triethylamine (321 mg, 3.18 mmol) in ethanol (20 ml) was heated to reflux for 12 h. After cooling, the product precipitated and was collected by filtration. The cake was washed with H₂O and cold MeOH.

5 After drying, 610 mg (67%) of compound **143** was obtained as a white solid.

¹H NMR (CD₃OD) δ 3.11-3.12 (m, 6H), 3.89-3.93 (m, 2H), 5.22-5.25 (m, 2H), 5.30 (s, 2H), 5.98 (s, 2H), 7.13-7.24 (m, 4H), 7.51-7.54 (m, 2H), 7.61-7.79 (m, 5H), 8.17-8.19 (m, 1H);

10 MS m/e 413 (MH⁺).

Compound 144




15

A solution of compound **143** (48 mg, 0.10 mmol) in Ac₂O (1 ml) was heated to 120°C for 4 h. The solvent was evaporated and the residue purified by prep-HPLC to yield 45 mg (88%) of compound **144** as a white solid.

20 ¹H NMR (CDCl₃) δ 3.07 (s, 9H), 3.79 (t, J = 7.6Hz, 2H), 5.08 (t, J = 7.9Hz, 2H), 5.19 (s, 2H), 5.74 (s, 2H), 7.10-7.18 (m, 3H), 7.40-7.58 (m, 5H), 7.74 (d, J = 7.5Hz, 1H), 7.89-7.99 (m, 3H);
MS m/e 508 (MH⁺).


25 Compound 145



To a suspension of compound **143** (976 mg, 2.0 mmol), TEA (404 mg, 5.0 mmol) and DMAP (50 mg, 0.41 mmol) in CH_2Cl_2 (100 ml) was added ethyl chloroformate (259 mg, 2.4 mmol). After stirring for 12 h, the solution was concentrated and the residue purified by preparative reverse phase HPLC to yield 980 mg (88%) of compound **145** as a white solid.

^1H NMR (DMSO-d_6) δ 1.25 (t, $J = 7.2\text{Hz}$, 3H), 2.95 (s, 6H), 3.55-3.58 (m, 2H), 4.16-4.20 (m, 2H), 4.80 (t, $J = 7.6\text{Hz}$, 2H), 5.18 (s, 2H), 5.52 (s, 2H), 6.82 (b, 1H), 7.02-7.08 (m, 2H), 7.16-7.17 (m, 1H), 7.23-7.26 (m, 1H), 7.31-7.35 (m, 2H), 7.41 (d, $J = 8.4\text{Hz}$, 2H), 7.61-7.70 (m, 4H), 9.99 (b, 1H);
MS m/e 556 (MH^+).

Compound 146




15

Compound **146** was prepared as described for compound **145** using N,N -dimethylcarbamoyl chloride.

^1H NMR (CD_3OD) 2.97-3.05 (m, 12H), 3.62-3.66 (m, 2H), 4.92-4.95 (m, 2H), 5.22 (s, 2H), 5.60 (s, 2H), 7.11-7.15 (m, 3H), 7.41-7.44 (m, 4H), 7.46-7.48 (m, 1H), 7.70-7.75 (m, 4H);
MS m/e 555 (MH^+).

Compound 147

25




A solution of compound **145** (110 mg, 0.20 mmol) and DBU (110 mg, 0.74 mmol) in THF (10 ml) was heated to 80°C in sealed tube for 3h. Evaporated the

solvent. The residue was purified by prep-HPLC to yield 94 mg (92%) of compound 147 as a white solid.

¹H NMR (CD₃OD) δ 3.08 (s, 6H), 3.71-3.78 (m, 2H), 5.00-5.08 (m, 2H), 5.25 (s, 2H),
5 5.68 (s, 2H), 7.08-7.18 (m, 3H), 7.41-7.58 (m, 5H), 7.69-7.78 (m, 3H), 7.82 (d, J = 7.9Hz, 1H);
MS m/e 510 (MH⁺).

Compound 148

10




Compound 91m was converted to the tetrazole as described for compound 52.

15 ¹H NMR (CD₃OD) δ 3.13 (s, 6H), 3.87 (t, J = 8.0 Hz, 2H), 5.23 (t, J = 7.1Hz, 2H),
5.30 (s, 2H), 5.94 (s, 2H), 7.22-7.24 (m, 3H), 7.49-7.52 (m, 1H), 7.63 (d, J = 8.4Hz, 2H), 7.68-7.81 (m, 3H), 8.03 (d, J = 8.3Hz, 2H), 8.12-8.15 (m, 1H).

Compound 149


20



Compound 149 was prepared by hydrogenation of compound 146 as described for the hydrogenation of compound 115.


25

¹H NMR (CD₃OD) δ 3.07 (s, 6H), 3.72 (t, J = 7.5Hz, 2H), 4.95-4.99 (m, 2H), 5.28 (s, 2H), 5.60 (s, 2H), 7.04-7.15 (m, 3H), 7.37-7.44 (m, 3H), 7.58-7.79 (m, 6H);
MS m/e 468 (MH⁺).

Compound 150

5 Compound **150** was prepared by catalytic hydrogenation of compound **91k** as described for compound **149** above.

¹H NMR (CD₃OD) δ 3.13 (s, 6H), 3.90 (t, J = 7.9 Hz, 2H), 5.21-5.26 (m, 4H), 5.97 (s, 2H), 7.16-7.26 (m, 3H), 7.42-7.52 (m, 3H), 7.61 (d, J = 8.5 Hz, 2H), 7.66-7.81 (m, 3H), 8.16 (d, J = 7.9 Hz, 2H);
10 MS m/e 441 (MH⁺).

Compound 151

15

A mixture of compound **150** (100 mg, 0.18 mmol) and Et₃N (55 mg, 0.54 mmol) in methylene chloride (4 mL) was cooled to 0°C. Acetyl chloride (18 mg, 0.23 mmol) was added followed by DMAP (5 mg, catalytic quantity). The reaction mixture was allowed to warm to room temperature gradually and stirring was continued for 16 hours at room temperature under nitrogen atmosphere. A white precipitate was observed. The organic material was washed with dilute aqueous sodium bicarbonate solution (10 mL). The aqueous layer was then extracted with methylene chloride (2 x 20 mL). The combined organic extracts were dried over magnesium sulfate, filtered and evaporated to give a white solid. The solid was triturated with anhydrous diethyl ether and filtered to give compound **151** as a white solid (50 mg, 53 % yield).
20
25

¹H NMR (DMSO-d₆) δ 2.00 (s, 3 H), 3.36 (t, *J* = 6.9 Hz, 2 H), 4.25 (s, 3 H), 4.80 (t, *J* = 6.9 Hz, 2 H), 5.14 (s, 2 H), 5.34 (s, 2 H), 6.97-7.02 (m, 2 H), 7.07-7.23 (m, 6 H), 7.28 (d, *J* = 8.5 Hz, 2 H), 7.48-7.54 (m, 4 H), 9.92 (s, 1H);


5 IR (KBr, cm⁻¹): 3308, 2929, 1694, 1610, 1516, 1495, 1407, 1311, 749.

MS *m/e* 522 (MH⁺).

Anal. Calcd for C₂₈H₂₇N₉O₂: C, 64.48; H, 5.22; N, 24.17

Found: C, 64.13; H, 5.32; N, 23.86.

10 **Compound 152**




A mixture of compound 150 (100 mg, 0.18 mmol) and Et₃N (55 mg, 0.54
15 mmol) in CH₂Cl₂ (5 mL) was cooled to 0 °C. Methanesulfonyl chloride (21 mg, 0.18
mmol) was added and the reaction mixture was allowed to warm gradually to room
temperature. After stirring for 5.5 h under nitrogen atmosphere, the organic material
was washed with dilute aqueous sodium bicarbonate solution (10 mL). The aqueous
layer was then extracted with CH₂Cl₂ (2 x 20 mL). The combined organic extracts
20 were dried over MgSO₄, filtered and evaporated. Trituration with anhydrous diethyl
ether followed by filtration gave compound 152 as a yellow solid (92 mg, 91%
yield).

¹H NMR (CD₃OD) δ 2.95 (s, 3 H), 3.07 (s, 1H), 3.68 (t, *J* = 6.5 Hz, 2H), 4.26 (s,
25 3H), 5.14 (t, *J* = 6.7 Hz, 2H), 5.15 (s, 2H), 5.81 (s, 2H), 7.16-7.28 (m, 6H), 7.43 (d,
J = 8.6 Hz, 2H), 7.63-7.75 (m, 3H), 7.99-8.02 (m, 1H);

IR (KBr, cm⁻¹): 3435, 2929, 1708, 1615, 1513, 1493, 1404, 1329, 1152, 752;


MS *m/e* 558 (MH⁺).

Compound 153

5 To a solution of compound **150** (600 mg, 1.36 mmol) and Et₃N (413 mg, 4.08 mmol) in CH₂Cl₂ (10 ml) at 0°C was triflic anhydride (460 mg, 1.63 mmol) dropwise. The solution was warmed to room temperature and stirred for 12 h, washed with sat. NH₄Cl, dried, evaporated, and purified by preparative reverse phase HPLC to yield compound **153** (522 mg, 67%) as white solid.


10 ¹H NMR (CD₃OD) δ 3.11 (s, 6H), 3.85 (t, J = 8.1 Hz, 2H), 5.18-5.23 (m, 4H), 5.89 (s, 2H), 7.20-7.29 (m, 5H), 7.43-7.50 (m, 3H), 7.67-7.79 (m, 3H), 8.12 (d, J = 8.0 Hz, 1H);
MS m/e 573 (MH⁺).

15 **Compound 154**



20 A mixture of compound **91m** (50 mg, 0.1 mmol), ethoxyvinyltributyltin (50 mg, 0.12 mmol) and palladium tetrakis(triphenylphosphine) (12 mg, 0.01 mmol) in toluene (1 ml) was heated to reflux under nitrogen. Diluted with CH₂Cl₂ (20 ml) and washed with sat. NaHCO₃, dried and concentrated. The residue was purified by prep-HPLC to yield 35 mg (67%) of compound **154** as a white solid.



25 ¹H NMR (CD₃OD) δ 2.55 (s, 3H), 3.06 (s, 6H), 3.76 (t, J = 7.5Hz, 2H), 5.02 (t, J = 7.5Hz, 2H), 5.23 (s, 2H), 5.67 (s, 2H), 7.07-7.18 (m, 3H), 7.41-7.57 (m, 5H), 7.72 (d, J = 7.4Hz, 1H), 7.81-7.83 (m, 1H), 7.96 (d, J = 8.0 Hz, 2H);
MS m/e 468 (MH⁺).

Compound 155

5 To a solution of compound **154** (24 mg, 0.05 mmol) in ethanol was added NaBH₄ (14 mg, 0.37 mmol) at 0°C. After stirring at this temperature for 30 min, the reaction mixture was quenched with 1 M HCl then extracted with EtOAc. The organic layer was washed with sat. NaHCO₃, dried, and concentrated. The residue was purified by preparative HPLC to yield 18 mg (75%) of compound **155** as a white solid.

¹H NMR (CD₃OD) δ 1.38 (d, J = 6.6 Hz, 3H), 3.03 (s, 6H), 3.67 (t, J = 7.8 Hz, 2H), 4.77-4.80 (m, 1H), 5.01 (t, J = 7.5 Hz, 2H), 5.14 (s, 2H), 5.64 (s, 2H), 7.11-7.14 (m, 3H), 7.32-7.55 (m, 7H), 7.72 (d, J = 7.2 Hz, 1H), 7.81 (d, J = 7.5 Hz, 1H);

15 MS m/e 470 (MH⁺).

Compounds 156 and 157

20

A mixture of 2-fluoro-4-methylbenzonitrile (5.0 g, 37 mmol), N-bromosuccinimide (6.4 g, 37 mmol) and AIBN (100 mg) was heated to reflux in CCl₄ (50 ml) for 12 h. The mixture was filtered and concentrated to give a 3:2 mixture of 2-fluoro-4-bromomethylbenzonitrile and starting material. A mixture of compound **128** (1.0 g, 2.98 mmol) and 2-fluoro-4-bromomethylbenzonitrile (0.91, 2.98 mmol) and Cs₂CO₃ (0.97 g, 2.98 mmol) in CH₃CN (50 ml) was heated to reflux for 30 minutes. The mixture was cooled, filtered and concentrated. The residue was purified by column chromatography (EtOAc to 3% MeOH/EtOAc as eluant) to give


25

(10 mg, 1%) of the first eluting vinyl compound **157** and (432 mg, 31%) of compound **156** product.

¹H NMR (DMSO-d₆): δ 2.20 (s, 6H), 2.49-2.55 (m, 2H), 4.44 (t, J = 5.7 Hz, 2H),
5 5.18 (s, 2H), 5.45 (s, 2H), 7.01-7.14 (m, 2H), 7.16-7.25 (m, 5H), 7.51-7.58 (m, 4H),
7.77-7.81 (m, 1H), 7.92-7.95 (m, 1H);
MS m/e 468 (MH⁺).


Compound 158

10



A mixture of compound **156** (210 mg, 0.45 mmol) and hydrazine (14 ml, 0.45 mmol) was heated to reflux in butanol for 12 h as described by R. F. Kaltenbach III,
15 R. M. Klabe, B. C. Cordova and S. P. Seitz in *Biorg. Med. Chem. Lett.* **1999**, *15*,
2259-2262. The reaction was incomplete as judged by thin layer chromatography. Additional hydrazine (0.2 ml) was added and stirring continued at reflux for 12 h. The solvent was removed and the residue purified by flash column chromatography (3% MeOH/CH₂Cl₂ to 3% MeOH/CH₂Cl₂/0.1% NH₄OH to give compound **158** (200
20 mg, 92%) as a white solid.

¹H NMR (DMSO-d₆) δ 2.19 (s, 6 H), 4.41-4.52 (m, 2 H), 5.13 (s, 2 H), 5.21-5.40 (m,
2 H), 5.45 (s, 2 H), 5.76 (s, 1 H), 6.95-7.08 (m, 2 H), 7.10-7.31 (m, 6 H), 7.52-7.59
(m, 2 H), 7.72 (s, 1 H), 11.40 (s, 1 H);
25 MS m/e 480 (MH⁺).

Compounds 159 and 160

5 Compound **158** was treated with methanesulfonyl chloride as described for compound **152** to give a mixture of monomethanesulfonamide compound **160** and dimethanesulfonamide compound **159**.

Compound 159; R = H:


10

1H NMR (DMSO- d_6) δ 2.33 (s, 6H), 3.36 (s, 3H), 3.50-3.60 (m, 2H), 4.84-4.90 (m, 2H), 5.27 (s, 2H), 5.57 (s, 3H), 7.00-7.15 (m, 2H), 7.18-7.25 (m, 2H), 7.25-7.40 (m, 2H), 7.40-7.50 (m, 3H), 7.59-7.65 (m, 1H), 7.78-7.81 (m, 2H);
MS m/e 558 (MH^+).

15

Compound 160; R = Ms

(DMSO- d_6) δ 2.96 (s, 6H), 3.32 (s, 3H), 3.36 (s, 3H), 3.25-3.65 (m, 2H), 4.80-4.95 (m, 2H), 5.27 (s, 2H), 5.55 (s, 2H), 7.00-7.18 (m, 2H), 7.19-7.40 (m, 3H), 7.60-7.65 (m, 2H), 7.65-7.78 (m, 2H), 7.85-7.95 (m, 1H), 8.01 (s, 1H);
20 MS m/e 636 (MH^+).

Compound 162

25

A mixture compound **91n** (600 mg, 1.05 mmol) and 10% palladium hydroxide on carbon (160 mg) in 2:1 MeOH/ THF (50 mL / 25 mL) was agitated under hydrogen at 55 psi for 48 hours. The reaction mixture was filtered through a pad of Celite and then subjected to column chromatography (2:1 EtOAc/CH₂Cl₂) to give compound **162** as a white solid (262 mg, 52% yield).

¹H NMR (DMSO-d₆) δ 3.35 (t, J = 6.8 Hz, 2H), 4.25 (s, 3H), 4.80 (t, J = 6.8 Hz, 2H), 4.94 (s, 2H), 5.33 (s, 2H), 6.68 (d, J = 8.5 Hz, 2H), 6.95-7.02 (m, 2H), 7.09-7.23 (m, 6H), 7.47-7.54 (m, 2H), 9.39 (s, 1H);


IR (KBr, cm⁻¹) 3247, 2944, 1664, 1613, 1597, 1515, 1491, 1445, 1413, 747;

MS m/e 481 (MH⁺);

Anal. Calcd for C₂₆H₂₄N₈O₂: C, 64.99; H, 5.03; N, 23.32

Found: C, 64.79; H, 4.98; N, 23.38.

15 Compound 163



To the compound **162** (127 mg, 0.26 mmol) DMF (5 mL) was added NaH (60% suspension in mineral oil, 13 mg, 0.32 mmol) while stirring under nitrogen atmosphere. After stirring for 15 minutes, methyl bromoacetate (48 mg, 0.32 mmol) was added. The reaction was stirred at room temperature for 16 hours. Column chromatography on silica gel (gradient, CH₂Cl₂ to 1% MeOH in CH₂Cl₂) gave compound **163** as a solid (142 mg, 97% yield).

¹H NMR (DMSO-d₆) δ 3.36 (t, J = 6.7 Hz, 2 H), 3.66 (s, 3 H), 4.25 (s, 3H), 4.74 (s, 3H), 4.80 (t, J = 6.9 Hz, 2 H), 5.00 (s, 2 H), 5.33 (s, 2 H), 6.87 (d, J = 8.7 Hz, 2 H), 6.98-7.01 (m, 2 H), 7.13-7.23 (m, 4 H), 7.30 (d, J = 8.7 Hz, 2 H), 7.51 (dd, J = 12.9, 7.4 Hz, 2 H);


IR (KBr, cm⁻¹): 2922, 1745, 1698, 1611, 1509, 1498, 1438, 1230, 742.

MS m/e 553 (MH⁺).

Anal. Calcd for C₂₉H₂₈N₈O₄: C, 63.03; H, 5.11; N, 20.28

Found: C, 63.20; H, 5.14; N, 18.48

Compound 164



5 A solution of 2-fluoronitrobenzene (30 mL, 2.84 mmol) in acetonitrile (30 mL) was added to a solution of ethylenediamine (76 mL, 1.14 mmol) in acetonitrile (50 mL). The mixture was stirred at room temperature for 12 h then concentrated to give 51 g (99% yield) of compound **164** as an orange oil.


10 ¹H NMR (DMSO-d₆) δ 2.82 (t, J = 6.0 Hz, 2 H), 3.30 (t, J = 6.0 Hz, 2 H), 6.66 (t, J = 8.4 Hz, 1 H), 7.05 (d, J = 8.7 Hz, 1 H), 7.53 (d, J = 8.4 Hz, 1 H), 8.30-8.34 (m, 1 H); IR (film, cm⁻¹) 1621, 1514, 1347, 740;

MS m/e 182 (MH^+);

Anal. Calcd for $C_8H_{11}N_3O_2 \cdot 0.20 H_2O$: C, 51.99; H, 6.22; N, 22.74

15 Found: C, 51.99; H, 6.29; N, 22.46.

Compound 165



20

To a mixture of amine **164** (2.0 g, 11 mmol) in CH₂Cl₂ (50 mL) was added triethyl amine (1.53 mL, 11 mol) and the mixture was cooled to 0°C.

Methanesulfonyl chloride (0.85 mL, 11 mmol) was added slowly. Once the addition was complete, the reaction mixture was warmed to room temperature and stirred for 12h. The mixture was poured into water and the aqueous layer separated, dried over MgSO₄, and evaporated. The residue was chromatographed with 3% methanol in dichloromethane to give 2.55 g (89%) of compound **165** as an orange oil:

¹H NMR (DMSO-d₆) δ 2.91 (s, 3H), 3.18 (dd, J = 6.1, 11.6 Hz, 2H), 3.39-3.42 (m, 2H), 6.70 (t, J = 9.0 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 7.28 (t, J = 6.1 Hz, exchanges with D₂O, 1H), 7.55 (td, J = 1.0, 6.0, Hz, 1H); 8.07 (dd, J = 1.0, 8.7 Hz, 1H); 8.23 (br s, 1H exchanges with D₂O);

5 IR (film, cm⁻¹) 1511, 1354, 1317, 1151;

MS m/e 260 (MH⁺);


Anal. Calcd for C₉H₁₃N₃O₄S • 0.5 H₂O • 0.08 EtOAc:

C, 40.66; H, 5.36; N, 15.26.

Found: C, 40.58; H, 5.29; N, 14.88.

10

Compound 166



15 A mixture of compound 165 (1.0 g, 3.9 mmol) and 10% Pd/C (100 mg) in ethanol (50 mL) was hydrogenated at 50 psi for 12 h. The mixture was filtered and the filtrate was evaporated to give an orange oil. The residue was chromatographed (1% MeOH in CH₂Cl₂) to give 0.55g (62% yield) of compound 166 as a dark oil:

20 ¹H NMR (DMSO-d₆) δ 2.91 (s, 3H), 3.17 (br s, 2H), 4.45 (br s, 3H, 1H exchanges with D₂O), 6.40-6.56 (m, 4H), 7.11 (br s, 1H, exchanges with D₂O);


IR (film, cm⁻¹) 3326, 1625, 1510, 1315, 1148, 738;

MS m/e 230 (MH⁺);

Anal. Calcd for C₉H₁₅N₃O₂S: C, 46.78; H, 6.63; N, 18.18

25

Found: C, 46.81 ; H, 6.79; N, 17.81.


Compound 167

5 Compound 167 was prepared as described for 166 above.

^1H NMR (DMSO- d_6) δ 3.17-3.21 (m, 2H), 3.31-3.35 (m, 4H, 2H exchange with D_2O), 6.42-6.57 (m, 4H);

IR (film, cm^{-1}) 1365, 1143;

10 MS m/e 283 (MH^+).

Compound 168

15

A mixture of 1,3 dihydro-2-H-1-ethylbenzimidazol-2-one (5.0 g, 30.8 mmol), ethyl bromoacetate (3.4 mL, 30.8 mmol) and potassium carbonate (4.25 g, 30.8 mmol) in acetonitrile (50 mL) was heated to reflux for 12h, and then evaporated. To the residue was added 6 N HCl (100 mL) and the resulting mixture was heated to
20 reflux for 4 h. The solution was cooled to room temperature and precipitate was filtered to give 6.2 g (99% yield) of compound 168 as white needles: mp 225-227°C;

^1H NMR (DMSO- d_6) δ 1.20 (t, $J = 7.1$ Hz, 3H), 3.87 (q, $J = 7.1, 14.1$ Hz, 2H), 4.60 (s, 2H), 7.00-7.10 (m, 2H), 7.13-7.16 (m, 1H), 7.21-7.24 (m, 2H);


25 IR (KBr, cm^{-1}) 3000, 1750, 1655, 752;

MS m/e 230 (MH^+);

Anal. Calcd for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_3$: C, 59.99; H, 5.49; N, 12.72.

Found: C, 59.82; H, 5.43; N, 12.64.

Compound 169



5 Acid **168** (0.48 g, 2.2 mmol) was refluxed with thionyl chloride (2 mL) for 30 minutes and then evaporated to dryness. To the residue was added a solution of diamine **166** (0.5 g, 2.2 mmol) and triethylamine (0.55 mL, 4.0 mmol) in CH₂Cl₂ (10 mL). The reaction mixture was stirred for 12 h and then poured into water. The organic layer was separated, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluted with 3% methanol in methylene chloride to give 810 mg (86% yield) of **169** as a light green solid: mp 82-85 °C;


¹H NMR (DMSO-d₆) δ 1.23 (t, J = 7.1 Hz, 3H), 2.90 (s, 3H), 3.13-3.17 (m, 2H), 3.18-2.24 (m, 2H), 3.90 (q, J = 7.1, 14.1 Hz, 2H), 4.71 (s, 2H), 5.18 (t, J = 7.1 Hz, 1H, exchanges with D₂O), 6.58 (t, J = 7.6 Hz, 1H), 6.67 (d, J = 7.5 Hz, 1H), 7.03-7.24 (m, 6H), 9.44 (s, 1H, exchanges with D₂O);

IR (KBr, cm^{-1}) 1686, 1522, 1317, 1149;

MS m/e 432 (MH⁺).

Anal. Calcd for $C_{20}H_{25}N_5O_4 \cdot 0.3 H_2O$: C, 54.98; H, 5.91; N, 16.03

20 Found: C, 55.07 ; H, 5.97; N, 15.65.

Compound 170


5 Amide **169** (0.72g, 1.67 mmol) was heated to reflux in acetic acid for 12 h and evaporated. The residue was purified by chromatography (3% MeOH in CH₂Cl₂) to give 0.37 g (53% yield) of compound **170** as a white solid: mp 57-60°C;

¹H NMR (DMSO-d₆) δ 1.24 (t, J = 7.1 Hz, 3H), 1.90 (s, 3H), 3.38-3.34 (m, 2H), 3.92
10 (q, J = 7.1, 14.7 Hz, 2H); 4.49 (t, J = 6.0 Hz, 2H); 5.41 (s, 2H); 6.98-7.28(m, 6H); 7.40 (t, J = 6.0, 1H, exchanged with D₂O), 7.54 (d, J = 7.7Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H);

IR (KBr cm⁻¹) 1693, 1317, 1140, 744;

MS m/e 414 (MH⁺).

15 Anal. Calcd for C₂₀H₂₅N₅O₄S • 1.1 H₂O: C, 55.65; H, 5.76; N, 14.75.
Found: C, 55.65; H, 5.74; N, 14.72.

Compound 171

20

To a mixture of amine **164** (3.0 g, 13.8 mmol) in CH₂Cl₂ (50 mL) was added triethyl amine (3.8 mL, 28 mol) and the mixture was cooled to 0°C.

Trifluoromethanesulfonic anhydride (2.32 mL, 13.8 mmol) was added slowly. Once
25 the addition was complete the reaction mixture was warmed to room temperature and stirred for 12h. The mixture was poured into water and the aqueous layer separated, dried over MgSO₄, and evaporated. The residue was dissolved in MeOH and treated with 25% NaOH (1 mL) and stirred for 6h. The mixture is acidified and

extracted with EtOAc. The organic layer was dried and concentrated to give 1.07 g (71%) of compound 171.


¹H NMR (DMSO-d₆) δ 3.38 (t, J = 5.8 Hz, 2H), 3.52-3.58 (m, 2H), 6.72 (t, J = 6.8 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 7.55 (t, J = 7.1 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 8.22 (t, J = 3.06 Hz, 1H, exchanges with D₂O)

MS m/e 313 (MH⁺);

Anal. Calcd for C₉H₁₀F₃N₃O₄S: C, 34.51; H, 3.22; N, 13.41


Found: C, 34.39 ; H, 3.20; N, 13.24.

10 Compound 172




To a solution of compound 164 (2 g, 9.2 mmol) in CH₂Cl₂ (70 ml) was added Triethylamine (2.32 g, 22.9 mmol) at 0°C. Benzenesulfonyl chloride (1.95 g, 11.04 mmol) was added slowly and the mixture was stirred overnight at room temperature. The mixture was diluted with CH₂Cl₂ and washed with water, 1N HCl, and brine. The organic layer was dried over Na₂SO₄ and concentrated to give 3.06 g (97% yield) of the compound 172 as a yellow solid.

20 Compound 173




To a solution of compound 164 (2 g, 9.2 mmol) in CH₂Cl₂ (70 ml) was added Triethylamine (2.32 g, 22.9 mmol) at 0 C. Isopropylsulfonyl chloride (1.57 g, 11.0 mmol) was added slowly and the mixture was stirred overnight at room temperature. The mixture was diluted with CH₂Cl₂ and washed with water, 1N HCl, and brine. The organic layer was dried over Na₂SO₄ and concentrated to give 830 mg (31% yield) of the compound 173 as a yellow oil.


**Table 14-** Compounds were prepared as described for compound 170.


#	R ₂	W ₁	¹ H-NMR Data	MS Data
174a	CH ₂ CO ₂ Et	Me	(DMSO-d ₆) δ 1.20 (t, J = 7.1Hz, 3H), 2.81 (s, 3H), 3.25 (t, J = 5.9Hz, 2H), 4.07 (q, J = 7.1Hz, 2H), 4.39 (t, J = 5.8 Hz, 2H), 4.69 (s, 2H), 5.34 (s, 2H), 6.94-6.98 (m, 2H), 7.08-7.16 (m, 4H), 7.45 (d, J = 7.7Hz, 1H), 7.49 (d, J = 7.9Hz, 1H)	471 (MH ⁺)
174b	CH ₂ CO ₂ Et	CF ₃	(DMSO-d ₆) δ 1.22 (t, J = 6.3Hz, 3H), 3.51-3.62 (m, 2H), 4.17 (q, J = 7.2Hz, 2H), 4.45-4.58 (m, 2H), 4.76 (s, 2H), 5.43 (s, 2 H), 7.05-7.10 (m, 2H), 7.16-7.29 (m, 4H), 7.57 (d, J = 7.8Hz, 2H), 9.81 (s, 1H, exchanges with D ₂ O)	525 (MH ⁺)
174c	CH ₂ CO ₂ Et	Ph	¹ H NMR (DMSO-d ₆) δ 1.21 (t, J = 7.1, 3 H), 3.09-3.13 (m, 2 H), 4.15 (q, J = 7.1, 2 H), 4.45-4.467 (m, 2 H), 4.78 (s, 2 H), 5.43 (s, 2 H), 7.01-7.26 (m, 6 H), 7.50-7.65 (m, 5 H), 7.73 (d, J = 7.1, 2 H), 8.03 (t, J = 6.2, 1 H);	MS m/e 534 (MH ⁺);

5

**Table 15 -** Prepared as described for compound 8.

#	R ₂	W ₁	¹ H-NMR Data	MS Data
175a	CH ₂ CO ₂ H	CF ₃	(DMSO-d ₆) δ 3.48-3.60 (m, 2H), 4.43-4.58 (m, 2H), 4.67 (s, 2H), 5.41 (s, 2H), 7.03-7.10 (m, 2 H), 7.14-7.27 (m, 5H), 7.54 (d, J = 7.8 Hz, 2H)	497 (MH ⁺)
175b	CH ₂ CO ₂ H	CH ₃	(DMSO-d ₆) δ 2.78 (s, 3H), 3.32 (t, J = 5.2 Hz, 2H), 4.45 (t, J = 5.8Hz, 2H), 4.65 (s, 3H), 5.41 (s, 2H), 6.99-7.10 (m, 2 H), 7.10-7.22 (m, 4H), 7.52-7.58	443 (MH ⁺)

			(m, 2H)	
175c		CH ₃	(DMSO-d ₆) δ 2.84 (s, 3H), 6.38-6.46 (m, 2H), 4.55-4.61 (m, 2H), 5.60 (s, 2H), 5.76 (s, 2H), 7.02-7.06 (m, 2H), 7.14-7.16 (m, 1H), 7.27-7.31 (m, 2H), 7.36-7.39 (m, 1H), 7.44-7.46 (m, 1H), 7.49 (d, J = 8.1 Hz, 2H), 7.61 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 8.1 Hz, 2H)	520 (MH ⁺)
175d	CH ₂ CO ₂ H	iPr	(DMSO-d ₆) δ 1.11 (d, J = 6.8, 6 H), 1.22 (t, J = 7.1, 3 H), 3.07-3.16 (m, 2 H), 4.16 (q, J = 7.1, 2 H), 4.31-4.33 (m, 2 H), 4.78 (s, 2 H), 5.44 (s, 2 H), 7.00-7.08 (m, 2 H), 7.13-7.27 (m, 3 H), 7.35 (t, J = 6.3, 1 H), 7.53-7.59 (m, 2 H);	500 (MH ⁺)

Compound 176

5


To a slurry of compound 164 (2.0 g, 9.2 mmol) and KHCO₃ (2.3 g, 23.0 mmol) was added methyl chloroformate (1.42 ml, 18.4 mmol) and the mixture stirred at 23°C for 12h. The reaction mixture is extracted with EtOAc. The organic extracts are combined, dried over MgSO₄ and concentrated to give 1.82 g (83%) of compound 176 as a yellow solid.

10

¹H NMR (DMSO-d₆) δ 3.19-3.25 (m, 2H), 3.39-3.45 (m, 2H), 3.52 (s, 3H), 6.67 (t, J = 7.3Hz, 1H), 7.12 (d, J = 8.7Hz, 1H), 7.37 (br t, 1H, exchanges with D₂O), 7.53 (t, 7.2 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 8.20 (br t, 1H, exchanges with D₂O)

15 IR (film, cm⁻¹) 1736, 1515, 1353;MS m/e 239 (MH⁺);Anal. Calcd for C₁₀H₁₃N₃O₄: C, 50.21; H, 5.48; N, 17.56

Found: C, 50.15 ; H, 5.61; N, 17.58.

Compound 177

5 Compound 177 was prepared as described for compound 166 above.

¹H NMR (DMSO-d₆) δ 3.03-3.10 (m, 2H), 3.16-3.22 (m, 2H), 3.53 (s, 3H), 4.40-4.45 (m, 2H, exchanges with D₂O), 6.38-6.55 (m, 4H), 7.21 (t, J = 5.3 Hz, 1H, exchanges with D₂O);

IR (film, cm⁻¹) 1702, 1565, 733;

10 MS m/e 209 (MH⁺).





Table 16- Compounds were prepared as described for compound 170 using 177.

#	R ₂	¹ H-NMR Data	MS Data
178a	Et	¹ H NMR (DMSO-d ₆) δ 1.23 (t, J = 7.1, 3 H), 3.32-3.38 (m, 2 H), 3.47 (s, 3 H), 3.91 (q, J = 7.2, 2 H), 4.43 (t, J = 6.0, 2 H), 5.33 (s, 2 H), 6.97-7.09 (m, 2 H), 7.13-7.24 (m, 4H), 7.46-7.55 (m, 2H);	MS m/e 394 (MH ⁺);
178b	CH ₂ CO ₂ Et	DMSO-d ₆ : 1.22 (t, J = 7.10 Hz, 3H), 3.33 (s, 3H), 3.32-3.42 (m, 2H), 4.17 (q, J = 7.10 Hz, 2H), 4.40-4.48 (m, 2H), 4.79 (s, 2H), 5.37 (s, 2H), 7.01-7.16 (m, 2H), 7.21-29 (m, 3H), 7.32-7.39 (m, 1H), 7.55-7.65 (m, 2H)	451 (MH ⁺)
178c ^a	CH ₂ CO ₂ H	(DMSO-d ₆) 3.25-3.34 (m, 2 H), 3.48 (s, 3 H), 4.41-4.45 (m, 2 H), 4.68 (s, 2 H), 5.37 (s, 2 H), 7.03-7.10 (m, 2 H), 7.05-7.30 (m, 4 H), 7.30-7.38 (m, 2 H), 7.43-7.58 (m, 2 H)	423 (MH ⁺)

15 a, ester hydrolyzed as described for compound 8.

Compound 179

5 A mixture of amine **164** (40 g, 220 mmol), trimethyl ortho formate (38.5 mL, 352 mmol) and sodium azide (15.7 g, 242 mmol) in acetic acid (400 mL) was heated to reflux for 12 h. The resulting mixture was cooled to room temperature and poured into 1N HCl in ice (300 mL). The precipitate was filtered and recrystallized from ethyl acetate to give 19.2 g (37% yield) of compound **179** as bright yellow needles:

10

^1H NMR (DMSO- d_6) δ 3.90 (J = 6.6 Hz, 2H), 4.73 (t, J = 6.6 Hz, 2H), 6.72 (t, J = 6.9 Hz, 1H), 7.07 (d, J = 10.2 Hz, 1H), 7.53 (d, J = 6.3 Hz, 1H), 8.06 (d, J = 10.1 Hz, 1H), 8.18 (t, J = 6.6 Hz, 1H); 9.40 (s, 1 H);

IR (KBr, cm^{-1}) 1621, 1514, 1347, 740;


15 MS m/e 235 (MH^+);

Anal. Calcd for $\text{C}_9\text{H}_9\text{N}_5\text{O}_2$: C, 46.15; H, 4.30; N, 35.88.

Found: C, 46.17; H, 4.35; N, 35.85.

Compound 180

20




25 A solution of nitroaniline **179** (3.5 g, 14.95 mmol) in ethanol (50 mL) containing 10% Pd/C (200 mg) was hydrogenated at 50 psi for 4 h. The reaction mixture was filtered and concentrated to give 2.8 g (93% yield) of compound **180** as a black solid:

^1H NMR (DMSO- d_6) δ 3.52 (q, J = 6.0, 2H), 4.46 (s, 3H), 4.63-4.69 (m, 3H), 6.45-6.57 (m, 4H), 9.4 (s, 1H);

MS m/e 205 (MH⁺).

Compound 181




5

N-isopropenyl-2-benzimidazolone (15.0g, 86.10mmol), methyl bromoacetate (13.2 g, 86.1 mmol) and potassium carbonate (14.25g, 103.26 mmol) were stirred in acetonitrile (300ml) at room temperature overnight. The next day the reaction mixture was filtered and concentrated to give 21.0g (99% yield) of product **181** as a clear oil:

¹H NMR (DMSO) δ 2.13 (s, 3H), 3.69 (s, 3H), 4.74 (s, 2H), 5.17 (s, 1H), 5.38 (s, 1H), 7.05-7.23 (m, 4H);
IR (KBr, cm⁻¹) 2955, 1755, 1714, 1493, 757;
MS m/e 247 (MH⁺).

15

Compound 182



20

The solution of ester **181** (3.33g, 17.79mmol) in methanol (20 mL) was stirred with 1N NaOH (19.19ml, 19.18mmol) at room temperature overnight. The solvent was evaporated and the residue dissolved in water and acidified with 1N HCl. The precipitate was filtered off, washed with water and dried under vacuum to give 2.7g (91% yield) of compound **182** as a white solid:

¹H NMR (DMSO-d₆) δ 2.15 (s, 3H), 4.62 (s, 2H), 5.18 (s, 1H), 5.4 (s, 1H), 7.07-7.21 (m, 4H);
IR (KBr, cm⁻¹) 2967, 1751 1675, 1206, 752;
MS m/e 233 (MH⁺);


30

Anal. Calcd for $C_{12}H_{12}N_2O_3$: C, 62.06; H, 5.21; N, 12.06

Found: C, 61.69; H, 5.33; N, 11.98

Compound 183

5



To a mixture of acid **182** (1.35g, 6.61mmol) and 2-chloro-1-methylpyridinium iodide (2.02g, 7.92mmol) in acetonitrile (30mL) was added triethylamine (3.21mL, 23.13 mmol), followed by diamine **180** (1.53g, 6.61mmol). The reaction mixture was stirred at room temperature overnight. The precipitate was filtered and dried under vacuum to give compound **183** (1.281g, 46% yield): mp 184-186 °C.


15 ^1H NMR (DMSO- d_6) δ 2.15 (s, 3H), 3.59 (q, J = 6.5 Hz, 2H), 4.64 (t, J = 6.6 Hz, 2H), 4.71 (s, 2H), 5.17 (s, 1H), 5.36-5.39 (m, 2H), 6.60 (t, J = 7.5 Hz, 1H), 6.70 (d, J = 7.4 Hz, 2H), 7.02-7.19 (m, 6H), 9.34 (s, 1H), 9.48 (s, 1H);

IR (KBr, cm^{-1}) 3400, 1710, 1680, 1493, 1426, 742;

MS m/e 419 (MH^+);

20 Anal. Calcd for $C_{21}H_{22}N_8O_2$: C, 60.28; H, 5.30; N, 26.78

Found: C, 59.92; H, 5.31; N, 26.41.

Compound 184

5 A solution of compound **183** (1.25g, 2.98mmol) in acetic acid (40 ml) was refluxed overnight. The solvent was evaporated to give compound **184** as an off-white solid (850mg, 79% yield): mp >200 °C


¹H NMR (DMSO-d₆) δ 4.91-4.98 (m, 4H), 5.14 (s, 2H), 6.95-7.0 (m, 3H), 7.10-7.17 (m, 3H), 7.25-7.27 (m, 1H), 7.50-7.54 (m, 1H), 9.28 (s, 1H), 11.03 (s, 1H);

IR (KBr, cm⁻¹) 3429, 3256, 1694, 1489, 738;

MS m/e 361 (MH⁺);

Anal. Calcd for C₁₈H₁₆N₈O • 0.33 H₂O • 0.35 EtOAc: C, 58.67; H, 4.94; N, 28.21

Found: C, 58.55; H, 4.69; N, 27.83

Compound 185

20 A mixture of compound **184** (1.0 g, 2.77 mmol) and Cs₂CO₃ (904 mg, 2.77 mmol) in CH₃CN (40mL) was heated to reflux for 10 minutes, and then methyl 4-(bromomethyl)benzoate (636mg, 2.77mmol) in CH₃CN (5 mL) was added. The resulting mixture was refluxed for 30 minutes and cooled to room temperature. The mixture was filtered and the filtrate was evaporated. Flash chromatography
25 (MeOH:CH₂Cl₂ = 5:95) gave 700 mg (50% yield) of compound **185** as a white solid: mp 144-147 °C;

¹H NMR (DMSO-d₆) δ 3.83 (s, 3H), 4.94-5.01 (m, 4H), 5.21 (s, 2H), 5.27 (s, 2H), 6.7-7.07 (m, 2H), 7.11-7.19 (m, 3H), 7.22-7.31 (m, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.54-7.56 (m, 1H), 7.93 (d, J = 8.3 Hz, 2H), 9.31 (s, 1H);


5 IR (KBr, cm⁻¹) 3423, 1714, 1437, 1284, 1110, 748;

MS m/e 509 (MH⁺);

HRMS calcd for C₂₇H₂₄N₈O₃, 509.2049; found, 509.2046

Compound 186

10




To a solution of compound **185** (1.82 g, 3.57 mmol) in methanol (110 mL) was added lithium hydroxide monohydrate (0.90g, 21.47mmol) in water (20 mL).

15 The resulting mixture was stirred overnight at room temperature and evaporated. The residue was diluted with water and acidified with 1N HCl. The white precipitate was filtered and dried under vacuum. To the solid in methanol (120 mL) was added one equivalent of 0.5 M NaOMe (5.5 mL) at room temperature under nitrogen and the solution was stirred for 3 hours. The solvent was evaporated and dried under vacuum
20 to give 1.38 g (74% yield) of compound **186** as a white solid:

¹H NMR (DMSO-d₆) δ 4.92-5.05 (m, 4H), 5.18 (s, 2H), 5.26 (s, 2H), 7.01-7.03 (m, 2H), 7.1-7.29 (m, 3H), 7.38-7.45 (m, 2H), 7.51-7.54 (m, 1H), 7.89 (d, J = 8.3, 4H), 9.29 (s, 1H);

25 IR (KBr, cm⁻¹) 3406, 1695, 1599, 1556, 1396, 750;

MS m/e 495(MH⁺).


Compound 187

5 To a mixture of acid **186** (250 mg, 0.5 mmol), dimethylamine hydrochloride (62 mg, 0.75 mmol) and diisopropyl ethylamine (131 mg, 1.0 mmol) in DMF (10 mL) was added PyBroP (283 mg, 0.60 mmol) in one portion. The reaction was stirred at room temperature overnight, quenched with MeOH (1 mL), and evaporated. The residue was taken into ethyl acetate and washed with 5% KHSO₄, 5% NaHCO₃,
10 brine, dried over Na₂SO₄, and evaporated. The crude solid was washed with ethyl acetate and large portions of water to give 181 mg (69% yield) of compound **187** as a white solid: mp >200 °C

¹H NMR (DMSO-d₆) δ 2.86 (s, 3H), 2.95 (s, 3H), 4.93-4.95 (m, 2H), 5.0-5.02 (m, 2H), 5.15 (s, 2H), 5.26 (s, 2H), 7.02-7.04 (m, 2H), 7.14-7.17 (m, 3H), 7.23-7.24 (m, 1H), 7.28-7.3 (m, 1H), 7.38 (q, J = 5.0 Hz, 4H), 7.53 (d, J = 5.3 Hz, 1H), 9.31 (s, 1H); MS m/e 521(MH⁺).

Compound 188

20




Compound **184** (300mg, 0.83mmol) in THF (5 mL) was added BTTP (0.51mL, 1.82mmol) under nitrogen at 0 °C. After stirring for 15 minutes, methyl 3-(bromomethyl)benzoate (190.7 mg, 0.83 mmol) was added. The reaction mixture
25 was allowed to warm up to room temperature overnight under nitrogen and

evapoarted. The residue was diluted with water and extracted with ether and ethyl acetate. The combined extracts were dried over Na_2SO_4 and evaporated. The crude product was purified by flash chromatography on silica gel using $\text{CH}_2\text{Cl}_2:\text{MeOH}:\text{NH}_4\text{OH} = 90:10:1$ to give 196mg (46% yield) of compound **188** as a white solid: mp 162-164 °C;


^1H NMR ($\text{DMSO}-d_6$) δ 3.85 (s, 3H), 4.92-5.05 (m, 4H), 5.19 (s, 2H), 5.27 (s, 2H), 6.99-7.05 (m, 2H), 7.11-7.17 (m, 3H), 7.20-7.28 (m, 2H), 7.48-7.55 (m, 2H), 7.63 (d, $J = 7.9$ Hz, 1H), 7.85 (d, $J = 6.5$ Hz, 1H), 7.97 (s, 1 H), 9.29 (s, 1H);
IR (KBr, cm^{-1}) 3424, 1701, 1494, 1434, 1289, 748;
MS m/e 509 (MH^+);
Anal. Calcd for $\text{C}_{27}\text{H}_{24}\text{N}_8\text{O}_3 \cdot 0.55 \text{ EtOAc}$: C, 62.97; H, 5.14; N, 20.12
Found: C, 63.22; H, 4.75; N, 19.73.

15 Compound 189



Compound **188** (100 mg, 0.19mmol) in methanol (10mL) was stirred with 1N NaOH (0.3 mL) at room temperature for 2 days, and then refluxed for 3 hours. The solvent was removed. The residue was diluted with water and acidified to pH 5 with 1N HCl. The white precipitate was filtered and dried under vacuum. The solid in methanol (5mL) was stirred with 0.5M NaOMe (0.34 mL) at room temperature under nitrogen for 3 hours. The solvent was evaporated and the residue was dried under vacuum to give 87mg (86% yield) of the sodium salt of compound **189** as a white solid:



^1H NMR ($\text{DMSO}-d_6$) δ 4.92-5.0 (m, 4H), 5.09 (s, 2H), 5.27 (s, 2H), 6.99-7.29 (m, 9H), 7.53-7.56 (m, 1H), 7.72 (d, $J = 7.2$ Hz, 1H), 7.81 (s, 1H), 9.34 (s, 1H);
IR (KBr, cm^{-1}) 3412, 1698, 1566, 1492, 1390, 750;
MS m/e 495 (MH^+).


Compound 190

5 The tetrazole was dissolved in MeOH (30 ml) and NaOH (1N, 2 eq) was added and the mixture stirred for 12 h. The solvent removed and the resulting mixture was adjusted to pH 7 with 1N HCl. The product was extracted with EtOAc and the organic extracts were combined, dried over Na₂SO₄ and concentrated to give the products in the table below.

10

Table 16- Compound prepared as described for 190.

#	R ₂	¹ H-NMR Data	MS Data
190a	CH ₂ CH ₂ CH ₂ CO ₂ H	¹ H NMR (DMSO-d ₆) δ 1.86-1.90 (m, 2 H), 2.29 (t, J = 7.2, 2 H), 3.90 (t, J = 7.0, 2 H), 4.39 (t, J = 6.3, 2 H), 5.19 (s, 2 H), 5.36 (s, 2 H), 6.13 (t, J = 5.9, 1 H), 6.98-7.13 (m, 6 H), 7.19-7.24 (m, 2 H), 7.49-7.57 (m, 2 H), 12.06 (s, 1H);	MS m/e 437 (MH ⁺);
190b		¹ H NMR (DMSO-d ₆) δ 3.34 (t, J = 6.0, 2 H), 4.41 (t, J = 6.0, 2 H), 5.19 (s, 2 H), 5.42 (s, 2 H), 5.60 (s, 2 H), 6.16 (t, J = 5.9, 1 H), 6.99-7.02 (m, 2 H), 7.10-7.26 (m, 4 H), 7.45 (d, J = 8.2, 2), 7.50-7.58 (m, 2H), 7.90 (d, J = 8.2, 2H);	MS m/e 485 (MH ⁺);
190c		¹ H NMR (DMSO-d ₆) δ 3.35-3.40 (m, 2 H), 4.44 (t, J = 6.9 Hz, 2 H), 5.47 (s, 2 H), 5.56 (s, 2 H), 5.62 (s, 2 H), 6.85-7.02 (m, 4 H), 7.15-7.30 (m, 5 H), 7.52-7.61 (m, 2 H), 7.81-7.88 (m, 1 H);	MS m/e 521 (MH ⁺);


Compound 191

5 Compound 191 was prepared using the same procedure described for compound 4, except that 3-methylbromobutane was replaced with 4-bromobutyl acetate.

10 ¹H NMR (CDCl₃) δ 1.68-1.72 (m, 2H), 1.91-1.94 (m, 2H), 2.03 (s, 3H), 4.07 (t, J = 6.4 Hz, 2H), 4.26 (t, J = 7.5 Hz, 2H), 4.86 (s, 2H), 6.86 (bs, 1H), 7.20-7.29 (m, 3H), 7.65 (dd, J = 1.8, 6.7 Hz, 1H);
MS m/e 263 (MH⁺).


Compound 192

15



20 Compound 192 was prepared according to the same procedure described for compound 6.

¹H NMR (CDCl₃) δ 1.80-1.86 (m, 2H), 2.03 (s, 3H), 2.06-2.12 (m, 2H), 4.14 (t, J = 6.1 Hz, 2H), 4.55 (t, J = 8.1 Hz, 2H), 5.42 (s, 2H), 7.48 (t, J = 7.3 Hz, 1H), 7.55 (t, J = 7.3 Hz, 1H), 7.64 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 8.2 Hz, 1H);
MS m/e 281 (MH⁺).


Compound 193

5 Compound 193 was prepared as described for compound 4. The acetate group was removed by stirring with MeOH for 1 hour before work-up as previously described.

10 ¹H NMR (DMSO-d₆) δ 1.38-1.45 (m, 2H), 1.46-1.65 (m, 2H), 2.19 (s, 3H), 3.15-3.21 (m, 2H), 4.32-4.40 (t, J = 7.5 Hz, 2H), 4.40-4.46 (m, 1 H), 5.20 (s, 1H), 5.38 (s, 2H), 5.43 (s, 1H), 7.02-7.16 (m, 2H), 7.16-7.36 (m, 3H), 7.50-7.62 (m, 2H), 8.55 (s, 1H); MS m/e 376 (MH⁺).


Compound 194

15



Compound 194 was prepared as described for compound 115.

20 ¹NMR (DMSO-d₆) δ 1.39-1.45 (m, 2H), 1.46 (d, J = 6.9 Hz, 6H), 1.54-1.59 (m, 2H), 3.33-3.37 (m, 2H), 4.33 (t, J = 7.5 Hz, 2H), 4.45 (t, J = 5.1 Hz, 1H), 4.63-4.68 (m, 1H), 5.35 (s, 2H), 6.98-7.05 (m, 2H), 7.17 (t, J = 7.6 Hz, 1H), 7.23 (t, J = 8.8 Hz, 2H), 7.33 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H); MS m/e 378 (MH⁺).


Compound 195

5 Compound 195 was prepared from compound 193 as described for compound 6.

¹H NMR (DMSO-d₆) δ 1.42-1.47 (m, 2H), 1.59-1.62 (m, 2H), 3.36-3.40 (m, 2H),
4.33 (t, J = 7.5 Hz, 2H), 4.46 (t, J = 5.1 Hz, 2H), 5.32 (s, 2H), 6.93-7.02 (m, 3H),
10 7.14-7.19 (m, 2H), 7.22-7.25 (m, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H);
MS m/e 336 (MH⁺).

Compound 196


15



20 Compound 196 was prepared by alkylation of compound 195 with compound 90.


25

¹H NMR (DMSO-d₆) δ 1.60-1.68 (m, 2H), 1.69-1.79 (m, 2H), 1.96 (s, 3H), 2.86 (s, 3H),
2.95 (s, 3H), 3.97 (t, J = 6.4 Hz, 2H), 4.37 (t, J = 7.15 Hz, 2H), 5.47 (s, 2H), 6.98-
7.03 (m, 2H), 7.14-7.18 (m, 2H), 7.19-7.28 (m, 2H), 7.35-7.42 (m, 4H), 7.58 (dd, J =
2.9, 8.2 Hz, 2H);
MS m/e 539 (MH⁺).

Compound 197

5 Compound 197 was prepared as described for compound 8.


¹H NMR (DMSO-d₆) δ 1.30-1.45 (m, 2H), 1.47-1.70 (m, 2H), 2.86-2.95 (m, 6H),
3.33-3.39 (m, 2H), 4.34-4.36 (m, 2H), 4.46-4.48 (m, 1H), 5.16 (s, 2H), 5.43 (s, 2H),
6.95-7.11 (m, 2H), 7.14-7.19 (m, 2H), 7.22-7.26 (m, 2H), 7.36-7.47 (m, 3H), 7.49-
10 7.59 (m, 3H);
MS m/e 496 (MH⁺).

Compound 198

15


Compound 198 was prepared by alkylation of compound 195.

¹H NMR (DMSO-d₆) δ 1.59-1.62 (m, 2H), 1.76-1.79 (m, 2H), 1.99-2.02 (m, 2H),
20 2.54-2.63 (m, 4H), 3.93 (t, *J* = 4.1, 2H), 4.41 (t, *J* = 4.5, 2H), 5.41 (s, 2H), 6.99-7.19
(m, 4H), 7.24-7.28 (m, 2H), 7.56-7.60 (m, 2H);
MS m/e 413 (MH⁺).

Compound 199

5 Compound **199** was prepared as described for compound **7** using Cs_2CO_3 as base.


^1H NMR (DMSO- d_6) δ 1.41-1.48 (m, 2H), 1.64-1.71 (m, 2H), 3.36-3.38 (m, 2H),
4.35 (t, $J = 7.8$ Hz, 2H), 4.48 (t, $J = 5.6$ Hz, 1H), 5.23 (s, 2H), 5.43 (s, 2H), 7.01-7.04
10 (m, 2H), 7.14-7.28 (m, 4H), 7.52-7.60 (m, 4H), 7.84 (d, $J = 8.2$ Hz, 2H);
MS m/z 452 (MH^+).

Compound 200

15

Compound **200** was prepared as described for compound **22**.

^1H NMR (DMSO- d_6) δ 1.45-1.50 (m, 2H), 1.69-1.75 (m, 2H), 3.39 (t, $J = 6.4$ Hz,
20 2H), 4.44 (t, $J = 7.4$ Hz, 2H), 5.22 (s, 2H), 5.55 (s, 2H), 7.03-7.07 (m, 2H), 7.17-7.21
(m, 1 H), 7.27-7.30 (m, 2H), 7.34-7.37 (m, 1H), 7.59 (d, $J = 8.3$ Hz, 2H), 7.65 (d, $J =$
8.0 Hz, 1H), 7.71 (d, $J = 7.4$ Hz, 1H), 8.04 (d, $J = 8.3$ Hz, 2H);
MS m/e 495 (MH^+).


Compound 201

5 Compound 201 was prepared as described for compound 9 except EDC was used as coupling reagent.

¹H NMR (DMSO-d₆) δ 1.11 (t, J = 6.9 Hz, 3H), 1.22 (t, J = 6.9 Hz, 3H), 1.20-1.38 (m, 2H), 1.65-1.80 (m, 2H), 3.41 (t, J = 6.3 Hz, 2H), 4.04-4.18 (m, 4H), 4.17 (s, 2 H),
10 4.40-4.52 (m, 2H), 5.17 (s, 2 H), 5.58 (s, 2H), 7.01-7.11 (m, 2H), 7.17-7.21 (m, 1H), 7.24-7.50 (m, 6H), 7.67 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 6.9 Hz, 1H);
MS m/e 598 (MH⁺).


Compound 202

15



Compound 202 was prepared as described for compound 201.


20 ¹H NMR (DMSO-d₆) δ 1.43-1.50 (m, 2H), 1.60-1.78 (m, 2H), 2.13 (s, 6H), 3.32-3.41 (m, 4H), 4.36 (t, J = 7.5 Hz, 2H), 4.61-4.68 (m, 2H), 5.17 (s, 2H), 5.43 (s, 2H), 6.99-7.05 (m, 2H), 7.09-7.26 (m, 3 H), 7.43 (d, J = 8.4 Hz, 2H), 7.57 (t, J = 7.2 Hz, 2H), 7.79 (d, J = 8.1 Hz, 2H), 8.35 (t, J = 5.7 Hz, 1H);
MS m/e 540 (MH⁺).

Compound 203

5 Compound **203** was prepared as described for compound **12**.

^1H NMR (DMSO- d_6) δ 1.25-1.42 (m, 2H), 1.43-1.63 (m, 2H) 3.20-3.40 (m, 2H),
3.62 -3.82 (m, 2H), 4.21-4.39 (m, 2H), 4.72-4.92 (bs, 1H), 5.13 (s, 2H), 5.43 (s, 2H),
6.92-7.10 (m, 2H), 7.10-7.36 (m, 6H), 7.37-7.43 (m, 2H), 7.54-7.62 (m, 2H);

10 MS m/e 585 (MH^+).


Compound 204

15

Compound **204** was prepared as described for compound **88** using 2-(3-chloro-propyl)-2-methyl-[1,3]dioxolane.

^1H NMR (CDCl_3) δ 1.18 (s, 3H), 1.55-1.72 (m, 4H), 2.25 (s, 3H), 3.67-3.71 (m, 2H),
20 3.81-3.84 (m, 2H), 4.33-4.36 (m, 2H), 5.27 (s, 1 H), 5.38 (s, 1 H), 5.42 (s, 2 H), 7.02-
7.09 (m, 3H), 7.25-7.36 (m, 2H), 7.35-7.36 (m, 1H), 7.45-7.47 (m, 1H), 7.80-7.81 (m,
1H);

MS m/e 432 (MH^+).


Compound 205

5 Compound **205** was prepared by deprotection of compound **204** as described for compound **6** followed by alkylation of the intermediate as described for compound **7**.

10 ¹H NMR (DMSO-d₆) δ 1.86-1.91 (m, 2H), 2.05 (s, 3H), 2.41-2.56 (m, 2H), 2.72-2.87 (m, 6H), 4.30-4.45 (m, 2H), 5.16 (s, 2H), 5.56 (s, 2H), 7.04-7.19 (m, 3H), 7.18-7.21 (m, 1H), 7.23-7.45 (m, 6H), 7.64 (d, J = 7.5 Hz, 1H), 7.75 (d, J = 7.5 Hz, 1H); MS m/s 509 (MH⁺).


Compound 206

15



Compound **206** was prepared by NaBH₄ reduction of compound **205**.

20 ¹H NMR (DMSO-d₆) δ 0.96 (d, J = 6.1 Hz, 3H), 1.28-1.32 (m, 2H), 1.60-1.63 (m, 1H), 1.72-1.75 (m, 1H), 2.86 (s, 3H), 2.96 (s, 3H), 3.50-3.59 (m, 1H), 4.34 (t, J = 7.4 Hz, 2H), 4.41-4.48 (m, 1H), 5.16 (s, 2H), 5.43 (s, 2H), 7.0-7.02 (m, 2H), 7.15-7.18 (m, 2H), 7.22-7.26 (m, 2H), 7.36-7.42 (m, 4H), 7.55 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H);
25 MS m/e 511 (MH⁺).


Compound 207

5 Compound **207** was prepared from compound **85** as described for compound **206**.

¹H NMR (CDCl₃) δ 1.19 (d, J = 6.18 Hz, 3 H), 1.67-1.78 (m, 1 H), 1.83-1.92 (m, 1 H), 2.25 (s, 3 H), 2.76 (d, J = 5.6 Hz, 1 H), 3.84-3.87 (m, 1 H), 4.43-4.52 (m, 2 H),
10 5.22 (s, 1 H), 5.40 (d, J = 1.4 Hz, 1 H), 5.46 (d, J = 4.5 Hz, 2 H), 7.08-7.12 (m, 3 H), 7.28-7.32 (m, 2 H), 7.37-7.40 (m, 1 H), 7.56-7.59 (m, 1 H), 7.79-7.82 (m, 1 H);
MS m/e 377 (MH⁺).

Compound 208


15



Compound **208** was prepared as described for compound **6**.

20 ¹H NMR (DMSO-d₆) δ 1.08 (d, J = 6.1 Hz, 3H), 1.77-1.82 (m, 2H), 3.62-3.74 (m, 1H), 4.56 (t, J = 7.1 Hz, 2H), 5.55-5.62 (m, 2H), 6.99-7.08 (m, 3H), 7.19 (d, J = 7.2 Hz, 1H), 7.43-7.53 (m, 2H), 7.69 (d, J = 7.4 Hz, 1H), 7.85 (d, J = 7.6 Hz, 1H);
MS m/e 337 (MH⁺).

Compound 209




5 Compound **209** was prepared by alkylation of compound **3**.

¹H NMR (CDCl₃) δ 1.81-1.91 (m, 2H), 2.07-2.22 (m, 2H), 2.25 (s, 3H), 4.44 (t, J = 7.8 Hz, 2H), 5.21 (s, 1H), 5.40 (s, 3H), 7.06-7.10 (m, 3H), 7.27-7.33 (m, 3H), 7.52-7.62 (m, 1H), 7.80-7.84 (m, 1H);

10 MS m/e 415 (MH⁺).

Compound 210




15

Compound **210** was prepared as described for compound **6**.

¹H NMR (CDCl₃) δ 1.76-1.86 (m, 2H), 2.10-2.27 (m, 2H), 4.41 (t, J = 8.0 Hz, 2H),
20 5.42 (s, 2H), 7.02-7.09 (m, 3H), 7.29-7.32 (m, 3H), 7.45-7.48 (m, 1H), 7.80-7.84 (m,
1H), 8.48 (s, 1H);
MS m/e 375 (MH⁺).


Compound 211



Compound **211** was prepared by alkylation of compound **210** as described for compound **7**.

¹H NMR (CDCl₃) δ 1.78-1.89 (m, 2H), 2.09-2.25 (m, 2H), 3.79 (s, 3H), 4.38 (t, J = 8.0 Hz, 2H), 4.67 (s, 2H), 6.87-6.92 (m, 1H), 7.05-7.12 (m, 1H), 7.29-7.32 (m, 3H), 7.47-7.50 (m, 1H), 7.81-7.84 (m, 1H); MS m/e 447 (MH⁺).


Compound 212



Compound **212** was prepared as described for compound **8**.

15 ¹H NMR (DMSO-d₆) δ 1.71-1.82 (m, 2H), 2.24-2.38 (m, 2 H), 4.05 (s, 2H), 4.39 (t, J = 7.7 Hz, 2H), 5.37 (s, 2H), 6.90-7.00 (m, 3H), 7.16-7.28 (m, 3H), 7.58 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H);
MS m/e 433 (MH⁺).

20 Compound 213




Compound **213** was prepared according to the same procedure described for
25 compound **106** except that 3-methylbutylbromide was replaced with 1-bromo-4-
fluorobutane.

¹H NMR (DMSO-d₆) δ 1.65-1.75 (m, 2H), 1.85-1.90 (m, 2H), 4.32 (t, J = 7.5 Hz, 2H), 4.41 (t, J = 6.0 Hz, 1H), 4.51 (t, J = 6.0 Hz, 1H), 4.71 (d, J = 5.8 Hz, 2H), 5.62 (t, J = 5.8 Hz, 1H), 7.18 (t, J = 7.0 Hz, 1H), 7.23 (t, J = 6.3 Hz, 1H), 7.56-7.60 (m, 2H);

5 MS m/e 222 (MH⁺).

Compound 214




10

Compound 214 was prepared according to the same procedure described for chloride 107 and was used immediately upon isolation.

Compound 215


15



Compound 215 was prepared as described for compound 4, followed by deprotection and alkylation as described for compound 7.


20

¹H NMR (DMSO-d₆) δ 1.71-1.84 (m, 4 H), 2.15 (s, 3 H), 4.12 (t, J = 3.5, 1 H), 4.50-4.54 (m, 3 H), 5.11 (s, 2 H), 5.65 (s, 2 H), 7.10-7.17 (m, 2 H), 7.34-7.38 (m, 2 H), 7.45-7.50 (m, 2 H), 7.71 (d, J = 4.8, 1H), 7.89 (d, J = 4.6, 1H);
MS m/e 399 (MH⁺).

Compound 216

5 Compound 216 was prepared as described for compound 215 except 4-bromo-1-fluorobutane was used as the alkylating agent.


¹H NMR (DMSO-d₆) δ 1.22-1.28 (m, 2H), 1.54-1.85 (m, 8H), 2.54-2.58 (m, 2H),
3.93 (t, *J* = 4.1, 2H), 4.35-4.40 (m, 2H), 5.39 (s, 2 H), 6.98-7.09 (m, 2H), 7.14-7.27
10 (m, 4H), 7.58 (t, *J* = 4.9, 2H);
MS *m/e* 420 (MH⁺).

Compound 217

15

Compound 217 was prepared as described for compound 4.


¹H NMR (DMSO-d₆) δ 1.13 (t, *J* = 6.9 Hz, 3H), 1.80-1.95 (m, 2H), 2.17 (s, 3H), 2.37
20 (t, *J* = 7.2 Hz, 2H), 4.02 (q, *J* = 7.2 Hz, 2H), 4.36 (t, *J* = 6.6 Hz, 2 H), 5.19 (s, 1H),
5.39 (s, 1H), 5.42 (s, 1H), 7.06-7.10 (m, 2H), 7.11-7.28 (m, 4H), 7.58-7.71 (m, 2H);
MS *m/e* 418 (MH⁺).

Compound 218

5 Compound 218 was prepared as described for compound 6.

^1H NMR (DMSO- d_6) δ 1.15 (t, J = 7.2 Hz, 3H), 1.81-1.98 (m, 2H), 4.02 (q, J = 7.2 Hz, 2H), 4.36 (t, J = 7.5 Hz, 2H), 5.32 (s, 2H), 6.91-7.08 (m, 3H), 7.15-7.30 (m, 3H), 7.58 (d, J = 8.1 Hz, 2H);

10 MS m/e 378 (MH^+).

Compound 219


15

Compound 219 was prepared as described for compound 4 using 2-chloroethyl thiomethyl ether as the alkylating agent.

^1H NMR (CDCl_3) δ 2.07 (s, 3H), 2.25 (s, 3H), 2.75 (t, J = 6.9 Hz, 2 H), 4.62 (t, J = 6.9 Hz, 2H), 5.23 (d, J = 0.5 Hz, 1H), 5.40 (d, J = 1.4 Hz, 1H), 5.48 (s, 2H), 7.05-7.09 (m, 3H), 7.28-7.37 (m, 3H), 7.53-7.57 (m, 1 H), 7.79-7.84 (m, 1H);

20


MS m/e 379 (MH^+).

Compound 220

5 Compound **220** was prepared as described for compound **6**.

¹H NMR CDCl₃) δ 1.61 (s, 3H), 2.09 (s, 3H), 2.74 (t, J = 7.1 Hz, 2H), 4.59 (t, J = 7.1 Hz, 2H), 5.47 (s, 2H), 7.04-7.08 (m, 3H), 7.28-7.37 (m, 3H), 7.46-7.50 (m, 1H), 7.79-7.84 (m, 1H), 8.65 (bs, 1 H);

10 MS m/e 339 (MH⁺).

Compound 221

15

2-Fluoronitrobenzene (35.4 g, 250.9 mmol), 3-(methylthio)propylamine (24.0g, 228.1 mmol) and potassium carbonate (47.3 g, 342 mmol) were stirred in CH₃CN (100 mL) at room temperature overnight. After stirring for an additional hour at reflux, the mixture was cooled to room temperature and filtered. The filtrate was evaporated. To the residue in DMF (150 mL), magnesium monoperoxyphthalate hexahydrate (MMPP, 168 g, 340 mmol) was added in several portions with ice-water cooling. The mixture was stirred at room temperature for 3 hours and the solvent was evaporated. The residue was dissolved in CH₂Cl₂ and washed with 1 N NaOH, water, brine, dried over MgSO₄ and evaporated. The residue was triturated with hot EtOAc to give compound **221** (48.7 g, 75% yield) as an orange solid.

20

25


^1H NMR (CDCl_3) δ 2.25-2.35 (m, 2H), 2.97 (s, 3H), 3.17 (t, $J = 7.2$ Hz, 2H), 3.59 (t, $J = 6.9$ Hz, 2H), 6.68-6.74 (m, 1H), 6.89 (d, $J = 8.1$ Hz, 1H), 7.45-7.51 (m, 1H), 8.20 (dd, $J = 1.5, 8.7$ Hz, 1H);

MS m/e 259 (MH^+);

5 Anal. Calcd for $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_4\text{S}$: C, 46.50; H, 5.46; N, 10.84

Found: C, 46.53; H, 5.54; N, 10.90.

Compound 222



10


To a suspension of compound 221 (48.5 g, 187.8 mmol) in a mixture of CHCl_3 and MeOH (150 mL, 1:3) was added 10% palladium on carbon (6 g) under nitrogen. The reduction was carried out in a Parr shaker with hydrogen pressure maintained between 40 and 60 psi for 25 minutes. The catalyst was removed by filtration through a pad of Celite and the filtrate was evaporated to give crude 222.

15

^1H NMR (CD_3OD) δ 2.11-2.21 (m, 2H), 2.98 (s, 3H), 3.28-3.36 (m, 4H), 6.75 (dt, $J = 0.9, 7.2$ Hz, 1H), 6.85 (d, $J = 7.5$ Hz, 1H), 7.06-7.12 (m, 2H);

20 MS m/e 229 (MH^+).

Compound 223



25

The crude diamine 222 obtained above was stirred at reflux overnight with glycolic acid (15.7 g, 207 mmol) in 6 N HCl (150 mL). The solution was cooled in an ice bath and neutralized with concentrated NH_4OH solution, extracted with


EtOAc, dried over MgSO_4 and evaporated. The residue was purified by chromatography (gradient, EtOAc/hexane, 1:1 to EtOAc/MeOH, 10:1) to give a product which crystallized from EtOAc/MeOH to afford 25.7 g (51% yield in two steps) of **223**.

5

^1H NMR (CD_3OD) δ 2.38-2.44 (m, 2H), 2.97 (s, 3H), 3.24 (t, $J = 7.6$ Hz, 2H), 4.54 (t, $J = 7.6$ Hz, 2H), 7.27 (t, $J = 1.1, 8.1$ Hz, 1H), 7.33 (dt, $J = 1.1, 8.0$ Hz, 1H), 7.62 (d, $J = 8.1$ Hz, 1H), 7.64 (dd, $J = 1.0, 8.0$ Hz, 1H);
MS m/e 269 (MH^+).

10


Compound 224



15 Compound **224** was prepared according to the same procedure described for compound **6**.

^1H NMR (CD_3OD) δ 2.46-2.52 (m, 2H), 3.03 (s, 3H), 3.37 (t, $J = 7.1$ Hz, 2H), 4.77 (t, $J = 7.8$ Hz, 2H), 5.31 (s, 2H), 7.68-7.73 (m, 2H), 7.86 (dd, $J = 2.8, 6.9$ Hz, 1H), 8.03
20 (dd, $J = 1.7, 6.1$ Hz, 1H);
MS m/e 287 (MH^+).

Compound 224a




25

To a solution of 4-(2-keto-1-benzimidazoliny)l)piperidine (3.0 g, 13.8 mmol), triethylamine (2.79 g, 27.6 mmol) and DMAP (17 mg, 0.1 mmol) in CH_2Cl_2 (50 ml) was added di-*tert* butyldicarbonate (3.31 g, 15.2 mmol) at 0°C and stirred for 2 h.




The reaction mixture was washed with NaHCO_3 , dried and evaporated. The residue was purified by flash chromatography using hexanes:EtOAc (2:1 to 1:1) as eluant to give 2.68 g (61%) of compound **224a** as a white solid.


- 5 ^1H NMR (CD_3OD) δ : 1.49 (s, 9H), 1.75-2.02 (m, 2H), 2.29-2.43 (m, 2H), 2.89-2.99 (m, 2H), 4.23-4.29 (m, 2H), 4.37-4.46 (m, 1H), 7.02-7.07 (m, 3H), 7.19-7.22 (m, 1H);
MS m/e 318 (MH^+).



10

Table 17- Sulfones were prepared as described for compound 7 using chloride **224** and a benzimidazolone such as **224a** with Cs_2CO_3 as base. Compound **225d** was prepared from compound **225c** as described for compound 6.

#	R_2	^1H -NMR Data	MS Data
225a	CH_3	(CDCl_3) δ 1.61-1.67 (m, 2H), 1.85-1.91 (m, 2H), 2.13-2.19 (m, 2H), 2.83 (s, 3H), 3.05 (t, J = 7.2 Hz, 2H), 3.70 (t, J = 6.2 Hz, 2H), 3.99 (t, J = 7.0 Hz, 2H), 4.57 (t, J = 7.2 Hz, 2H), 5.48 (s, 2H), 7.01-7.05 (m, 1H), 7.07-7.14 (m, 2H), 7.32-7.35 (m, 2H), 7.42-7.43 (m, 1H), 7.55-7.58 (m, 1H), 7.83-7.85 (m, 1H)	457 (MH^+)
225b		(DMSO- d_6) δ 2.07-2.15 (m, 2H), 2.18 (s, 3H), 2.98 (s, 3H), 3.21 (t, J = 7.4 Hz, 2H), 4.50 (t, J = 7.4 Hz, 2H), 5.22 (s, 1H), 5.40-5.41 (m, 3H), 7.06-7.09 (m, 2H), 7.16-7.32 (m, 4H), 7.38-7.64 (m, 2H)	425 (MH^+)
225c		(CDCl_3) δ 1.52 (s, 9H), 1.82-1.88 (m, 2H), 2.18-2.38 (m, 4H), 2.85 (s, 3H), 2.86-2.94 (m, 2H), 3.04 (t, J = 7.3 Hz, 2H), 4.27-4.38 (m, 2H), 4.40-4.49 (m, 1H), 4.62 (t, J = 7.5 Hz, 2H), 5.49 (s, 2H), 7.07-7.15 (m, 2H), 7.36-7.39 (m, 2H), 7.44-7.49 (m, 1H), 7.63-7.66 (m, 1H), 7.84-7.88 (m, 1H)	568 (MH^+)
225d		(CD_3OD) δ 2.12-2.16 (m, 2H), 2.44-2.48 (m, 2H), 2.76-2.80 (m, 2H), 3.02 (s, 3H), 3.22-3.28 (m, 2H), 3.32-3.35 (m, 2H), 3.58-3.65 (m, 2H), 4.64-4.69 (m, 1H), 4.83 (t, J = 7.9 Hz, 2H), 5.79 (s, 2H), 7.20-7.28 (m, 2H), 7.35 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.65-7.72 (m, 2H), 7.75 (d, J = 8.2 Hz, 1H), 8.05 (d, J = 8.2 Hz, 1H)	468 (MH^+)

Compound 226


5

Compound **226** was prepared as described for compound **6**.

¹H NMR (DMSO-d₆) δ 2.03-2.14 (m, 2H), 2.97 (s, 3H), 3.21 (t, J = 8.0 Hz, 2H), 4.48 (t, J = 7.4 Hz, 2H), 5.34 (s, 2H), 6.95-7.02 (m, 3H), 7.16-7.29 (m, 3H), 7.57-7.63 (m, 2H);

10


MS m/e 385 (MH⁺).

**227**

15 **Table 18-** Compounds were prepared by alkylation of **226** as described for compound **7**.


#	R ₂	¹ H-NMR Data	MS Data
227a		(CDCl ₃) δ 2.16-2.26 (m, 2 H), 2.90 (s, 3 H), 3.08 (t, J = 7.3 Hz, 2 H), 4.58 (t, J = 7.7 Hz, 2 H), 5.45 (s, 2 H), 7.18-7.23 (m, 2 H), 7.35-7.45 (m, 4 H), 7.62-7.66 (m, 1 H), 7.81-7.86 (m, 1 H)	435 (MH ⁺)
227b^a		(CDCl ₃) δ 1.61-1.67 (m, 2 H), 1.85-1.91 (m, 2 H), 2.13-2.19 (m, 2 H), 2.83 (s, 3 H), 3.05 (t, J = 7.2 Hz, 2 H), 3.70 (t, J = 6.2 Hz, 2 H), 3.99 (t, J = 7.0 Hz, 2 H), 4.57 (t, J = 7.2 Hz, 2 H), 5.48 (s, 2 H), 7.01-7.05 (m, 1 H), 7.07-7.14 (m, 2 H), 7.32-7.35 (m, 2 H), 7.42-7.43 (m, 1 H), 7.55-7.58 (m, 1 H), 7.83-7.85 (m, 1 H)	457 (MH ⁺)
227c^a		(DMSO-d ₆) δ 2.12-2.17 (m, 2 H), 3.00 (s, 3 H), 3.22 (t, J = 7.9 Hz, 2 H), 4.50 (t, J = 8.0 Hz, 2 H), 5.23 (s, 2 H), 5.47 (s, 2 H), 7.01-7.06 (m, 2 H), 7.13-7.22 (m, 2 H), 7.28-7.31 (m, 2 H), 7.53 (d, J = 8.2 Hz, 2 H), 7.58-7.65 (m, 2 H), 7.83 (d, J = 8.2 Hz, 2 H)	500 (MH ⁺)

^a, Cs₂CO₃ was used as base instead of BTTP.

Compound 228

5 To a solution of **225b** (42 mg, 0.1 mmol) in THF (1 ml) was added 9-BBN (0.5 M in THF) (1.0 ml, 0.5 mmol) at 0°C and the final solution was stirred for 12 h. The reaction mixture was quenched with 1 M NaOH (2 ml) and 30% H₂O₂ (1 ml) and the mixture was stirred for 2 h then extracted with EtOAc. The organic layer was washed with brine, dried, evaporated. The residue was purified by preparative reverse
10 phase HPLC to yield 28 mg (63%) of **228** as a hygroscopic solid.


¹H NMR (CD₃OD) δ 1.54 (d, J = 7.1 Hz, 3H), 2.41-2.47 (m, 2H), 3.00 (s, 3H), 3.31-3.32 (m, 2H), 3.82-3.86 (m, 1H), 4.14-4.18 (m, 1H), 4.61-4.66 (m, 1H), 4.76 (t, J = 7.6 Hz, 2H), 5.70 (s, 2H), 7.13-7.21 (m, 2H), 7.27 (d, J = 7.7 Hz, 1H), 7.39 (d, J = 8.0
15 Hz, 1H), 7.53-7.62 (m, 2H), 7.69 (d, J = 8.0 Hz, 1H), 7.92 (d, J = 8.3 Hz, 1H); MS m/e 443 (MH⁺).

Compound 229

20

Compound **229** was prepared as described for compound **52**.


¹H NMR (DMSO-d₆) δ 2.12-2.17 (m, 2H), 3.00 (s, 3H), 3.24 (t, J = 7.7 Hz, 2H), 4.52 (t, J = 7.4 Hz, 2H), 5.22 (s, 2H), 5.48 (s, 2H), 7.031-7.06 (m, 2H), 7.16-7.22 (m, 2H),
25 7.26-7.31 (m, 2H), 7.57-7.60 (m, 3H), 7.64 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 8.3 Hz, 2H); MS m/e 543 (MH⁺).

Compound 230

5

Compound 230 was prepared as described compound 4.

¹H NMR (CDCl₃) δ 0.77 (t, J = 7.1 Hz, 3H), 0.83 (t, J = 7.1 Hz, 3H), 0.90-0.98 (m, 1H), 1.20-1.29 (m, 1H), 2.13-2.35 (m, 2H), 2.24 (s, 3H), 3.78-3.94 (m, 2H), 5.19 (s, 1H), 5.36 (d, J = 15.8 Hz, 1H), 5.39 (d, J = 1.4 Hz, 1H), 5.51 (d, J = 15.7 Hz, 1H), 5.52-5.57 (m, 1H), 7.01-7.09 (m, 3H), 7.21-7.31 (m, 2H), 7.37 (d, J = 7.3 Hz, 1H), 7.44-7.46 (m, 1H), 7.82 (d, J = 7.4 Hz, 1H);
MS m/e 433 (MH⁺).


15 **Compound 231**

Compound 231 was prepared as described for compound 4.

20

¹H NMR (CDCl₃) δ 1.19 (d, J = 7.1 Hz, 3H), 1.52-1.64 (m, 1H), 2.03-2.15 (m, 1H), 2.25 (s, 3H), 2.53-2.62 (m, 1H), 3.67 (s, 3H), 4.29-4.50 (m, 2H), 5.21 (s, 1H), 5.39 (d, J = 1.1 Hz, 1H), 5.34-5.48 (m, 2H), 7.04-7.12 (m, 3H), 7.25-7.34 (m, 2H), 7.40-7.44 (m, 1H), 7.49-7.53 (m, 1H), 7.77-7.83 (m, 1H);
MS m/e 405 (MH⁺).


25

Compound 232

5 Compound 232 was prepared as described for compound 8.

^1H NMR(CD_3OD) δ 1.15 (d, $J = 7.1$ Hz, 3 H), 1.50-1.64 (m, 1 H), 1.99-2.11 (m, 1 H), 2.27 (s, 3 H), 2.29-2.43 (m, 1 H), 4.35-4.44 (m, 2 H), 5.29 (s, 1 H), 5.40-5.59 (m, 3 H), 7.04-7.34 (m, 5 H), 7.59 (d, $J = 8.2$ Hz, 1 H), 7.66 (d, $J = 7.5$ Hz, 1 H);

10 MS m/e 405 (MH^+).

Compound 233 (Scheme III)

15

A solution of 2-fluoronitrobenzene (5.0 g, 35.5 mmol) and 1-amino-4-butanol (3.2 g, 35.5 mmol) in CH_3CN (100 mL) and triethylamine (3.80 g, 35.5 mmol) was heated to reflux for 12 h, and evaporated. The residue was dissolved in ethyl acetate and washed with 1N HCl, dried over magnesium sulfate and evaporated to give 7.21 g (97% yield) of compound 233 as a dark orange solid:

20

^1H NMR ($\text{DMSO}-d_6$) δ 1.45-1.56 (m, 2H), 1.58-1.69 (m, 2H), 3.35 (t, $J = 6.7$ Hz, 2H), 3.43 (t, $J = 6.4$ Hz, 2H), 3.90-4.0 (br, 1H, exchanges with D_2O), 6.66 (t, $J = 6.0$ Hz, 1H); 7.04 (d, $J = 9.0$ Hz, 1H); 7.52 (t, $J = 7, 2$ Hz, 1H); 8.04 (d, $J = 7.2$ Hz, 1H); 8.13 (br s, 1H, exchanges with D_2O);

25


IR (KBr cm^{-1}) 1350, 1154;

MS m/e 211 (MH^+);

Anal. Calcd for $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_3 \cdot 0.28 \text{ H}_2\text{O}$: C, 55.80; H, 6.82; N, 13.01

Found: C, 55.80; H, 6.62; N, 12.97.

Compound 234



5

A mixture of nitro compound **233** (5.0 g, 23.8 mmol) and 10% Pd/C (100 mg) in ethanol (50 mL) was hydrogenated at 40 psi for 4 h. The catalyst was removed by filtration and the filtrate was evaporated to give 4.3 g (99% yield) of compound **234** as a dark oil:

10

^1H NMR(DMSO- d_6) δ 1.47-1.66 (m, 4 H), 2.99 (t, J = 6.6 Hz, 2 H), 3.43 (t, J = 6.6 Hz, 2 H), 4.31-4.5(br, 4 H, exchange with D_2O), 6.36-6.42 (m, 2 H) 6.54-6.82 (m, 2 H);


15 IR (film, cm^{-1}) 1055, 739;

MS m/e 181 (MH^+);

Anal. Calcd for $\text{C}_{10}\text{H}_{16}\text{N}_2\text{O} \cdot 0.71 \text{ H}_2\text{O}$: C, 62.23; H, 9.10; N, 14.51

Found: C, 62.23; H, 8.78; N, 14.41.

20 Compound 235



To a solution of diamine **234** (1.0 g, 6.0 mmol) in methylene chloride (50 mL) at -78°C was added a solution of an acid chloride which was prepared from the acid **125** (2.05 g, 6.02 mmol) with excess SOCl_2 , followed by addition of triethylamine (0.97 mL, 7.0 mmol). The mixture was stirred at -78°C for 1 hr then at room temperature for 12 h. The solvent was evaporated and the black residue (2.7 g)

25


was dissolved in acetic acid and heated to reflux for 4h. The solvent was evaporated. The black residue was purified by chromatography on silica gel and eluted with 3% methanol in methylene chloride to give 2.3 g of a mixture of esters as a yellow oil. The mixture in methanol (20 mL) was treated with 1N sodium hydroxide (10 mL, 10 mmol) and heated to reflux for 1 h, and concentrated under reduced pressure. The precipitate was filtered to give 0.65 g (31% yield) of the sodium salt of compound 235 as a white solid: mp >240°C;

¹H NMR (DMSO-d₆) δ 1.47-1.40 (m, 2 H), 1.68-1.60 (m, 2 H), 3.37 (t, J = 6.3Hz, 2 H), 4.35 (t, J = 7.5Hz, 2 H), 5.15 (s, 2 H), 5.43 (s, 2 H), 7.03-6.99 (m, 2 H), 7.38-7.15 (m, 3 H), 7.35 (d, J = 8.1 Hz, 2 H), 7.57 (d, J = 7.2 Hz, 1 H), 7.87 (d, J = 8.1 Hz, 2 H);

IR (KBr cm⁻¹) 1701, 750;


MS m/e 471 (MH⁺);

HRMS m/e (M⁺) calcd for C₂₇H₂₆N₄O₄: 470.1954, found 470.2039.

Compound 236

5 Compound **236** was prepared as described for compound **235** using compound **169**.

¹H NMR (DMSO-d₆) δ 1.23 (t, J = 7.1 Hz, 3H), 1.45-1.55 (m, 4H), 19.2 (s, 3H),
3.50-3.61 (m, 2H), 3.81-3.90 (m, 4H), 4.25-4.35 (m, 1H), 5.35 (s, 2H), 6.97-7.15 (m,
10 2H), 7.15-7.25 (m, 4H), 7.53-7.60 (m, 2H);
MS m/e 406 (MH⁺)


Compound 237

15

Compound **237** was prepared from compound **236** as described for compound
8.


20 ¹H NMR (DMSO-d₆) δ 1.23 (t, J = 7.1 Hz, 3H), 1.30-1.45 (m, 2H), 3.20-3.40 (m,
2H), 1.45-1.60 (m, 2H), 3.20-3.40 (m, 2H), 3.92 (q, J = 7.2 Hz, 2H), 4.33 (t, J = 7.3
Hz, 2 H), 4.46(t, J = 5.0 Hz, 1H), 5.36 (s, 2H), 6.97-7.12 (m, 2H), 7.12-7.25 (m, 4H),
7.52-7.59 (m, 2H);
MS m/e 364 (MH⁺).

25

Compound 238

5 Compound **238** was prepared as described for compound **235** before the hydrolysis step.

¹H NMR (DMSO-d₆) δ 1.22 (t, J = 6.2 Hz, 3H), 1.53-1.78 (m, 4H), 1.97 (s, 3H), 3.99 (t, J = 6.0 Hz, 2H), 4.17 (q, J = 7.2 Hz, 2H), 4.35 (t, J = 6.6 Hz, 2H), 4.79 (s, 2H),
10 5.40 (s, 2H), 7.04-7.07 (m, 2H), 7.08-7.31 (m, 4H), 7.56 (t, J = 8.1 Hz, 2H);
MS m/e 464 (MH⁺).

Compound 239

15

Compound **239** was prepared from 1-aminopropanol and 2-fluoronitrobenzene as previously described for compound **233**.

20 ¹H NMR (CDCl₃) δ 1.97-2.02 (m, 2H), 3.46-3.50 (m, 2H), 3.84-3.87 (m, 2H), 6.64 (t, J = 8.0 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 7.43 (t, J = 7.05, 1H), 8.17 (d, J = 7.2 Hz, 1H);
MS m/e 166 (MH⁺).

177





Table 20- Compounds were prepared as described for compound 235. The acetates were removed by mild acid hydrolysis.


#	W ₁	R ₂	¹ H-NMR Data	MS Data
240a	OAc ^a	Et	(DMSO-d ₆) 1.23 (t, J = 7.3 Hz, 3 H), 1.90-2.10 (m, 2 H), 1.97 (s, 3 H), 3.92 (q, J = 7.2 Hz, 2 H), 3.99-4.06 (m, 2 H), 4.42 (t, J = 7.3 Hz, 2 H), 5.37 (s, 2 H), 6.98-7.08 (m, 2 H), 7.14-7.25 (m, 4 H), 7.53-7.60 (m, 2H)	392 (MH ⁺)
240b	H ^b	Et	DMSO-d ₆ : 1.24 (t, J = 7.0 Hz, 3H), 1.76-1.82 (m, 2H), 3.39-3.42 (m, 2H), 3.92 (q, J = 7.0 Hz, 2H), 4.40 (t, J = 7.1 Hz, 2H), 4.71 (t, J = 4.8 Hz, 1H), 5.39 (s, 2H), 7.01-7.14 (m, 2H), 7.15-7.26 (m, 4H), 7.55 (t, J = 8.6 Hz, 2H)	350 (MH ⁺)
240c	OAc	CH ₂ CO ₂ Et	DMSO-d ₆ : 1.21 (t, J = 7.1 Hz, 3H), 1.89-2.02 (m, 2H), 1.98 (s, 3H), 4.10 (t, J = 6.1 Hz, 2H), 4.16 (q, J = 7.1 Hz, 2H), 4.15 (t, J = 7.4 Hz, 2H), 4.79 (q, J = 7.1 Hz, 2H), 5.40 (s, 2H), 7.01-7.08 (m, 2H), 7.15-7.28 (m, 4H), 7.55 (d, J = 7.7 Hz, 1H), 7.60 (d, J = 7.5 Hz, 1H)	450 (MH ⁺)
240d	H	CH ₂ CO ₂ H	(DMSO-d ₆) 1.59-1.65 (m, 2 H), 3.35 (t, J = 6.2 Hz, 2 H), 4.12 (s, 2 H), 4.33 (t, 7.2 Hz, 2 H), 5.35-5.38 (m, 2 H), 6.89-7.01 (m, 3 H), 7.11-7.25 (m, 3 H), 7.52 (d, J = 7.4 Hz, 1 H), 7.58 (d, J = 7.3 Hz, 1 H)	380 (MH ⁺)
240e ^c	H		(DMSO-d ₆) 1.80-1.94 (m, 2 H), 3.42 (t, J = 7.2 Hz, 2 H), 3.82 (s, 3 H), 4.51 (t, J = 6.8 Hz, 2 H), 5.20 (s, 2 H), 5.60 (s, 2 H), 7.01-7.07 (m, 2 H), 7.12-7.16 (m, 1 H), 7.23-7.26 (m, 1 H), 7.25-7.40 (m, 2 H), 7.48 (d, J = 7.3 Hz, 2 H), 7.63 (d, J = 7.3 Hz, 1 H), 7.73 (d, J = 7.9 Hz, 1 H), 7.93 (d, J = 7.3 Hz, 2 H)	470 (MH ⁺)
240f	H		(DMSO-d ₆) 1.84 (m, 2 H), 3.31-3.45 (m, 2 H), 4.35-4.45 (m, 2 H), 4.78-4.91 (m, 1 H), 5.10(s, 2 H), 5.46 (s, 2 H), 6.92-7.09 (m, 2 H), 7.10-7.38 (m, 6 H), 7.56 (d, J = 7.8 Hz, 2 H), 7.81 (d, J = 7.5 Hz, 2 H)	456 (MH ⁺)

5 a, acetate is isolated by silica gel chromatography prior to hydrolysis; b, hydrolysis carried out as described for compound 4; c, cyclization step carried using TFA instead of AcOH.

Compound 241


5 Compound **241** was prepared by addition of ethanolamine to 2-fluoronitrobenzene as previously described for compound **233**.

¹H NMR (CDCl₃) δ 3.39-3.43 (m, 2H), 3.63-3.69 (m, 2H), 6.68 (t, J = 7.2 Hz, 1H),
7.07 (d, J = 8.7 Hz, 1H), 7.53 (t, J = 6.9 Hz, 1H), 8.06 (d, 8.7 Hz, 1H), 8.23-8.35 (m,
10 1H);
MS m/e 196 (MH⁺).

Compound 242

15

To a solution of 2-(2-nitro-phenylamino)-ethanol (2 g, 10.97 mmol) in CH₂Cl₂ (70 ml) were added triethylamine (2.77 g, 27.37 mmol) and acetic anhydride (1.68 g, 16.45 mmol). The mixture was refluxed overnight. The next day it was diluted with
20 CH₂Cl₂ and washed with 1N HCl, and brine. The organic layer was dried over Na₂SO₄ and concentrated to give 2.40 g (98% yield) of compound **242** as yellow solid.


Compound 243

- 5 Compound **243** was prepared as described for compound **170** using acetic acid 2-(2-amino-phenylamino)-ethyl ester and (3-ethoxycarbonylmethyl-2-oxo-2,3-dihydro-benzimidazol-1-yl)-acetic acid as described for compound **170**.

10 ¹H NMR (DMSO-d₆) δ 1.22 (t, *J* = 7.1, 3H), 1.90 (s, 3H), 4.16 (q, *J* = 7.1, 2H), 4.35 (t, *J* = 5.0, 2H), 4.68 (t, *J* = 5.1, H), 4.79 (s, 2H), 5.45 (s, 2H), 7.03-7.10 (m, 2H), 7.15-7.27 (m, 4H), 7.55-7.62 (m, 2H);
MS *m/e* 437 (MH⁺).

Compound 244


15



- 20 To a solution of compound **243** (570 mg, 1.30 mmol) in EtOH (40 ml) was added 3 drops of H₂SO₄ and the solution was refluxed overnight. The solvent was evaporated. The residue was diluted with EtOAc and washed with saturated aqueous sodium bicarbonate solution. The organic layer was dried over Na₂SO₄, and evaporated to give 473 mg (92% yield) of compound **244** as a white solid.

25 ¹H NMR (DMSO-d₆) δ 1.22 (t, *J* = 7.1, 3 H), 3.71 (t, *J* = 4.8, 2 H), 4.17 (q, *J* = 7.1, 2 H), 4.46 (t, *J* = 4.9, 2 H), 4.78 (s, 2 H), 5.11 (s, 1 H), 5.45 (s, 2 H), 7.00-7.08 (m, 2 H), 7.12-7.24 (m, 4 H), 7.53-7.57 (m, 2 H);
MS *m/e* 395 (MH⁺)

Compound 245




5 Compound **245** was prepared as described for compound **236**.

¹H NMR (DMSO-d₆) δ 1.24 (t, J = 7.2 Hz, 3H), 1.87 (s, 3H), 3.93 (t, J = 7.6 Hz, 2H), 4.32 (t, J = 4.8 Hz, 2 H), 4.69 (t, J = 5.1 Hz, 2H), 5.42 (s, 2H), 7.03-7.18 (m, 2H), 7.19-7.31 (m, 2 H), 7.55-7.61 (m, 2H);

10 MS m/e 378 (MH⁺).

Compound 246




15

Compound **246** was prepared as described for compound **240b**.

¹H NMR (DMSO-d₆) δ 1.25 (t, J = 6.6 Hz, 3H), 3.60-3.70 (m, 2H), 3.93 (q, J = 7.2 Hz, 2H), 4.47 (t, J = 5.1 Hz, 2H), 5.09 (t, J = 5.1 Hz, 1H), 5.42 (s, 2H), 7.00-7.11 (m, 2H), 7.11-7.27 (m, 4H), 7.52-7.57 (m, 2H);
MS m/e 336 (MH⁺).


20

Compound 247

5 Compound 247 was prepared as previously described for compound 234 using 2-methoxyethylamine.

¹H NMR (CDCl₃) δ 3.18 (dt, 5.7, 6.0 Hz, 2H), 3.21 (s, 3H), 3.53 (t, J = 5.7 Hz, 2H), 4.32-4.40 (m, 1H), 4.40-4.49 (s, 2H), 6.42-6.56 (m, 4H);


10 MS m/e 166 (MH⁺).

Compound 248

15

Compound 248 was prepared as described for compound 235 using N-(2-methoxy-ethyl)-benzene-1,2-diamine and (3-ethoxycarbonylmethyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-acetic acid.

20 ¹H NMR (DMSO-d₆) δ 1.23 (t, J = 6.9 Hz, 3H), 3.19 (s, 3H), 3.28-3.72 (m, 2H), 4.17 (q, J = 7.2 Hz, 2H), 4.51-4.62 (m, 2H), 4.79 (s, 2H), 5.42 (s, 2H), 7.01-7.06 (m, 2H), 7.19-7.25 (m, 4H), 7.56 (d, J = 8.1 Hz, 2H);
MS m/e 408 (MH⁺).


Compound 249

5 To a 0°C solution of compound **246** (2.38 g, 0.71 mmol) in CH₂Cl₂ (100 ml) was added Et₃N (0.12 ml, 0.9 mmol) followed by methanesulfonyl chloride (0.085 ml, 0.75 mmol). The mixture was warmed to room temperature, stirred for 12 h then poured into 1N HCl. The organic layer was separated and dried over MgSO₄ and concentrated to give 0.196 mg (67%) of compound **249** as a white solid.

10

¹H NMR (DMSO-d₆) δ 1.25 (t, J = 7.2 Hz, 3H), 3.01 (s, 3H), 3.82-3.99 (m, 2H), 4.54 (t, J = 5.4 Hz, 2H), 4.76 (m, J = 5.4 Hz, 2H), 5.41 (s, 2H), 7.02-7.12 (m, 3H), 7.15-7.34 (m, 3H), 7.51-7.65 (m, 2H);
MS (m/e) 414 (MH⁺)

15


Compound 250

20 To a slurry of NaH (38 mg, 0.95 mmol) in DMF (5 ml) was added pyrazine (63 mg, 0.92 mmol) followed by a solution of mesylate prepared above. The mixture was stirred at 23°C for 12 h. The solvent was removed and the residue dissolved in EtOAc and washed with water. The organic layers was dried over MgSO₄ concentrated and the residue chromatographed (3 % MeOH/CH₂Cl₂ as eluant to give
25 compound **250** as a clear glass (120 mg, 85% yield).

¹H NMR (DMSO-d₆) δ 1.23 (t, J = 6.9 Hz, 3H), 3.92 (q, J = 7.2 Hz, 2H), 4.55 (t, J = 5.3 Hz, 2H), 4.80 (t, J = 4.8 Hz, 2H), 4.94 (s, 2H), 6.17-6.19 (m, 1H), 7.00-7.25 (m, 6H), 7.27-7.58 (m, 3H);

MS (m/e) 386 (MH⁺).

Compound 251




5

Compound 251 was prepared from compound 244 as described for compound 249 above.


10 ¹H NMR (DMSO-d₆) δ 1.18-1.23 (m, 3H), 3.06 (s, 3H), 4.11-4.20 (m, 3H), 4.56-4.59 (m, 2H), 4.59-4.84 (m, 3H), 5.52 (s, 2H), 7.05-7.11 (m, 2H), 7.16-7.35 (m, 4H), 7.62 (d, *J* = 7.4 Hz, 1H), 7.72 (d, *J* = 8.0, 1H);
MS (m/e) 473 (MH⁺)

15 **Compound 252**




20 Compound 252 was prepared from compound 251 as described for compound 250 above.

¹H NMR (DMSO-d₆) δ 1.19 (t, *J* = 7.1, 3H), 4.14 (q, *J* = 7.1, 2H), 4.50-4.54 (m, 2H), 4.75-4.79 (m, 3H), 5.00 (s, 2H), 6.17 (s, 1H), 7.00-7.07 (m, 2H), 7.10-7.20 (m, 3H), 7.34-7.41 (m, 2H), 7.46-7.53 (m, 2H);
25 MS (m/e) 445 (MH⁺).

Compound 253

5 Compound **253** was prepared as described for compound **252** using tetrazole instead of pyrazole.


¹H NMR (DMSO-d₆) δ 1.21 (t, *J* = 7.1 Hz, 3H), 2.09 (s, 2H), 4.15 (q, *J* = 7.1 Hz, 2H), 4.77 (s, 2H), 5.00-5.03 (m, 1H), 5.19-5.22 (m, 3H), 7.04-7.07 (m, 1H), 7.13-7.16 (m, 1H), 7.18-7.23 (m, 2H), 7.51-7.65 (m, 3H), 8.91 (s, 1H);
10 MS (m/e) 447 (MH⁺).

Compound 254

15

 Compound **254** was prepared by transesterification using NaOMe as previously described for compound **131**.

20 ¹H NMR (DMSO-d₆) δ 3.34 (bs, 2H), 4.08 (s, 2H), 4.86 (bs, 2H), 5.26 (s, 2H), 6.93-7.02 (m, 3H), 7.14-7.24 (m, 3H), 7.24-7.31 (m, 1H), 7.61-7.63 (m, 1H), 9.33 (s, 1H);
 MS (m/e) 431 (MH⁺).

Compound 255 (Scheme III)

A mixture of 6-amino-3,4-difluoroaniline (1.2g, 8.33 mmol, from Specs), acid
5 **182** (2.13 g, 8.33 mmol), and EEDQ (2.06 g, 8.33 mmol) were stirred in THF (40
mL) at reflux for 12 h. The mixture was evaporated and the residue was purified by
chromatography on silica gel to give 850 mg of compound **255**:

¹H NMR (CD₃OD) δ 2.26 (s, 3H), 5.28 (s, 1H), 5.37 (s, 2H), 5.49 (s, 1H), 7.03-7.24
10 (m, 4H), 7.37-7.43 (m, 2H);


IR (KBr, cm⁻¹) 1686, 1655, 1491, 1471, 1405, 1346, 1157, 883, 859, 634, 600;

MS m/e 339 (MH⁺);

Anal. Calcd for C₁₈H₁₄F₂N₄O: C, 63.53; H, 4.15; N, 16.46

Found: C, 63.28; H, 4.37; N, 16.21.

15

Compound 256

20 Compound **256** was prepared from **255** and 4-bromobutyronitrile in the same
manner as compound **4**.


¹H NMR (CDCl₃) δ 1.60 (s, 3H), 1.92-2.02 (m, 2H), 2.25 (s, 3H), 2.47 (t, J = 7.3 Hz,
2H), 4.44-4.49 (m, 2H), 5.22 (s, 1H), 5.35 (s, 2H), 5.42 (s, 1H), 7.11-7.13 (m, 3H),
25 7.17 (dd, J = 6.7, 9.5 Hz, 1H), 7.49-7.53 (m, 1H), 7.58 (dd, J = 7.2, 10.2 Hz, 1H);

IR (KBr, cm⁻¹) 1686, 1487, 1471, 1401, 1155, 753;

MS m/e 408 (MH⁺);

Anal. Calcd for C₂₂H₁₉F₂N₅O .0.25 H₂O C, 64.14; H, 4.77; N, 17.00

Found: C, 64.03; H, 4.97; N, 17.18.

Compound 257

5


Compound 257 was prepared in the same manner as compound 52.

¹H NMR (CD₃OD) δ 2.13-2.23 (m, 2H), 2.21 (s, 3H), 2.94 (t, J = 7.6 Hz, 2H), 4.44 (t, J = 7.6 Hz, 2H), 5.37 (s, 1H), 5.43 (s, 2H), 5.45 (s, 1H), 7.06-7.23 (m, 4H), 7.41-7.52 (m, 2H);
IR (KBr, cm⁻¹) 3411, 1698, 1681, 1654, 1487, 1470, 1407, 1157, 753;
MS m/e 451 (MH⁺).

10

Compound 258


15



Compound 258 was prepared as described for compound 105.


¹H NMR (DMSO-d₆) δ 2.07-2.13 (m, 2H), 2.63 (t, J = 7.4Hz, 2H), 3.20 (s, 3H), 4.42 (t, J = 7.4Hz, 2H), 5.24 (s, 2H), 5.46 (s, 2H), 7.19 (t, J = 7.5Hz, 1H), 7.27 (t, J = 7.5Hz, 1H), 7.50-7.54 (m, 1H), 7.56 (d, J = 7.8Hz, 1H), 7.61 (d, J = 8.3Hz, 2H), 7.92 (d, J = 8.3Hz, 2H);
MS m/e 535 (MH⁺).

20

Compound 259

5 Compound **259** was prepared described for compound **105**.


¹H NMR (DMSO-d₆) δ 2.07-2.15 (m, 2H), 2.64 (t, J = 7.5Hz, 2H), 3.20 (s, 3H), 4.42
(t, J = 7.5Hz, 2H), 5.23 (s, 2H), 5.45 (s, 2H), 7.15 (td, J = 2.5, 9.3Hz, 1H), 7.40 (dd,
2.4, 9.8Hz, 1H), 7.45-7.53 (m, 2H), 7.60 (d, J = 8.3Hz, 2H), 7.63-7.65 (m, 1H), 7.92
10 (d, J = 8.3Hz, 2H);
MS m/e 553 (MH⁺).

Compound 260

15

Compound **260** was prepared as described for compound **266**.

20 **Compounds 261 and 262**



A mixture of 3-fluorobenzenediamine (6.3 g, 50.0 mmol) and ethyl acetoacetate (6.50 g, 50.0 mmol) and DBU (0.76 g, 5.0 mmol) in p-xylene (50 mL) was heated to reflux for 2 h. Water formed during reaction was removed with a Dean-Stark trap. After cooling, the solvent was removed in vacuo. The residue was purified
5 by flash chromatography (gradient, hexanes:EtOAc 4:1 to 1:1) to give 0.76 mg (8%) of 5-fluoro-1-isopropenyl-1,3-dihydro-benzoimidazol-2-one, **261** and 1.10 (11%) of 6-fluoro-1-isopropenyl-1,3-dihydro-benzoimidazol-2-one **262** as white solids.


261: 5-Fluoro-1-isopropenyl-1,3-dihydro-benzoimidazol-2-one

10 ¹H NMR (CDCl₃) δ 2.24 (s, 3H), 5.24 (d, J = 0.4 Hz, 1H), 5.41-5.43 (m, 1H), 6.77-6.81 (m, 1H), 6.89-6.91 (m, 1H), 6.98-7.00 (m, 1H);
MS m/e 193 (MH⁺);

262: 6-Fluoro-1-isopropenyl-1,3-dihydro-benzoimidazol-2-one


¹H NMR (CDCl₃) δ 2.24 (s, 3H), 5.24 (s, 1H), 5.42 (d, J = 1.2 Hz, 1H), 6.78-6.85 (m,
15 2H), 7.03-7.06 (m, 1H);
MS m/e 193 (MH⁺).

Compound 263




A solution of 2,5-difluoronitrobenzene (15.4 g, 96.8 mmol), 4-aminobutyronitrile (7.4 g, 88 mmol) and diisopropylethylamine (23 ml, 132 mmol) in DMF (250 ml) was stirred at room temperature for 32 hours. After filtration, the
25 solvent was evaporated and the orange solid was recrystallized from MeOH (250 ml) to afford **263** (14 g, 65% yield) as orange crystals.

¹H NMR (CDCl₃) δ 2.06-2.12 (m, 2H), 2.54 (t, J = 7.0 Hz, 2H), 3.48-3.53 (m, 2H),
6.85-6.88 (m, 1H), 7.27-7.31 (m, 1H), 7.89-7.92 (m, 1H);
30 MS m/e 224 (MH⁺).

Compound 264

5 To a suspension of nitrile **263** (10.8 g, 48.4 mmol) and potassium carbonate (20.1 g, 145 mmol) in CH₃CN (200 ml) was added benzyloxycarbonyl chloride (7.64 ml, 48.4 mmol) dropwise. After stirring at room temperature for 12 hours, the mixture was diluted with EtOAc (500 ml) and filtered. The filtrate was washed with 1 N HCl, brine, dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (gradient, EtOAc/hexane, 1:2 to 1:1) to yield **264** (7.5 g, 42% yield) as a viscous pale yellow oil.

¹H NMR (CDCl₃) δ 1.86-1.98 (m, 2H), 2.38-2.51 (m, 2H), 3.34-3.39 (m, 1H), 3.80-3.87 (m, 2H), 4.06-4.14 (m, 1H), 4.40-4.48 (m, 2H), 7.18-7.19 (m, 1H), 7.26-7.40 (m, 5H), 7.72-7.74 (m, 1H);
MS m/e 394 (MH⁺).

Compound 265


20

In a flask equipped with a mechanical stirrer, a suspension of compound **264** (6.40 g, 17.25 mmol), iron powder (2.89 g, 51.8 mmol) and ammonium chloride (4.61 g, 86.2 mmol) in a mixture of MeOH and H₂O (200 ml, 1:1) was stirred at reflux for 4 hours. The mixture was filtered through a pad of Celite and washed with MeOH. The filtrate was evaporated and the residue was taken up in EtOAc (500 ml), washed with brine, dried over MgSO₄, and evaporated. To the residue was added CH₃CN (100 ml) and acetic acid (1 ml), and the mixture was stirred at reflux for 4

hours. The solvent was evaporated and the residue was purified by flash chromatography (gradient, EtOAc/hexane, 1:2 to 2:1) to give **265** (4.42 g, 75% yield) as a viscous oil which solidified upon standing.

- 5 ¹H NMR (CDCl₃) δ 2.15-2.20 (m, 2H), 2.31 (t, J = 7.0 Hz, 2H), 4.35 (t, J = 7.2 Hz, 2H), 4.62 (s, 2H), 4.83 (s, 2H), 7.07-7.11 (m, 1H), 7.29-7.38 (m, 6H), 7.43-7.46 (dd, J = 2.4, 9.2 Hz, 1H);
MS m/e 324 (MH⁺).


10 **Compound 266**



- 15 To a solution of **265** (3.23 g, 10 mmol) in CH₂Cl₂ (100 ml) at 0 °C was added boron tribromide (2.84 ml, 30 mmol). After stirring for 1 hour, the mixture was quenched with saturated NaHCO₃ solution with ice bath cooling and extracted with EtOAc. The combined extracts were dried over MgSO₄ and evaporated. The residue was purified by flash chromatography (gradient, CH₂Cl₂/MeOH, 40:1 to 20:1) to give **266** (1.68 g, 72% yield) as an off-white solid.


20

¹H NMR (CDCl₃) δ 2.25-2.30 (m, 2H), 2.43 (t, J = 7.1 Hz, 2H), 4.41 (t, J = 7.1 Hz, 2H), 4.85 (s, 2H), 7.04-7.081 (m, 1H), 7.29-7.34 (m, 2H);
MS m/e 234 (MH⁺).

Compound 267

5 Compound **267** was prepared according to the same procedure described for compound **6**.


¹H NMR (CD₃OD) δ 2.30-2.36 (m, 2H), 2.70 (t, J = 7.2 Hz, 2H), 4.67 (t, J = 7.6 Hz, 2H), 5.30 (s, 2H), 7.49-7.54 (dt, J = 2.4, 9.2 Hz, 1H), 7.62-7.64 (dd, J = 2.4, 8.0 Hz, 1H), 8.01-8.04 (dd, J = 2.0, 9.2 Hz, 1H);
10 MS m/e 252 (MH⁺).

Compound 268

15

Compound **268** was prepared as described for compound **106** using intermediates **267** and **261**.


20 ¹H NMR (CDCl₃) δ 1.90-1.95 (m, 2H), 2.16 (s, 3H), 2.37-2.40 (m, 2H), 4.43 (t, J = 7.6 Hz, 2H), 5.12 (s, 1H), 5.26 (s, 2H), 5.33 (s, 1H), 6.71-6.75 (m, 1H), 6.92-6.95 (m, 1H), 7.00-7.04 (m, 1H), 7.22-7.40 (m, 2H), 7.40-7.42 (m, 1H).

Compound 269

5 Prepared from compound 268 as described for compound 6.

^1H NMR (DMSO- d_6) δ 2.09-2.16 (m, 2H), 2.67 (t, J = 7.5Hz, 2H), 4.51 (t, J = 7.5Hz, 2H), 5.50 (s, 2H), 6.84-6.88 (m, 1H), 7.01-7.04 (m, 1H), 7.21-7.23 (m, 1H), 7.30-7.34 (m, 1H), 7.49-7.52 (m, 1H), 7.83-7.86 (m, 1H);


10 MS m/e 368 (MH^+).

Compound 270

15

Compound 270 was prepared as described for compound 106 using 262 and 267.

^1H NMR (CDCl_3) δ 0.95 (d, J = 6.6 Hz, 6H), 1.42-1.46 (m, 2H), 1.67-1.71 (m, 1H), 2.23 (s, 3H), 4.29-4.32 (m, 2H), 5.19 (s, 1H), 5.34 (s, 2H), 5.39 (s, 1H), 6.75-6.85 (m, 2H), 7.02-7.07 (m, 1H), 7.21-7.24 (m, 1H), 7.36-7.46 (m, 2H);
20 MS m/e 411 (MH^+).


Compound 271

5 Compound 271 was prepared from compound 270 as described for compound 115.

¹H NMR (CDCl₃) δ 0.95 (d, J = 6.6 Hz, 6H), 1.41-1.45 (m, 2H), 1.53 (d, J = 7.0 Hz, 6H), 1.66-1.72 (m, 1H), 4.28-4.31 (m, 2H), 4.70-4.74 (m, 1H), 5.32 (s, 2H), 6.72-6.76 (m, 1H), 6.85-6.87 (m, 1H), 7.02-7.06 (m, 1H), 7.20-7.23 (m, 1H), 7.34-7.36 (m, 1H), 7.43-7.46 (m, 1H);
10 MS m/e 411 (MH⁺).


Compound 272

15



Compound 272 was prepared as described for compound 115.

20 ¹H NMR (DMSO-d₆) δ 1.45 (d, J = 5.2Hz, 6H), 3.21-3.33 (m, 2H), 4.51-4.71 (m, 2H), 4.81-5.10 (m, 4H), 5.41 (s, 2H), 6.91-7.15 (m, 1H), 7.21-7.51 (m, 3H), 7.52-7.62 (m, 1H), 9.30 (s, 1H);
 MS m/e 456 (MH⁺).

Compound 273

- 5 Compound **273** was prepared by addition of 3-methyl-butylamine to 3-chloro-4-nitro benzonitrile as described for compound **233**.


¹H NMR (CDCl₃) δ 1.01 (d, J = 6.5 Hz, 6H), 1.63-1.70 (m, 2H), 1.74-1.83 (m, 1H),
3.34-3.41 (m, 2H), 6.93 (d, J = 9.0 Hz, 1H), 7.62 (dd, J = 1.9, 8.9 Hz, 1H), 8.35-8.40
10 (m, 1H), 8.53 (d, J = 2.0 Hz, 1H);

MS m/e 321 (M⁺NH₄⁺).

Calcd for C₁₂H₁₅N₃O₂: C 61.69; H 6.48; N 18.01;

Found: C 61.75; H 6.39; N 17.94.

15 **Compound 274**




- 20 To a mixture of compound **273** (10.8 g, 48.4 mmol) and K₂CO₃ (20.1 g, 145 mmol) in CH₃CN (200 ml) was added benzyloxycarboxylic chloride and stirred for 12 h. Diluted with EtOAc, filtered. The filtrate was washed with NaHCO₃ and brine, dried, evaporated. The residue was recrystallized from MeOH to yield 7.5 g (42%) of compound **274** as a pale yellow solid.

25 ¹H NMR (CDCl₃) δ 0.94 (d, J = 6.6 Hz, 6H), 1.58 (q, J = 6.8 Hz, 2H), 1.66-1.77 (m, 1H), 2.26 (s, 3H), 3.18 (t, J = 7.3 Hz, 2H), 4.73 (s, 2H), 6.76-6.78 (m, 1H), 7.46-7.53 (m, 3H);

MS m/e 315 (MH⁺).

Anal. Calcd for C₂₁H₂₅N₃O₂: C: 63.35; H 6.98; N 13.85.


30 Found: C, 63.37; H 6.87; N 13.72.

Compound 274a

A mixture of compound 274 (6.4 g, 17.2 mmol), iron powder (2.89 g, 51.8 mmol) and ammonium chloride (4.61 g, 86.2 mmol) in MeOH (100 ml) and H₂O (100 ml) was heated to reflux for 4 h. The reaction mixture was filtered while hot through celite and the aqueous layer extracted with EtOAc. The organic layer was washed with brine, dried and evaporated. The residue was dissolved in CH₃CN (100 ml) and acetic acid (1 ml) and heated to reflux 4 h. The solvent was removed and the residue purified by flash chromatography eluting with hexanes-EtOAc (2:1 to 1:2) to yield 4.17 g (75%) of compound 274a as a viscous oil.

¹H NMR (CDCl₃) δ 1.86-1.98 (m, 2 H), 2.38-2.51 (m, 2 H), 3.34-3.39 (m, 1 H), 3.80-3.87 (m, 2 H), 4.06-4.14 (m, 1 H), 4.38-4.66 (m, 2 H), 7.18-7.19 (m, 1 H), 7.26-7.40 (m, 6 H), 7.72-7.74 (m, 1 H);

MS m/e 372 (MH⁺).


Compound 275

20

To a solution of compound 274a (3.23 g, 10 mmol) in CH₂Cl₂ at 0°C was added BBr₃ (7.50 g, 30 mmol) and the reaction mixture stirred for 1 h. The reaction mixture was quenched with aqueous NaHCO₃ and extracted with EtOAc. The organic layer was washed with brine, dried and evaporated. The residue was purified by flash chromatography eluting with CH₂Cl₂-MeOH (40:1 to 20:1) to yield 1.68 g (72%) of compound 275 as an off-white solid.

¹H NMR (CDCl₃) 2.25-2.31 (m, 2H), 2.43 (t, J = 7.1 Hz, 2H), 4.41 (t, J = 7.1 Hz, 2H), 4.85 (s, 2H), 6.09 (b, 1H), 7.04-7.08 (m, 1H), 7.29-7.34 (m, 2H)

MS m/e 234 (MH⁺).


Compound 276

5

Compound 276 was prepared as described for compound 3.

¹H NMR (DMSO-d₆) δ 2.18 (s, 3H), 5.21 (s, 1H), 5.35 (s, 2H), 5.42 (d, J = 1.3Hz, 1H), 7.02-7.13 (m, 3H), 7.17-7.20 (m, 1H), 7.55-7.71 (m, 2H), 8.12 (bs, 1H), 13.08 (bs, 1H);
MS m/e 329 (MH⁺).

10


Compound 277

15

Compound 277 was prepared as described for compound 4.

¹H NMR (CDCl₃) δ 0.96 (d, J = 6.6 Hz, 6H), 1.41-1.49 (m, 2H), 1.67-1.76 (m, 1H), 2.23 (s, 3H), 4.43 (t, J = 8.1 Hz, 2H), 5.20 (s, 1H), 5.39 (s, J = 1.3 Hz, 1H), 5.50 (s, 2H), 7.09-7.10 (m, 3H), 7.43 (d, J = 8.5 Hz, 1H), 7.55-7.61 (m, 2H), 8.19 (s, 1H);
MS m/e 400 (MH⁺).


20

Compound 278

5 Compound 278 was prepared as described for compound 6.

^1H NMR (CD_3OD) δ 1.21 (d, $J = 6.6$ Hz, 6H), 1.63-1.66 (m, 2H), 1.91-2.05 (m, 1H), 4.45 (t, $J = 8.3$ Hz, 2H), 5.70 (s, 2H), 7.28-7.39 (m, 4H), 7.88-7.90 (m, 2H), 8.29 (s, 1H);

10 MS m/e 360 (MH^+).


Compound 279

15

Compound 279 was prepared as described for compound 52.


^1H NMR ($\text{DMSO}-d_6$) δ 0.92 (d, $J = 6.6$ Hz, 6H), 1.35-1.43 (m, 2H), 1.63-1.72 (m, 1H), 4.35 (t, $J = 8.0$ Hz, 2H), 5.37 (s, 2H), 6.91-7.03 (m, 3H), 7.12-7.15 (m, 1H), 7.75 (d, $J = 8.5$ Hz, 1H), 7.95 (dd, $J = 1.6, 8.5$ Hz, 1H), 8.26 (d, $J = 1.2$ Hz, 1H), 11.11 (s, 1H);

20 MS m/e 403 (MH^+).

Compound 280

5 Compound **280** was prepared as described for compound **7** using tert-butylbromoacetate.


¹H NMR (CDCl₃) δ 0.97 (d, J = 6.6 Hz, 6H), 1.45-1.57 (m, 2H), 1.48 (s, 9H), 1.68-1.77 (m, 1H), 4.34 (t, J = 8.3 Hz, 2H), 5.43 (s, 2H), 6.86-6.89 (m, 1H), 7.04-7.12 (m, 10 2H), 7.36-7.39 (m, 2H), 7.54 (dd, J = 1.2, 8.4 Hz, 1H), 8.13 (s, 1H);
MS m/e 474 (MH⁺).

Compound 281

15


Compound **281** was prepared as described for **6**.

¹H NMR (CDCl₃) δ 2.07-2.14 (m, 2H), 4.43 (t, J = 6.1Hz, 2H), 4.55 (t, J = 7.6Hz, 20 2H), 5.41 (s, 2H), 7.05-7.14 (m, 3H), 7.38-7.45 (m, 2H), 7.58 (dd, J = 1.4, 8.4Hz, 1H), 8.00 (s, 1H), 8.15 (d, J = 5.4Hz, 1H);
MS m/e 347 (MH⁺).

Compound 282

5 4-chloro-3-nitroacetophenone was treated with 3-methylbutyl amine to give 1-[4-(3-methyl-butylamino)-3-nitro-phenyl]-ethanone, compound **282**.


¹H NMR (CDCl₃) δ 0.99 (d, J = 6.6 Hz, 6H), 1.37-1.67 (m, 2H), 1.72-1.83 (m, 1H),
2.55 (s, 3H), 3.36-3.42 (m, 2H), 6.90 (d, J = 9.3 Hz, 1H), 8.07 (dq, J = 0.6, 9.3 Hz,
10 1H), 8.39-8.44 (s, 1H), 8.79 (d, J = 2Hz, 1H);
MS m/e 250 (MH⁺).

Compound 283

15

1-[4-(3-methyl-butylamino)-3-nitro-phenyl]-ethanone was reduced with catalytic hydrogenation as previously described for compound **164**.

20 ¹H NMR (CDCl₃) δ 0.97 (d, J = 6.6 Hz, 6H), 1.58 (q, J = 7.2 Hz, 2H), 1.73-1.78 (m, 1H), 2.50 (s, 3H), 3.20 (t, J = 7.5 Hz, 2H), 6.58 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 1.8 Hz, 1H), 7.52 (dd, J = 1.8, 8.2 Hz, 1H);
MS m/e 220 (MH⁺).


Compound 284

- 5 1-[3-Amino-4-(3-methyl-butylamino)-phenyl]-ethanone was coupled with compound 182 to give the final product using EEDQ as shown in Scheme IV.

¹H NMR (CDCl₃) δ 0.96 (d, J = 6.6 Hz, 6H), 1.42-1.50 (m, 2H), 1.65-1.76 (m, 1H), 2.69 (s, 3H), 4.35-4.40 (m, 2H), 5.22 (s, 1H), 5.40 (d, J = 1.4 Hz, 1H), 5.43 (s, 2H),
10 7.05-7.12 (m, 3H), 7.36 (d, J = 8.6 Hz, 1H), 7.45-7.48 (m, 1H), 7.99 (dd, J = 1.5, 8.6 Hz, 1H), 8.43 (s, 1H);
MS m/e 417 (MH⁺).


Compound 285

15



Compound 285 was prepared as previously described for compound 6.

- 20 ¹H NMR (DMSO-d₆) δ 0.92 (d, J = 6.6 Hz, 6H), 1.36-1.44 (m, 2H), 1.62-1.70 (m, 1H), 2.61 (s, 3H), 4.34 (t, J = 8.1 Hz, 2H), 5.37 (s, 2H), 6.91-7.03 (m, 3H), 7.10-7.14 (m, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.86 (dd, J = 1.6, 8.5 Hz, 1H), 8.29 (d, J = 1.0 Hz, 1H), 11.09 (s, 1H);
MS m/e 377 (MH⁺).


Compound 286

5 Compound 286 was alkylated with methyl iodide with sodium hydride as base as described for compound 7.

¹H NMR (CDCl₃) δ 0.96 (d, J = 6.6 Hz, 6H), 1.34-1.42 (m, 2H), 1.66-1.75 (m, 1H),
2.68 (s, 3H), 3.47 (s, 3H), 4.31-4.37 (m, 2H), 5.43 (s, 2H), 6.92-7.14 (m, 3H), 7.35
10 (d, J = 8.6 Hz, 1H), 7.38-7.41 (m, 1H), 7.98 (dd, J = 1.5, 8.6 Hz, 1H), 8.42 (d, J = 1.3
Hz, 1H);
MS m/e 391 (MH⁺).

Compound 287


15



Compound 287 was prepared using the procedure of J. Davoll, J. Chem. Soc. 1960, p 308) using 2-amino-4,5-difluoroaniline.


20

¹H NMR (DMSO-d₆) δ 2.21 (s, 3H), 5.20 (s, 1H), 5.36 (s, 1H), 7.03-7.12 (m, 2H).

(5,6-Difluoro-3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-acetic acid

- 5 Compound **287** was alkylated with methyl bromo acetate as described for compound **181**. The isopropenyl group was reduced as described for compound **155** and the ester hydrolyzed as described for compound **182**.


¹H NMR CDCl₃: 1.52 (d, J = 7.0 Hz, 6H), 4.61 (s, 2H), 4.60-4.71 (m, 1H), 6.79-6.85
10 (m, 1H), 6.99-7.04 (m, 1H).

Compound 288

15

Compound **288** was prepared using the procedure shown in Scheme IV.

¹H NMR (DMSO-d₆) δ 0.93 (d, J = 6.6 Hz, 6H), 1.52-1.57 (m, 2H), 1.64-1.69 (m, 1H), 3.19 (s, 3H), 4.32 (t, J = 7.8 Hz, 2H), 5.23 (s, 2H), 5.43 (s, 2H), 7.18 (t, J = 7.6 Hz, 1H), 7.25 (t, J = 7.3 Hz, 1H), 7.46-7.50 (m, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.58-
20 7.62 (m, 4H), 7.91 (d, J = 8.2 Hz, 2H);
MS m/e 538 (MH⁺).


Compound 289

5 Prepared from compound 107 and 2-oxo-6-trifluoromethyl-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester [mixture of 5 and 6 regioisomers 2-oxo-trifluoromethyl-2,3-dihydro-benzoimidazole (Meanwell et al. *J. Org. Chem.* 1995, 60, 1565-1582) were separated by column chromatography and alkylated with methyl bromoacetate] as previously described for compound 108.

10


¹H NMR (CDCl₃) δ 0.91 (d, J = 6.6 Hz, 6H), 1.36-1.43 (m, 2H), 1.61 (s, 9H), 1.64-1.73 (m, 1H), 4.23-4.29 (m, 2H), 5.32 (s, 2H), 7.19-7.25 (m, 4H), 7.31-7.34 (m, 1H), 7.70-7.76 (m, 2H), 7.82 (d, J = 8.5 Hz, 1H);
MS m/e 503 (MH⁺).

15

Compound 290

20


The t-butylcarbamate was removed as previously described for compound 6.
¹H NMR (CD₃OD) δ 0.96 (d, J = 6.6 Hz, 6H), 1.39-1.47 (m, 2H), 1.67-1.75 (m, 1H), 4.35 (t, J = 8.3 Hz, 2H), 5.44 (s, 2H), 7.19-7.38 (m, 4H), 7.45-7.47 (m, 2H), 7.46 (d, J = 7.3 Hz, 1H);
MS m/e 403 (MH⁺).

Compound 291

5 Compound **291** was prepared in a similar manner as for compound **290** above.

¹H NMR (DMSO-d₆) δ 0.92 (d, J = 6.6 Hz, 6H), 1.39-1.46 (m, 2H), 1.61-1.70 (m, 1H), 4.29 (t, J = 8.1 Hz, 2H), 5.37 (s, 2H), 7.05-7.25 (m, 3H), 7.29-7.36 (m, 2H), 7.49 (d, J = 7.7 Hz, 1H), 7.56 (d, J = 7.5 Hz, 1H), 11.44 (s, 1H).

10

(5,6-Difluoro-3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-acetic acid

15 (5,6-Difluoro-3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-acetic acid was prepared by hydrogenation of (5,6-Difluoro-3-isopropenyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-acetic acid as described for compound **115** then alkylated as described for compound **181** and hydrolysis to the acid as described for **182**.

¹H NMR (CDCl₃) δ 1.52 (d, J = 7.0 Hz, 6H), 4.61 (s, 2H), 4.60-4.71 (m, 1H), 6.79-
20 6.85 (m, 1H), 6.99-7.04 (m, 1H).

BIOLOGICAL ACTIVITY

25 The antiviral activity of these compounds against respiratory syncytial virus was determined in HEp-2 (ATCC CCL 23) cells that were seeded in 96 well microtiter plates at 1.5x10⁴ cells/100 μL/well in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with penicillin, streptomycin, glutamine, and 10%


fetal bovine serum. The cells were incubated overnight at 37 °C, the culture medium was removed, and cells were infected (100 µL volume in medium containing 2% fetal bovine serum) with respiratory syncytial virus Long strain at 5000 plaque forming units/mL. The compounds, 100 µL at appropriate dilution, were added to the cells 1 hour post infection. After incubation for 4 days at 37 °C, the plates were stained with MTT solution (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and incubated for 4 hours at 37 °C. The media was aspirated from the cells and 100 µL/well of acidified isopropanol (per liter: 900 mL isopropanol, 100 mL Triton X100, and 4 mL conc. HCl) was added. Plates were incubated for 15 minutes at room temperature with shaking, and an optical density (OD 540) reading at 540 nanometer (nm) was obtained. The optical density reading is proportional to the number of viable cells. The increase in the number of viable cells reflects the protective, antiviral activity of the compound. Assays comparing MTT staining in uninfected cells containing compound with uninfected cells in the absence of compound provide a measure of cellular toxicity. The control compound in this assay is Ribavirin which exhibits 100% cell protection at 2.5 µg/mL (corresponding to 10.2 µM).

The antiviral activity of compounds, designated as EC₅₀, is presented as a concentration that produces 50% cell protection in the assay. The compounds disclosed in this application show antiviral activity with EC₅₀s between 50 µM and 0.001 µM. Ribavirin has an EC₅₀ of 3 µM in this assay.

CLAIMS

What is claimed is:

- 5 1. A compound having the Formula I, and pharmaceutically acceptable salts thereof,



Formula I


10

wherein:

R_1 is $-(CR^vR^w)_n-X$;

- 15 R^v and R^w are independently selected from the group consisting of H, C_{1-6} alkyl, and C_{2-6} alkenyl; optionally substituted with 1-6 of the same or different halogen;

- 20 X is H, C_{1-6} alkyl, C_{2-6} alkenyl; each of said C_{1-6} alkyl, C_{2-6} alkenyl being optionally substituted with (1) one to six same or different halogen or hydroxy; (2) a member selected from the group consisting of phenyl, $-C(=NOH)NH_2$, $-CH(OH)-Ph$, $-Ph-S(O)_2C_{1-6}$ alkyl,



(3) a member from Group A1;

- 5 Group A1 is CN, OR', NR'R'', R'NCOR'', NR'CONR''R'', NR'SO₂R'', NR'COOR'', COR', COOR', OS(O)₂R', S(O)_tR' or PO(OR')₂;

n is 1-6;

- 10 t is 0-2;

R₂ is

- (i) H, C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl, or a functionality selected from Group A2
 15 or Group B; each of said C₁₋₆ alkyl, C₂₋₆ alkenyl, and phenyl being optionally substituted with (1) one to six same or different halogen or hydroxy or (2) one to two same or different members of Group A or Group B;
- (ii) -(CR^xR^y)_n-(CO)_p-C₆H₄-(Z₁)(Z₂), wherein Z₁ and Z₂ are each independently
 20 selected from the group consisting of Group A, Group B, and -(CH₂)_n-Z'; wherein said Z' is heterocycle or -(NR_dR_eR_f) + (halogen)-; and the Z₁ and Z₂ groups may each be in the ortho, meta or para position relative to the -(CR^xR^y)_n-(CO)_p- group; wherein R_d, R_e and R_f are independently C₁₋₆ alkyl, C₂₋₆ alkenyl, OH or C₁₋₆ alkyl COOH;

25

p is 0 or 1;

n' is 1-6; or

5 (iii) $-(CR^xR^y)_{n''}$ -heterocycle;


n'' is 0-6;

R₃, R₆, R₇ and R₁₀ are each independently H;

10

R₅, R₈ and R₉ are each independently H, halogen or CF₃;

R₄ is selected from the group consisting of H, halogen, CN, -C(O)C₁₋₆ alkyl and



15

R₁₁, R₁₂ are each independently H;

R^x, R^y are each independently H or C₁₋₆ alkyl;

20 Group A2 is COR', COOR', CONR'R'' or CONR'SO₂R'';

Group A3 is CN, NO₂, OR', OCONR'R'', NR'R'', N(R')COR'', N(R')CONR''R''',
NR'SO₂R'', NR'COOR'', SO_mR', SO₂NR'R'', SO₂NR'COR'' or PO(OR')₂;

25 Group A is a member selected from Group A2 and Group A3;

R', R'', R''' are each independently selected from the group consisting of H,
C₁₋₆ alkyl, phenyl and heterocycle; and each of said C₁₋₆ alkyl, phenyl and heterocycle
being optionally substituted with (1) one to six of same or different halogen or

30 hydroxy; (2) one to two of the same or different members of Group A' or Group B; or
(3) heterocycle; or R' and R'' taken together form a 5 to 6 membered aromatic or non-
aromatic ring containing one to four of the same or different heteroatoms selected
from the group consisting of N, S and O;

Group A' is halogen, CN, NO₂, OR^a, OCONR^aR^b, NR^aR^b, R^aNCOR^b, NR^aCONR^bR^c, NR^aSO₂R^b, NR^aCOOR^b, COR^c, CR^cNNR^aR^b, CR^aNOR^b, COOR^a, CONR^aR^b, CONR^aSO₂R^b, SO_mR^a, SO₂NR^aR^b, SO₂NR^aCOR^b or PO(OR^a)₂;

- 5 R^a, R^b, R^c are each independently selected from the group consisting of H and C₁₋₆ alkyl;

Group B is -(CH₂)_nQ, -(CH₂)_nSO_m-R₁₃ or -COQ;

- 10 Q is an N-linked amino acid selected from the group consisting of alanine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, pipecolic acid, α-amino-butyric acid, α-amino-propanoic acid, 2-amino-3-phenopropionic acid and iminodiacetic acid; wherein Q is linked to the adjacent carbon atom in Group B through a nitrogen atom of said N-linked amino acid; wherein said N-linked amino
15 acid includes D- or L-enantiomers or mixtures thereof;

R₁₃ is selected from a group consisting of H and C₁₋₆ alkyl; said C₁₋₆ alkyl being optionally substituted with (1) one to five hydroxy groups or (2) two of the same or different functionalities selected from the group consisting of COOR^x and CONR^xR^y;

20

m, m' and m'' are independently 0-2;

n''' is 1-6;

- 25 heterocycle is a 5-6 membered aromatic or non-aromatic ring which contains one to four heteroatoms independently selected from the group consisting of O, N and S; wherein said aromatic or non-aromatic ring is optionally fused to a phenyl ring; wherein the aromatic or non-aromatic ring is optionally substituted with one to five of the same or different substituents selected from the group consisting of C₁₋₆ alkyl,
30 Group A and Group B; and halogen is bromine, chlorine, fluorine or iodine.

2. A compound of claim 1 wherein heterocycle is an aromatic ring selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl,
35 1,2,4-oxadiazol-5-one, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl,

pyrazinyl, 1,3,5-triazinyl, indoliziny, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, tetrazole, uridiny and cytosiny.

- 5 3. A compound of claim 1 wherein the heterocycle is a non-aromatic ring selected from the group consisting of pyrrolidine, imidazoline, 2-imidazolidone, 2-pyrrolidone, pyrrolin-2-one, tetrahydrofuran, 1,3-dioxolane, piperidine, tetrahydropyran, oxazoline, 1,3-dioxane, 1,4-piperazine, morpholine and thiomorpholine.

10

4. A compound of claim 1 wherein:

R_1 is $-(CH_2)_n-X$.


- 15 5. A compound of claim 1 wherein in R_2 , substituents R^x and R^y are each hydrogen.

6. A compound of claim 1 wherein in R_1 , n is 1-4.

- 20 7. A compound of claim 5 wherein in R_2 , n' is 1; and n'' is 3-4.

8. A compound of claim 1 wherein:


25 R_1 is vinyl, allyl, 3-methyl-2-butene or $-(CH_2)_n-X$, wherein n is 2-4, and X is a functionality selected from the group consisting of



R_2 is

30


(i)



wherein R_{17} is H or C_{1-4} alkyl;

5 (ii) $-\text{CH}_2-\text{C}_6\text{H}_4-\text{Z}$;

(iii) $-(\text{CH}_2)_k-\text{Z}''$, wherein k is 1-6; wherein Z and Z'' are each independently selected from the group consisting of:



a

and b are each independently 0-2; and

R₁₅ and R₁₆ are each independently H, C₁₋₄ alkyl, wherein said C₁₋₄ alkyl is optionally substituted with 1-3 same or different halogens.

5

9. A method for treating mammals infected with RSV, and in need thereof, which comprises administering to said mammal a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1-8.

10 10. A pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned anti-RSV compounds as claimed in any one of claims 1-8 and a pharmaceutically acceptable carrier.

15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/29498

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MEANWELL et al. Regiospecific Functionalization of 1,3-Dihydro-2H-benzimidazol-2-one and Structurally Related Cyclic Urea Derivatives. J. Org. Chem. 24 March 1995, Vol. 60, No. 6, pages 1565-1582, especially page 1571, entry 75.	1-10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T"	Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

27 NOVEMBER 2001

Date of mailing of the international search report

17 JAN 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LAURA L. STOCKTON

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/29493

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 31/4184, 31/443, 31/422, 31/427, 31/454, 31/501, 31/5377; C07D 401/14, 403/06, 403/14, 413/14, 417/14 .

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/81, 234.5, 254.06, 274, 322, 338, 363, 364, 369, 376, 381, 387; 544/139, 310, 370; 546/199, 273.7; 548/113, 132, 139, 181, 250, 251, 252, 305.7

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/81, 234.5, 254.06, 274, 322, 338, 363, 364, 369, 376, 381, 387; 544/139, 310, 370; 546/199, 273.7; 548/113, 132, 139, 181, 250, 251, 252, 305.7